

BETH C. DRAIN, CA CSR NO. 7152

BEFORE THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE
AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: HYATT REGENCY
SAN FRANCISCO AIRPORT
CYPRESS ROOM BC
1333 OLD BAYSHORE HIGHWAY
BURLINGAME, CA

DATE: MARCH 28, 2024
9 A.M.

REPORTER: BETH C. DRAIN, CA CSR
CSR. NO. 7152

FILE NO.: 2024-17

BETH C. DRAIN, CA CSR NO. 7152

I N D E X

ITEM DESCRIPTION	PAGE NO.
OPEN SESSION	
1. CALL TO ORDER	5
2. ROLL CALL	5
3. CHAIR'S REPORT	9
4. VICE-CHAIR'S REPORT	11
5. INTERIM PRESIDENT'S REPORT	15, 64
STRATEGIC ALLOCATION FRAMEWORK	22
COMPASS PROGRAM	54
CONSENT CALENDAR	72
6. CONSIDERATION OF MINUTES FROM FEBRUARY 22 ICOC/ARS MEETING	
7. CONSIDERATION OF APPOINTMENT OF SCIENTIFIC MEMBERS TO THE GRANTS WORKING GROUP	
8. CONSIDERATION OF APPOINTMENT OF A MEMBER TO THE ACCESSIBILITY & AFFORDABILITY WORKING GROUP POSTPONED	
9. APPROVAL OF REQUESTS TO ATTEND REMOTELY (GOV'T CODE SECTION 11123.2(J))	
OPEN SESSION	
10. CONSIDERATION OF ICOC	75
CHAIR/VICE-CHAIR REVIEW PROCEDURES: JOB DESCRIPTIONS, AND SURVEY QUESTIONS	
CHAIR JOB DESCRIPTION	
VICE-CHAIR JOB DESCRIPTION	
CHAIR SURVEY QUESTIONS	
VICE-CHAIR SURVEY QUESTIONS	
OVERVIEW AND TIMELINE	

BETH C. DRAIN, CA CSR NO. 7152

I N D E X (CONT'D.)

11. CONSIDERATION OF THE PRESIDENT & CEO JOB DESCRIPTION	90
12. DISCUSSION OF BOARD CHAIR'S PLAN FOR ONBOARDING NEW PRESIDENT & CEO	97
13. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO INFRASTRUCTURE PROGRAM ANNOUNCEMENTS (INFR7)	99
14. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO CLINICAL TRIAL STAGE PROJECTS PROGRAM ANNOUNCEMENTS (CLIN 1 OR 2)	131
15. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO DISCOVERY PROGRAM ANNOUNCEMENTS (DISC0)	137
CLOSED SESSION	168
16. DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO APPLICATIONS SUBMITTED IN RESPONSE TO AGENDA ITEMS 13, 14, AND 15. (HEALTH & SAFETY CODE 125290.30(F) (3) (B) AND (C)).	
17. DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO BLA STATUS FOR CLIN PORTFOLIO. (HEALTH & SAFETY CODE 125290.30(F) (3) (B) AND (C)).	
OPEN SESSION	
18. UPDATE FROM PRESIDENTIAL SEARCH SUBCOMMITTEE	169
19. UPDATE FROM NEURO TASK FORCE	
20. UPDATE FROM SCIENCE SUBCOMMITTEE	
21. UPDATE FROM COMMUNICATIONS SUBCOMMITTEE	174

BETH C. DRAIN, CA CSR NO. 7152

I N D E X (CONT'D.)

22. DISCUSSION OF MANAGEMENT'S RESPONSE TO THE PERFORMANCE AUDIT	183
23. GENERAL COMMENTS ON ARS PROCESS	
24. PUBLIC COMMENT	NONE
25. ADJOURNMENT	202

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MARCH 28, 2024; 9 A.M.

CHAIRMAN IMBASCIANI: LADIES AND GENTLEMEN, GOOD MORNING. I WOULD LIKE TO CALL TO ORDER THE MEETING OF THE INDEPENDENT CITIZENS OVERSIGHT COMMITTEE, THE BOARD OF DIRECTORS FOR CIRM, AND WELCOME MEMBERS OF THE BOARD TO THIS MEETING. THANK YOU FOR COMING HERE TO SOUTH SAN FRANCISCO. AND WELCOME TO MEMBERS OF THE PUBLIC WHO ARE EITHER IN PERSON OR LISTENING IN.

WE'LL START THE MEETING WITH THE PLEDGE OF ALLEGIANCE. MR. TOCHER, WOULD YOU LIKE TO LEAD US. THANK YOU.

(THE PLEDGE OF ALLEGIANCE.)

CHAIRMAN IMBASCIANI: THANK YOU, MR. TOCHER. THE FIRST ORDER OF BUSINESS IS TO CALL THE ROLL.

MR. TOCHER: THANK YOU. MOHAMED ABOUSALEM.

DR. ABOUSALEM: PRESENT.

MR. TOCHER: KIM BARRETT.

DR. BARRETT: PRESENT.

MR. TOCHER: DAN BERNAL. GEORGE BLUMENTHAL.

DR. BLUMENTHAL: HERE.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. TOCHER: MARIA BONNEVILLE.
2 VICE CHAIR BONNEVILLE: PRESENT.
3 MR. TOCHER: JUDY CHOU.
4 DR. CHOU: PRESENT.
5 MR. TOCHER: CAROL CHRIST. LEONDR
6 CLARK-HARVEY.
7 DR. CLARK-HARVEY: MORNING. PRESENT.
8 MR. TOCHER: DEBORAH DEAS.
9 DR. DEAS: HERE.
10 MR. TOCHER: ANNE-MARIE DULIEGE.
11 DR. DULIEGE: PRESENT.
12 MR. TOCHER: YSABEL DURON. MARK
13 FISCHER-COLBRIE.
14 DR. FISCHER-COLBRIE: HERE.
15 MR. TOCHER: FRED FISHER.
16 DR. FISHER: HERE.
17 MR. TOCHER: ELENA FLOWERS.
18 DR. FLOWERS: PRESENT.
19 MR. TOCHER: JUDY GASSON.
20 DR. GASSON: HERE.
21 MR. TOCHER: LARRY GOLDSTEIN.
22 DR. GOLDSTEIN: HERE.
23 MR. TOCHER: DAVID HIGGINS.
24 DR. HIGGINS: PRESENT.
25 MR. TOCHER: VITO IMBASCIANI.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN IMBASCIANI: HERE.
2 MR. TOCHER: STEPHEN JUELSGAARD.
3 MR. JUELSGAARD: HERE.
4 MR. TOCHER: RICH LAJARA.
5 MR. LAJARA: PRESENT.
6 MR. TOCHER: PAT LEVITT.
7 DR. LEVITT: PRESENT.
8 MR. TOCHER: LINDA MALKAS.
9 DR. MALKAS: PRESENT.
10 MR. TOCHER: SHLOMO MELMED.
11 DR. MELMED: PRESENT.
12 MR. TOCHER: CHRISTINE MIASKOWSKI. LAUREN
13 MILLER-ROGEN. ADRIANA PADILLA.
14 DR. PADILLA: HERE.
15 MR. TOCHER: JOE PANETTA. JOYCE SACKY.
16 DR. SACKY: PRESENT.
17 MR. TOCHER: MARVIN SOUTHARD.
18 DR. SOUTHARD: PRESENT.
19 MR. TOCHER: MICHAEL STAMOS.
20 DR. STAMOS: PRESENT.
21 MR. TOCHER: KAROL WATSON.
22 DR. WATSON: HERE.
23 MR. TOCHER: KEVIN XU.
24 DR. XU: HERE.
25 MR. TOCHER: KEITH YAMAMOTO.

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DR. YAMAMOTO: HERE.

MR. TOCHER. GREAT. THANK YOU VERY MUCH.

WE HAVE A QUORUM.

BETH C. DRAIN, CA CSR NO. 7152

CHAIRMAN IMBASCIANI: THANK YOU VERY MUCH,
MR. TOCHER.

I'D LIKE TO ORIENT THE BOARD MEMBERS IN
THIS NEXT SECTION TO TODAY'S AGENDA WHICH IS FULL
AND VARIED. WE ARE GOING TO, YOU WILL NOTICE,
COMPLETE THE CONSIDERATION OF THREE ITEMS THAT WERE
LEFT OVER FROM THE FEBRUARY 2024 ICOC MEETING. AND
THAT WOULD INCLUDE PRESENTATION OF OUR PERFORMANCE
AUDIT, ITEM NO. 22; REPORT FROM THE PRESIDENTIAL
SEARCH COMMITTEE, ITEM 18; AND THREE ITEMS FROM THE
GOVERNANCE SUBCOMMITTEE, ITEMS 10, 11, AND 12.

WE'RE GOING TO HEAR FROM OUR COMMS
SUBCOMMITTEE, DISCUSS ISSUES RELATED TO THE PATIENT
SUPPORT PROGRAM, AND HEAR FROM OUR LEGAL COUNSEL ON
THE PERFORMANCE AUDIT, AND WE'LL HEAR FROM THE
PUBLIC.

WE WILL FORMALIZE TODAY THE JOB
DESCRIPTION OF THE NEW PRESIDENT AND CEO AS WELL AS
FORMALIZE THE REVIEW PROCESS OF THE CHAIR AND THE
VICE CHAIR CONDUCTED BY THE GOVERNANCE SUBCOMMITTEE.
AND THE PRESIDENT AND CEO WILL START A CONVERSATION
AT TODAY'S MEETING WITH THE BOARD ON OUR ALLOCATION
STRATEGY THAT IS LIKELY TO CONTINUE OVER THE NEXT
SIX MONTHS.

THERE WILL BE THREE SETS OF VOTES ON

BETH C. DRAIN, CA CSR NO. 7152

APPLICATIONS RECOMMENDED FROM THE APPLICATION SUBCOMMITTEE, AND THOSE WILL BE ON THE INFRASTRUCTURE7 PROGRAM, THE PATIENT SUPPORT PROGRAM, IF YOU WILL; CLIN1/2 PROGRAM, AND THE SEMIANNUAL READOUT OF THE DISC PROGRAM RECOMMENDATIONS. WE WILL HAVE A CLOSED SESSION DISCUSSION OF ONE ITEM TODAY.

AND I WANT TO, FOR THE FIRST TIME IN A YEAR, MENTION SOME NUMBERS. THIS IS THE MATH SECTION. A REPORT ON THE UPDATE OF OUR BOND SALES. SO IF YOU'RE INTERESTED IN DOLLAR AMOUNTS, LAST SPRING, ABOUT A YEAR AGO, \$146,780,000 IN BONDS WERE SOLD. AND THAT BROKE DOWN TO 16,780,000 DEDICATED TO CAPITALIZED INTEREST. THE REMAINING 130 MILLION WENT TO SUPPORT OUR GRANTS, OUR OPERATIONS, AND THE COST OF BOND ISSUANCE.

IN OCTOBER OF 2023, 199,465,000 WERE SOLD. THE BREAKDOWN, 24,465,000 DEDICATED TO CAPITALIZED INTEREST. THE REMAINING 175 MILLION, ONCE AGAIN, TO GRANTS, OPERATIONS, AND COST OF BOND ISSUANCE. THAT'S A TOTAL IN THE LAST 12 MONTHS OF \$346,245,000. THE NEXT BOND SALE FOR APPROXIMATELY \$200 MILLION WILL COME IN MID-APRIL.

AND WITH THAT, I'M GOING TO VERY HAPPILY PUNT IT TO OUR VICE CHAIR MARIA BONNEVILLE WHO,

**133 HENNA COURT, SANDPOINT, IDAHO 83864
208-920-3543 DRAIBE@HOTMAIL.COM**

BETH C. DRAIN, CA CSR NO. 7152

AMONG OTHER THINGS, WILL REPORT ON OUR LEG DAY.

VICE CHAIR BONNEVILLE: GOOD MORNING,
EVERYONE. A QUICK UPDATE ON OUR SACRAMENTO
OUTREACH.

VITO AND I HAD A VERY PRODUCTIVE AND BUSY
DAY IN SACRAMENTO LAST WEEK. WE MET WITH TEN
MEMBERS OF THE ASSEMBLY AND SENATE, SPANNING
SOUTHERN, CENTRAL, AND NORTHERN CALIFORNIA.

IT HAD BEEN SEVERAL YEARS SINCE WE VISITED
THE CAPITOL TO MEET WITH LEGISLATORS, AND WE WERE
MET WITH GREAT ENTHUSIASM. WE SPOKE ABOUT THE DEPTH
OF CIRM'S RESEARCH PORTFOLIO, UNDERSCORING THE
NUMBER OF ACTIVE CLINICAL TRIALS. WE SHARED PATIENT
STORIES, DISCUSSED THE ECONOMIC IMPACT THAT CIRM HAS
HAD ON CALIFORNIA, HIGHLIGHTING GRANT FUNDS FLOWING
INTO THEIR SPECIFIC DISTRICT, EXPLAINED THE
IMPORTANCE OF THE ALPHA CLINIC PROGRAM, AND THE NEED
FOR COMMUNITY CARE CENTERS OF EXCELLENCE, AND THE
IMPORTANCE OF PROVIDING ASSISTANCE TO PATIENTS IN
CIRM-FUNDED CLINICAL TRIALS VIA THE PATIENT
ASSISTANCE FUND.

WE HAVE NO ASK OF THE LEGISLATURE YET.
HOWEVER, WE DID EMPHASIZE THE IMPORTANCE OF WORKING
COLLABORATIVELY TO TACKLE THE PROBLEMS AROUND ACCESS
TO CELL AND GENE THERAPIES, AND THAT IN THE NEXT FEW

BETH C. DRAIN, CA CSR NO. 7152

YEARS THERE MAY BE A MORE SPECIFIC ASK FOR THEM TO CONSIDER.

IN ADDITION, WE CONTINUE OUR OUTREACH EFFORTS WITH SEVERAL OTHER STATE AGENCIES WITH WHOM WE MAY BE ABLE TO COLLABORATE: GO BIZ, WHICH IS THE GOVERNOR'S ECONOMIC DEVELOPMENT DEPARTMENT; MEDI-CAL; AND THE CALIFORNIA HEALTH AND HUMAN SERVICES AGENCY; THE OFFICE OF HEALTHCARE AFFORDABILITY; CALIFORNIA DEPARTMENT OF PUBLIC HEALTH; AND THE CALIFORNIA SURGEON GENERAL'S OFFICE.

VITO, DO YOU WANT TO ADD ANYTHING?

CHAIRMAN IMBASCIANI: NO. THAT'S VERY COMPREHENSIVE. THANK YOU, MARIA.

VICE CHAIR BONNEVILLE: IF THERE ARE ANY QUESTIONS, I'M HAPPY TO ANSWER THEM.

DR. LEVITT: I HAVE A QUESTION. DID YOU GET A SENSE FROM MEETING WITH THE LEGISLATORS ABOUT HOW FAMILIAR OR UNFAMILIAR THEY WERE WITH WHAT CIRM IS AND WHAT CIRM HAS BEEN DOING OVER THE LAST 20 YEARS?

VICE CHAIR BONNEVILLE: I'D SAY OF THE TEN WE MET WITH -- I MEAN THERE'S BEEN A LOT OF TURNOVER IN THE LEGISLATURE, AS YOU CAN IMAGINE, OVER THE LAST EVEN TWO YEARS, BUT DEFINITELY OVER THE LAST 20. THERE WERE TWO MEMBERS OF THE TEN WHO HAVE BEEN

BETH C. DRAIN, CA CSR NO. 7152

THERE FOR A BIT AND DID KNOW ABOUT US AND UNDERSTAND WHO WE WERE. A LOT OF THEM -- WE WERE ON THE BALLOT IN 2020, SO THEY UNDERSTOOD THAT WE EXISTED, BUT NOT TO THE DEPTH OF WHAT WE DID.

SO IT WAS A REALLY GREAT SORT OF REINTRODUCING OURSELVES TO THEM AND WHO WE ARE. AND THAT WILL CONTINUE. OUR LOBBYISTS IN SACRAMENTO ARE FANTASTIC, AND SO THEY'VE MADE A REALLY GREAT EFFORT TO GET US IN FRONT OF THE RIGHT PEOPLE.

MR. GOLDSTEIN: I HAVE A QUESTION.

CHAIRMAN IMBASCIANI: ANY OTHER QUESTIONS ON THE REPORT OF THE VICE CHAIR?

DR. GOLDSTEIN: MAYBE YOU DIDN'T SEE MY HAND, VITO, BUT IT'S UP.

CHAIRMAN IMBASCIANI: OKAY.

DR. GOLDSTEIN: WOULD IT MAKE SENSE AT SOME POINT TO HELP ICOC MEMBERS LEARN TO WORK WITH THEIR OWN MEMBERS AND SENATORS FROM THEIR DISTRICTS? I WORK WITH A NUMBER OF ORGANIZATIONS THAT REALLY FOCUS ON DEVELOPING THOSE ONE-TO-ONE CONTACTS BETWEEN REPRESENTED MEMBERS OF OUR ORGANIZATION AND THEIR REPRESENTATIVES.

VICE CHAIR BONNEVILLE: A HUNDRED PERCENT. PAT AND I WERE ACTUALLY TALKING ABOUT THAT THIS MORNING ABOUT THEY ALL HAVE TOWNHALLS IN THEIR

BETH C. DRAIN, CA CSR NO. 7152

DISTRICT. AND GETTING IN FRONT OF THEM AND IN FRONT OF THEIR CONSTITUENTS DURING SOME OF THOSE TOWNHALLS COULD BE INCREDIBLY EFFECTIVE AND WOULD WELCOME ALL BOARD MEMBER PARTICIPATION BASED ON THE DISTRICT FOR THAT. THANK YOU, LARRY. ABSOLUTELY.

DR. GOLDSTEIN: GOOD. IT HELPS TO PROVIDE A LITTLE BIT OF POLITICAL GREASE FOR OUR FOLKS WHO AREN'T USED TO DOING THAT SORT OF THING.

VICE CHAIR BONNEVILLE: SURE. I'M HAPPY TO WORK WITH ALL THE BOARD MEMBERS IN THAT REGARD.

DR. GOLDSTEIN: GREAT.

DR. CLARK-HARVEY: I JUST WANT TO UNDERSCORE THOSE COMMENTS, NOT JUST IN YOUR DISTRICTS, BUT IN SACRAMENTO AS WELL. THERE A FEW OF US THAT ARE IN TOWN AND HAVING FREQUENT INTERACTIONS WITH THESE FOLKS. IF THERE ARE TALKING POINTS THAT COULD BE SHARED.

VICE CHAIR BONNEVILLE: ABSOLUTELY. I CAN SEND THOSE TO YOU. WE PUT TOGETHER A FOLDER. I HAVE A COPY OF IT HERE. AND INSIDE THERE ARE LEAVE-BEHINDS. SO THERE ARE ONE-PAGERS ON EVERYTHING THAT I MENTIONED THAT WE DISCUSSED. SO IT WAS GREAT.

DR. CLARK-HARVEY: YEAH. JUST SO WE CAN ALL LIFT UP WHAT YOU'RE LIFTING UP AS WE'RE IN TOWN

BETH C. DRAIN, CA CSR NO. 7152

FOR OUR OWN WORK AS WELL.

VICE CHAIR BONNEVILLE: THANK YOU.

CHAIRMAN IMBASCIANI: I DON'T SEE ANY OTHER HANDS. THANK YOU.

OKAY. WE'RE GOING TO PROCEED TO THE INTERIM PRESIDENT'S REPORT, MR. JONATHAN THOMAS.

MR. TOCHER: IN THE MEANTIME I'D LIKE TO WELCOME YSABEL DURON ON THE PHONE AND ANNE-MARIE DULIEGE IN PERSON.

CHAIRMAN IMBASCIANI: THANK YOU.

DR. THOMAS: MR. CHAIR, MADAM VICE CHAIR, MEMBERS OF THE BOARD, AND THE PUBLIC, IT'S WITH A GREAT DEAL OF PLEASURE THAT I GIVE YOU THE INTERIM PRESIDENT AND CEO'S REPORT.

I AT THIS MOMENT PLAN TO REVIEW FOR YOU SOME OF THE KEY THINGS THAT HAVE HAPPENED INTERNALLY AT CIRM OVER THE THREE MONTHS THAT I'VE BEEN IN OFFICE. I WILL THEN TURN IT OVER TO DR. ROSA CANET-AVILES TO GIVE A PRESENTATION ON ONE ASPECT OF SOMETHING WE'RE SPENDING A GREAT DEAL OF TIME ON, WHICH IS REPRIORITIZING WHERE WE WANT TO SPEND CIRM FUNDS GOING FORWARD. WE'LL FOLLOW THAT WITH A PRESENTATION ON ONE OF OUR GREAT PROGRAMS, WHICH IS OUR EDUCATIONAL PROGRAM, HIGHLIGHTING THE NEW COMPASS PROGRAM WE HAVE IN PLACE FOR THE LAST YEAR,

BETH C. DRAIN, CA CSR NO. 7152

AS WELL AS A SHORT VIDEO ON EDUCATION PROGRAMS IN GENERAL TO BE LED BY DR. KELLY SHEPARD.

AT THE CLOSED SESSION, AS PART OF THE PRESIDENT'S REPORT, DR. ABLA CREASEY WILL PRESENT TO MEMBERS OF THE BOARD A REPORT ON THE ADVANCEMENT OF CIRM PROJECTS TOWARDS COMMERCIALIZATION. AND AT THE END OF MY REMARKS, GIVEN THAT THIS IS OPENING DAY, I WILL TAKE IT AS THE PRESIDENT'S PREROGATIVE TO MAKE A FEW STATEMENTS ABOUT A SPORTING EVENT THAT I THINK YOU WILL FIND OF GREAT INTEREST. DON'T BELIEVE ALL YOU HEAR.

SO BEFORE I GET INTO MY REMARKS ON WHAT WE'VE BEEN DOING, I WANT TO START TODAY'S SESSION FOR THE BENEFIT OF THE BOARD WITH A SALUTE TO OUR CIRM TEAM. SO AS YOU HEARD LAST WEEK, SORRY, LAST MONTH, EVERYBODY IS INCREDIBLY BUSY AT CIRM. FROM THE VANTAGE POINT OF A BOARD MEMBER AS ARE ALL OF YOU, I'VE ALWAYS KNOWN HOW GREAT OUR CIRM TEAM IS, BUT I CAN TELL YOU NOW, BEING ON THE OTHER SIDE OF THE TABLE, HAVING THE PRIVILEGE OF DEALING WITH MEMBERS OF THE TEAM ON A DAY-TO-DAY BASIS AND SEEING THE EXTRAORDINARY AMOUNT OF DEDICATION, HARD WORK, AND CONSISTENTLY GOING ABOVE AND BEYOND THE CALL, THAT I WANT EVERYBODY TO KNOW HOW EXCEPTIONAL OUR TEAM IS. AND THEY ARE WHAT MAKES ALL OF WHAT WE DO

BETH C. DRAIN, CA CSR NO. 7152

POSSIBLE, AND I DIDN'T WANT LET THIS MOMENT PASS WITHOUT THAT SALUTE.

SO IF I COULD JUST HAVE A ROUND OF APPLAUSE FOR OUR TEAM.

(APPLAUSE.)

DR. THOMAS: LADIES AND GENTLEMEN, AS I NOTED TO THE SCIENCE SUBCOMMITTEE A COUPLE OF DAYS AGO, CIRM IS AT AN INFLECTION POINT. AS WE'VE BEEN DISCUSSING IN THE LAST FEW MONTHS, WE HAVE HAD A CONFLUENCE OF CIRCUMSTANCE THAT FINDS US IN A POSITION WHERE WE NEED TO REEXAMINE A NUMBER OF THINGS THAT CIRM IS DOING ALL IN AN EFFORT UNDER THE STRATEGIC PLAN TO TAKE WHAT WAS ALREADY AN A-PLUS WORK PRODUCT AND MAKE IT EVEN BETTER.

WE HAVE, AS WE HAVE DISCUSSED, BUDGETARY CONSTRAINTS, A MAJOR INCREASE IN GRANT APPLICATIONS, ADVANCEMENTS IN SCIENCE THAT ARE MAKING MORE AND MORE THINGS POSSIBLE, ALL OF WHICH HAVE COME TOGETHER TO IMPOSE UPON US A RESPONSIBILITY TO REEXAMINE SOME OF THE THINGS WE'RE DOING.

AT THE FEBRUARY BOARD MEETING, WE TALKED ABOUT THE NEED, GIVEN THOSE CIRCUMSTANCES, TO HAVE A PERIOD OF A SHORT FEW MONTHS WHERE WE WOULD NOT BE ACCEPTING NEW CLIN APPLICATIONS TO ALLOW OUR REVIEW TEAM AND OTHERS WHO SUPPORT THEM TO ADDRESS THE

BETH C. DRAIN, CA CSR NO. 7152

ISSUES POSED BY THESE CIRCUMSTANCES I HAVE DESCRIBED.

HAVING SAID THAT, WE INITIATED THE FLOW CONTROL MEASURE THAT THE BOARD APPROVED LAST MONTH, ALL WITH AN EYE TOWARDS COMING BACK IN THE JUNE ICOC MEETING TO LAY OUT FOR THE BOARD OUR THOUGHTS ON THE REVIEW PROCESS AND WITH THE GOAL OF REINSTITUTING RECEIPT OF GRANT APPLICATIONS AT THAT POINT.

THIS REEXAMINATION THAT WE'RE TALKING ABOUT HERE TAKES A NUMBER OF FORMS. FIRST AND FOREMOST IS THE REPRIORITIZING WHERE WE'RE GOING TO PUT CIRM'S REMAINING DOLLARS, WHICH SOUND LIKE A LOT OF MONEY, BUT IT GOES QUICKLY. AND IF WE'RE NOT CAREFUL AND GIVING ATTENTION TO THE CIRCUMSTANCES OF THE DAY, WE WILL NOT SPEND IT MOST WISELY AND TOWARDS THE BEST POSSIBLE PROJECTS.

THE REPRIORITIZING EFFORT IS LED BY DR. CANET-AVILES WHO WILL GIVE THE PRESENTATION, AS I SAY, ON THAT. WE ALSO, IN ADDITION IN A WORKING GROUP THAT'S CHAIRED BY DR. SAMBRANO, ARE TAKING A LOOK AT THE REVIEW PROCESS ITSELF, REEXAMINING CRITERIA, ELIGIBILITY, AND ALL SUCH THINGS THAT GO INTO THAT PROCESS SO THAT WE CAN FINE-TUNE IT TO BRING IT UP TO THE LEVEL THAT IT NEEDS TO BE GIVEN THE CIRCUMSTANCES WE HAVE DESCRIBED.

BETH C. DRAIN, CA CSR NO. 7152

SO WITH THE FLOW CONTROL, THE REPRIORITIZING, THE REEXAMINATION OF REVIEW CRITERIA, ALL OF THIS, AT THE END OF THE DAY, IS GOING TO LEAD IN THE COMING MONTHS TO WORK WITH THE MEMBERS OF THE SCIENCE SUBCOMMITTEE AND MEMBERS OF THE BOARD AND AT REGULAR INTERVAL TO KEEP EVERYBODY APPRISED OF THE PROGRESS THAT WE'RE MAKING IN THESE EFFORTS ALL TOWARDS A SEPTEMBER BOARD MEETING AT WHICH THE TEAM WILL PROPOSE A SET OF RECOMMENDATIONS ON REPRIORITIZATION FOR THE BOARD'S CONSIDERATION, WHICH, AS I SAY, WILL BE OF NO SURPRISE SINCE YOU WILL HAVE HEARD MANY INTERIM REPORTS EN ROUTE. AND AT THAT POINT WE WISH TO HAVE, HOPEFULLY, THE BOARD APPROVE, AND WE WILL PROCEED FROM THERE.

I'D LIKE TO POINT OUT THAT THE GOAL OF THIS REPRIORITIZATION IS NOT TO PUT IN PLACE SOMETHING THAT'S GOING TO BE IN EFFECT FOR A YEAR OR TWO. WE ARE LOOKING AT THE REMAINING LIFE OF CIRM AND LOOKING TO DETERMINE HOW BEST WE CAN DEPLOY OUR FUNDS TOWARDS THAT DATE, WHATEVER THAT DATE MAY BE. SO THIS IS A LONG-TERM ADJUSTMENT IN ADVANCING THE STRATEGIC PLAN THAT WILL BE IN PLACE EITHER THROUGH THE END OF CIRM'S PROP 14 LIFE OR, SHOULD THE BOARD AND TEAM DOWN THE ROAD DECIDE THAT ANOTHER COURSE CORRECTION IS NEEDED, AT THAT POINT OBVIOUSLY WE CAN

BETH C. DRAIN, CA CSR NO. 7152

REVISIT AND DO THAT EXERCISE AGAIN. SO THIS IS NOT SOMETHING CAST IN STONE, BUT THE GOAL IS TO PUT IN PLACE A LONG-TERM PLAN FOR THE REMAINING CIRM FUNDS.

WHEN WE GET TO THE REPORT BY DR. CANET-AVILES, I WANT TO EMPHASIZE THAT TODAY'S REPORT, AS WAS THE CASE TO THE SCIENCE SUBCOMMITTEE, IS NOT ON SUBSTANCE. THIS IS ALL ABOUT THE PROCESS THAT WE HAVE DEVELOPED INTERNALLY TO RECOMMEND TO THE BOARD FOR HOW THIS REPRIORITIZING SHALL PROCEED.

SO I WANT TO MAKE THAT POINT SO THAT -- I'M SURE THERE ARE MANY SUBSTANTIVE QUESTIONS MEMBERS OF THE BOARD WILL WANT TO ASK, BUT MY ADMONITION TO YOU AT THE MOMENT IS THIS IS NOT THE TIME FOR THAT. THIS IS THE TIME TO DISCUSS PROCESS. IF OZ WERE HERE, HE'D BE VERY PROUD OF US, RIGHT?

VICE CHAIR BONNEVILLE: YES.

DR. THOMAS: SO THE MEMBERS OF THE TEAM, AS I SAID IN MY OPENING SALUTE, HAVE BEEN ASKED TO DO A LOT. THEY HAVE A TREMENDOUS WORKLOAD, AND WE'VE LAID ON TOP OF THAT ALL OF THESE REEXAMINATIONS WHICH TAKE A GREAT DEAL OF WORK. I CAN REPORT TO YOU, FOR EXAMPLE, THE PRIORITIZATION WORKING GROUP THAT WE'VE ASSEMBLED TO TALK ABOUT THAT PARTICULAR TOPIC HAS ALREADY HAD FOUR, I THINK, MEETINGS RANGING FROM TWO TO FOUR AND A HALF HOURS

BETH C. DRAIN, CA CSR NO. 7152

OF DISCUSSION. AND THAT'S LED US TO WHERE WE ARE TODAY. WE HAVE ANOTHER FULL DAY SESSION COMING UP IN ABOUT TEN DAYS TO CONTINUE THAT. AND WE ARE PROCEEDING FULL SPEED AHEAD BECAUSE, EVEN THOUGH THE ULTIMATE GOAL IS A VOTE IN SEPTEMBER, THERE ARE MANY INTERIM STEPS THAT NEED TO BE UNDERTAKEN IN THE INTERIM. AND MY REPORT TO THE BOARD IS WE'RE ON IT. SO YOU SHOULD FEEL VERY GOOD ABOUT THE WORK PRODUCT THAT'S GETTING PRODUCED IN THIS.

PART AND PARCEL OF THAT REPRIORITIZING IS, AMONG OTHER THINGS, A NEED TO VISIT WHAT WE PLAN ON DOING WITH ONE OF THE AREAS THAT WE HAVE HAD A GREAT DEAL OF FUNDING IN IN THE PAST WHICH IS RARE DISEASE. TOWARDS THAT END, DR. CREASEY IS TAKING THE LEAD IN DEVELOPING A STRATEGY FOR HOW TO DEAL WITH THAT SUBSET OF CONDITIONS TO PARSE INTO THIS REPRIORITIZING PLAN IN GENERAL, ANOTHER EFFORT THAT TAKES A GREAT OF WORK AND HAS ENGENDERED A LOT OF DISCUSSION BY MEMBERS OF OUR WORKING GROUP.

ALL OF THIS HAS A GREAT IMPACT ON HOW WE MANAGE OUR MONEY. THAT FALLS TO JEN AND HER TEAM IN GRANTS MANAGEMENT. THERE ARE LOTS OF ASPECTS OF THIS WHICH ARE VERY COMPLICATED. AND I WANT TO SHOUT OUT TO JEN AND HER TEAM, WHO DO TREMENDOUS WORK IN MAKING SURE THAT ONCE WE AWARD THE GRANTS,

BETH C. DRAIN, CA CSR NO. 7152

EVERYTHING GOES SMOOTHLY THEREAFTER. WHEN WE'VE MADE, WHATEVER IT IS NOW, 1400 GRANTS OVER CIRM'S LIFE, THAT'S A LOT OF WORK. SO, JEN, THANK YOU TO YOU AND YOUR TEAM.

I WANT TO SAY THAT WHILE WE SPEND A LOT OF TIME AT THE LEADERSHIP TEAM LEVEL DEVELOPING STRATEGY, WORKING THROUGH OPERATIONS ISSUES, NONE OF THAT WOULD BE POSSIBLE WITHOUT THE HARD WORK OF EVERYBODY ON ALL THE MEMBERS OF THE LEADERSHIP'S TEAMS WHO PUT IN MANY, MANY HOURS TO INFORM MANAGEMENT ON WHAT'S GOING ON AND TO MAKE THINGS WORK. SO THIS IS A REAL TEAM EFFORT AGAIN.

SO WITH THAT, I WOULD LIKE TO TURN IT OVER TO ROSA TO COME UP AND TALK TO YOU ABOUT OUR REPRIORITIZING EFFORT. AND AT THE END OF HER PRESENTATION, SHE AND I WILL TAKE Q AND A ON THE SUBJECT. AND CHECKING WITH MR. TOCHER, WE WILL HAVE ANY PUBLIC COMMENT ON THAT PARTICULAR REPORT THEREAFTER RATHER THAN HAVING PEOPLE WAIT TO THE END OF THE MEETING FOR THE CUSTOMARY PUBLIC COMMENT PERIOD. THANK YOU. ROSA.

DR. CANET-AVILES: THANK YOU, J.T. I WANT TO THANK ALSO MY COLLEAGUES BECAUSE LEADING THIS PROCESS IS NOT POSSIBLE WITHOUT THE COLLABORATION OF THE WHOLE LEADERSHIP TEAM WHO'S HERE WITH US TODAY

BETH C. DRAIN, CA CSR NO. 7152

AS WELL.

SO AS J.T. MENTIONED, THIS STRATEGIC ALLOCATION FRAMEWORK IS PART OF THE REEXAMINATION THAT HAS BEEN TAKING A NUMBER OF FORMS. AND NEXT SLIDE. I'M JUST WARMING UP. COFFEE IS KICKING IN.

SO ULTIMATELY THE STRATEGIC PRIORITIZATION FOR CIRM IS A TESTAMENT TO OUR PROFOUND DEDICATION TO OUR MISSION, WHICH IS HERE AND ULTIMATELY IS TRANSFORMING HEALTHCARE THROUGH THE POWER OF REGENERATIVE MEDICINE. AND AS MANY OF YOU HAVE ASKED BEFORE, THIS IS STILL WITHIN THE STRATEGIC PLAN. THIS IS IN THE CONTEXT OF OUR STRATEGIC PLAN.

AND WHAT WE ARE PRESENTING TODAY IS THE PROCESS FOR A STRUCTURED AND DATA-DRIVEN APPROACH TO PRIORITIZE RESOURCE ALLOCATION AND PROVIDE FURTHER GRANULARITY IN TERMS OF IMPACT GOALS AND THEIR SUCCESS MEASURES, WHICH WAS BROUGHT UP BY STEVE JUELSGAARD THE OTHER DAY DURING THE GOVERNANCE SUBCOMMITTEE, AND ULTIMATELY LEAD TO RECOMMENDATIONS FOR CONTINUED IMPLEMENTATION OF OUR STRATEGIC PLAN TO GUIDE US.

IN TERMS OF BACKGROUND, WHAT IS THE BACKGROUND THAT LED TO THIS FRAMEWORK? THE FRAMEWORK WAS DEVELOPED OVER THE PAST FEW MONTHS AND IS POISED TO GUIDE CIRM IN MAKING INFORMED DECISIONS

BETH C. DRAIN, CA CSR NO. 7152

REGARDING THE DISTRIBUTION OF FUNDING, AS J.T. MENTIONED. AS A PIONEER ENTITY THAT WE ARE IN THE REALMS OF STEM CELL RESEARCH AND REGENERATIVE MEDICINE, OUR LEGACY IS FOUNDED IN THE ADVANCEMENT OF SCIENTIFIC DISCOVERY TOWARDS TANGIBLE MEDICAL BREAKTHROUGHS AND ULTIMATELY THERAPIES IN THE MARKET.

THE INSTITUTE HAS BEEN INSTRUMENTAL IN FUNDING CUTTING EDGE RESEARCH, DEVELOPING A ROBUST INFRASTRUCTURE AS WE'VE SEEN OVER THE YEARS, AND PIONEERING EDUCATIONAL PROGRAMS LIKE KELLY WILL BE PRESENTING ONE OF THEM TODAY, AND THE VIDEO IS GOING TO TALK ABOUT THE OUTREACH THAT WE ARE DOING ALSO IN TERMS OF EDUCATIONAL PROGRAMS, AS WELL AS CATALYZING THE PROGRESSION FROM REGENERATIVE MEDICINE RESEARCH TO PRACTICAL APPLICATIONS.

AS WE WILL SEE IN THE NEXT SLIDES, THE FIELD OF REGENERATIVE MEDICINE HAS GROWN EXPONENTIALLY IN THE PAST 17 YEARS. AND CIRM HAS LIMITED, NOT LIMITED, BUT FINITE RESOURCES AND FUNDING. AS A CONSEQUENCE OF THIS, DURING THE LAST SEPTEMBER SCIENCE SUBCOMMITTEE, BOARD MEMBER FISCHER-COLBRIE PROVIDED A PRIORITIZATION DISCUSSION. HE KICKED OFF THE PRIORITIZATION DISCUSSION. AND THAT LED TO THE CONCLUSION THAT WE

BETH C. DRAIN, CA CSR NO. 7152

NEED A STRATEGIC PLAN TO DEVELOP THIS -- TO IMPLEMENT THIS PRIORITIZATION.

DURING THAT MEETING, THE BOARD ASKED CIRM TO LEAD THE EXERCISE OF THIS STRATEGIC ALLOCATION FRAMEWORK. NOTE THAT WE DON'T CALL IT PRIORITIZATION ANY LONGER. WE CALL IT A STRATEGIC ALLOCATION FRAMEWORK, WHICH IS THE SAME THING, BUT A LITTLE BIT MORE IN THE CONTEXT OF WHAT WE ARE DOING.

SO OVER THE PAST MONTH, AS J.T. MENTIONED, OUR TEAM HAS BEEN DEVELOPING A FRAMEWORK TO PROVIDE THESE STRATEGIC RECOMMENDATIONS FOR FUNDING ALLOCATION, AND THE FRAMEWORK PRESENTED REFLECTS A COMPREHENSIVE STRATEGY THAT DEFINES THE RATIONALE, THE OBJECTIVES, THE SCOPE, AND THE TIMELINE NECESSARY TO ESTABLISH CIRM'S FUTURE COURSE OF ACTION. THIS STRATEGY IS GOING TO SERVE AS A ROADMAP FOR CIRM TO MAXIMIZE ITS IMPACT AND CONTINUE ITS PIVOTAL ROLE OF TRANSFORMING HEALTHCARE THROUGH REGENERATIVE MEDICINE FOR CALIFORNIA AND ULTIMATELY THE WORLD AS WELL.

THE STRATEGIC ALLOCATION FRAMEWORK THAT WE ARE PRESENTING IS A STRUCTURE, AS WE SAID AND WE ARE REPEATING HERE, AS A DATA-DRIVEN APPROACH TO PRIORITIZE OUR RESOURCE ALLOCATION AND PROVIDE FURTHER GRANULARITY IN TERMS OF IMPACT GOALS AND

BETH C. DRAIN, CA CSR NO. 7152

SUCCESS MEASURES ULTIMATELY LEADING TO THE RECOMMENDATIONS THAT COULD BE COMING IN SEPTEMBER AS WE WILL SHOW IN THE TIMELINE FOR CONTINUED IMPLEMENTATION OF OUR STRATEGIC PLAN.

THE DOCUMENT WHICH WAS PROVIDED AS BACKGROUND FOR TODAY'S MEETING IS STRUCTURED AS FOLLOWS. WE HAVE A BACKGROUND ON RATIONALE, WE TALK ABOUT THE REMAINING FUNDS THAT WE HAVE FOR ALLOCATION, AND WHAT HAS BEEN SPENT ALREADY, WHAT'S THE REGENERATIVE MEDICINE LANDSCAPE, WHICH I'M GOING TO GO OVER VERY QUICKLY IN ONE SLIDE. AND THEN WE EVALUATE WHAT'S THE CIRM IMPACT UP TO DATE, WHICH HELPS US DEFINE WHERE ARE WE GOING NEXT, RIGHT, WHICH WE HAD TO REDEFINE AS WELL. AND ULTIMATELY WE TALK ABOUT THE PROCESS OF THE FRAMEWORK. WHAT DOES THAT CONSIST? AND THEN THE PROPOSED TIMELINE, WHICH WILL LEAD TO THE OUTPUT WHICH WOULD BE THE RECOMMENDATIONS FOR STRATEGIC PRIORITIES.

THE INITIAL THINKING IS THAT WE COULD BE ABLE PROVIDE THESE RECOMMENDATIONS IN SEPTEMBER. AND THE TIMELINE WILL SHOW THE STEPS GETTING TO THERE AND OUR INTERACTION WITH THE BOARD TO GATHER FEEDBACK AND UPDATE YOU ON OUR PROCESS.

SO WHAT'S THE BUDGET REMAINING? THIS SLIDE PROVIDES A SNAPSHOT OF CIRM'S REMAINING FUNDS

BETH C. DRAIN, CA CSR NO. 7152

FOR THE STRATEGIC ALLOCATION. THE TOTAL RESEARCH BUDGET AUTHORITY FROM PROP 71 AND PROP 14 IS \$7.64 BILLION. THIS IS NET OF OPERATIONAL AND COMPLIANCE OVERSIGHT COSTS FROM THE 8.5 BILLION INITIALLY ALLOCATED BY PROPOSITION 71 AND 14 RESPECTIVELY, \$3 BILLION AND 5.5 BILLION RESPECTIVELY.

IN TERMS OF CURRENT FUND ALLOCATION, CIRM HAS A REMAINING BALANCE OF \$3.54 BILLION. THIS BALANCE RESULTS FROM ACCOUNTING FOR ALL EXPENDED SCHEDULED PAYMENTS AND APPROVED ALLOCATIONS TO DATE. WITHIN THIS REMAINING BALANCE, SPECIFIC EARMARKS HAVE BEEN MADE TO ADDRESS CRITICAL AREAS OF NEED. ONE OF THEM IS THE NEURO ALLOCATION. WE HAD INITIALLY \$1.5 BILLION. OF THOSE, IF WE ACCOUNT FOR THE ADMINISTRATIVE AND COMPLIANCE, THE BUDGET AUTHORITY FOR NEURO WAS \$1.38 BILLION. AND OF THOSE WE HAVE CURRENTLY 1.11 BILLION LEFT FOR ALLOCATION. WE ALSO HAVE THE ACCESSIBILITY AND AFFORDABILITY INITIATIVE, AND IT HAS \$93.56 MILLION ALLOCATED CURRENTLY LEFT FOR THAT INITIATIVE.

SO THIS FINANCIAL REPORT SETS THE STAGE FOR CIRM TO DELIBERATE ON STRATEGIC ALLOCATION DECISIONS THAT WILL SHAPE THE FUTURE OF REGENERATIVE MEDICINE, BALANCING THE DRIVE FOR INNOVATION WITH AN IMPERATIVE FOR TREATMENTS TO BE BOTH ACCESSIBLE AND

BETH C. DRAIN, CA CSR NO. 7152

AFFORDABLE .

NOW, IN TERMS OF THE LANDSCAPE THAT I WAS MENTIONING, SO THIS IS THE SLIDE THAT REPRESENTS THE FINITE FUNDS. AND THIS IS THE LANDSCAPE THAT SHOWS HOW THE REGENERATIVE MEDICINE FIELD HAS BEEN EXPERIENCING A PROFOUND AND RAPID EXPANSION, WHICH LEADS TO A VERY HIGH DEMAND AS WELL. SO THE DATA SHOWN HERE IS CAPTURED FROM THE ALLIANCE FOR REGENERATIVE MEDICINE ANNUAL DATA REPORT FROM 2023 AND THE AMERICAN SOCIETY OF GENE AND CELL THERAPY, ASGT, QUARTERLY REPORT OF Q2 2021. AND THE SLIDE UNDERSCORES THE EXPONENTIAL GROWTH WITNESSED IN THE SECTOR SINCE 2005, MARKING A TRAJECTORY OF ACCELERATED ADVANCEMENTS IN THE STEM CELL AND GENETIC THERAPIES. THIS EXPANSION IS EVIDENT ACROSS VARIOUS PARAMETERS THAT YOU CAN SEE IN THE SLIDES. THE NUMBERS ARE PROBABLY VERY SMALL, SO I HAVE HERE A LITTLE BIT OF WHAT THIS REPRESENTS.

THERE IS A SURGE IN THE NUMBER OF COMPANIES ENGAGED IN THESE THERAPIES. THERE'S AN EXPANDING PORTFOLIO OF PRODUCTS AND A GROWING NUMBER OF ACADEMIC FACULTY DEDICATED TO THE RESEARCH AND A ROBUST PIPELINE OF RESEARCH PROJECTS AND CLINICAL TRIALS.

SO THE FIRST CHART ON THE LEFT ILLUSTRATES

BETH C. DRAIN, CA CSR NO. 7152

A STEEP INCREASE FROM 2005 TO 2022 IN PUBLICATIONS RELATED TO STEM CELLS, GENE THERAPY, OR CELL THERAPY WHICH IS A TESTAMENT TO THE GROWING INTEREST AND ADVANCEMENTS IN THESE FIELDS.

THE MIDDLE AND RIGHT GRAPHS DELINEATE THE EXPANDING PIPELINES FOR GENE THERAPIES AND NON-GENETICALLY MODIFIED GENE THERAPIES CORRESPONDINGLY. SO THE MIDDLE IS GENE THERAPIES, THE OTHER IS NON-GENETICALLY MODIFIED CELL THERAPIES. EACH BAR REPRESENTS A SNAPSHOT OF ACTIVE PROGRAMS AND REFLECT NOT ONLY THE INITIATION OF PRECLINICAL AND PHASE 1 TRIALS, BUT ALSO THE PROGRESSION TO MORE ADVANCED STAGES OF CLINICAL TESTING.

SO THIS LANDSCAPE BRINGS TO THE FOREFRONT A COMPELLING NARRATIVE. THE FIELD OF REGENERATIVE MEDICINE IS NOT JUST GROWING. IT'S THRIVING AT A PACE THAT REQUIRES A STRATEGIC AND THOUGHTFUL ALLOCATION OF FUNDS. WITH SUCH A FERTILE GROUND FOR DISCOVERY AND DEVELOPMENT, THE IMPLICATIONS FOR HEALTHCARE ARE IMMENSE. AND THE IMPLICATIONS FOR CIRM ARE ALSO VERY BIG, UNDERSCORING THE IMPORTANCE OF CIRM'S ROLE IN THIS STRATEGICAL FUNDING OF THE MOST PROMISING AVENUES FOR RESEARCH THAT CAN TRANSLATE INTO LIFE-ALTERING TREATMENTS FOR

BETH C. DRAIN, CA CSR NO. 7152

PATIENTS.

NOW, WHAT HAS BEEN THE IMPACT TO DATE AT CIRM? THE IMPACT TO DATE IS SHOWN IN THIS SLIDE. WE HAVE FOUR MAIN STRATEGIC -- KEY AREAS OF EMPHASIS. THE FIRST ONE IS THE DEVELOPMENT OF CELL AND GENE THERAPIES. CIRM IS CURRENTLY COMMITTED TO ADVANCING CELL AND/OR GENE THERAPIES FROM RESEARCH TO MARKET THROUGH CIRM'S CLINICAL TRIAL FUNDING MODEL AND CLINICAL INFRASTRUCTURE, EMPHASIZING NOT ONLY PATIENT ACCESS, BUT ALSO THE SCALING OF MANUFACTURING PROCESSES TO MEET CLINICAL DEMAND.

THE SECOND POINT OF EMPHASIS IN OUR IMPACT IS COLLABORATIVE NETWORKS FOR DISCOVERY RESEARCH. CIRM IS FOSTERING COLLABORATIVE NETWORKS TO UNITE MULTIDISCIPLINARY TEAMS AND LEVERAGE EXTERNAL OPPORTUNITIES, ENHANCING OUR UNDERSTANDING OF DISEASE MECHANISMS AND LEADING TO THE DISCOVERY OF NOVEL TARGETS AND BIOMARKERS THAT WILL PUSH THE BOUNDARIES IN TREATMENT DEVELOPMENT FOR THESE DISEASES.

AND IN LINE WITH PROP 14'S EMPHASIS IN NEURO, CIRM HAS PRIORITIZED THIS FIRST COLLABORATIVE NETWORK FOR DISCOVERY RESEARCH IN THE REALM, IN THE CONTEXT OF NEUROPSYCHIATRIC DISORDERS, BUT THERE IS A POSSIBILITY FOR EXPANSION TO OTHER DISEASES AS

BETH C. DRAIN, CA CSR NO. 7152

WELL.

TRAINING AND WORKFORCE DEVELOPMENT.

CIRM'S, AS YOU KNOW, EDUCATIONAL INITIATIVES HAVE SET A NEW STANDARD FOR OUR WORKFORCE DEVELOPMENT IN REGENERATIVE MEDICINE, CREATING A COMPREHENSIVE NETWORK THAT CONNECTS TRAINING WITH REAL-WORLD APPLICATION AND ALSO PROVIDING OPPORTUNITIES TO UNDERSERVED AND UNDERREPRESENTED POPULATIONS IN CALIFORNIA AND ULTIMATELY THE ADVANCEMENT OF REGENERATIVE MEDICINE TECHNOLOGIES. WE'VE BEEN SUPPORTING INITIATIVES WHICH ADVANCE OUR UNDERSTANDING OF COMPLEX DISEASES, AND WE HOPE TO BE ABLE TO TRANSLATE THE SCIENTIFIC EXCELLENCE INTO SUBSTANTIAL PATIENT BENEFITS.

AS IT STANDS, THIS IS HOW WE SEE OUR IMPACT MOVING FORWARD. AND AS PART OF THE RECOMMENDATIONS, WE HAVE REEVALUATED ALREADY THIS IMPACT AS PART OF THE PROCESS. AND THAT HAS LED TO THE REDEVELOPMENT OF IMPACT GOALS THAT WILL LEAD TO THIS REPRIORITIZATION. SO THIS LINKS NOW TO THE PROCESS.

THE PAST IMPACT, HOW ARE WE SEEING IMPACT MOVING FORWARD? SO THE FOLLOWING IS THE PROCESS THAT OUR TEAM IS INTEGRALLY, AND OUR TEAM IS ALL HERE, INVOLVED FOR THE STRATEGIC ALLOCATION

**133 HENNA COURT, SANDPOINT, IDAHO 83864
208-920-3543 DRAIBE@HOTMAIL.COM**

BETH C. DRAIN, CA CSR NO. 7152

FRAMEWORK. THIS PROCESS BEGINS WITH DEFINING OUR IMPACT GOALS, AS I WAS SAYING, WITH MEASURABLE SUCCESS METRICS. THESE ARE THE BEACONS THAT GUIDE ALL OF OUR EFFORTS AND ARE ALIGNED WITH OUR STRATEGIC PLAN. THESE GOALS ARTICULATE THE DESIRED OUTCOMES AND MILESTONES WE AIM TO ACHIEVE, ENSURING THAT EVERY DOLLAR ALLOCATED MOVES CLOSER TO THE REALIZATION OF OUR MISSION.

FROM THERE THE NEXT PHASE INVOLVES FORMULATING GUIDING QUESTIONS. THAT'S WHERE WE ARE RIGHT NOW AT THE MOMENT. THESE QUESTIONS ARE DESIGNED TO PROBE DEEPLY INTO THE POTENTIAL IMPACT, THE FEASIBILITY, AND ALIGNMENT WITH OUR MISSION. AND THEY SERVE AS A CRITICAL TOOL FOR DECISION-MAKING, HELPING TO CLARIFY OBJECTIVES, AND REFINE OUR STRATEGIC DIRECTION.

THE THIRD PART IS THE DATA COLLECTION AND ANALYSIS. THIS IS A CRITICAL PHASE IN OUR FRAMEWORK. HERE THIS IS THE ONE THAT WILL TAKE THE LONGEST AS WELL. WE ARE GOING TO GATHER COMPREHENSIVE DATA AND CONDUCT A RIGOROUS ANALYSIS TO UNDERSTAND THE LANDSCAPE, EVALUATE THE OPPORTUNITIES, AND ALSO ASSESS RISKS. THIS STEP IS ESSENTIAL TO MAKE INFORMED DECISIONS THAT ARE BACKED BY EMPIRICAL EVIDENCE. AND THIS IS THE POINT WHERE

BETH C. DRAIN, CA CSR NO. 7152

WE WILL BE ACTUALLY HAVING THE DISCUSSION, THE BACK AND FORTH FROM THE SCIENCE SUBCOMMITTEE. WE ARE GOING TO PRESENT THE QUESTIONS. WE WILL BE COMING WITH THE DATA, AND WE WILL BE SAYING ARE YOU IN AGREEMENT? IS THIS GOING -- IF WE COME WITH A RECOMMENDATION BASED ON THESE EMPIRICAL DATA, ARE YOU GOING TO HAVE ENOUGH, OR DO YOU NEED MORE, RIGHT, OR DO YOU NEED LESS? SO THAT'S THE KIND OF RAPPORT THAT WE AIM TO ESTABLISH WITH THE BOARD.

AND, FINALLY, WE WILL ARRIVE TO THE CIRM RECOMMENDATION. THIS IS WHERE THE INSIGHTS FROM OUR ANALYSIS WILL COALESCE INTO STRATEGIC DIRECTIVES. THE GOAL OF THE RECOMMENDATION IS TO STEER INVESTMENTS TOWARDS THE MOST PROMISING RESEARCH AND DEVELOPMENT AREAS WITH THE ULTIMATE GOAL OF MAXIMIZING THE IMPACT FOR CIRM FUNDING, AND ALSO TO FIND WHERE IS OUR NICHE AMONGST THE WORLD OF REGENERATIVE MEDICINE. TOGETHER THIS PROCESS SHOWS OUR COMMITMENT TO ADVANCING THE FIELD OF REGENERATIVE MEDICINE THROUGH STRATEGIC FUNDING ALLOCATIONS THAT ARE BOTH THOUGHTFUL AND IMPACTFUL.

SO THAT'S THE PROCESS. AND NOW TO START, BEFORE WE WENT INTO THE IMPACT GOALS, THE FIRST TWO QUESTIONS WE STARTED FROM WERE: HOW CAN CIRM MAKE THE GREATEST IMPACT ON ITS MISSION? AND HOW MIGHT

BETH C. DRAIN, CA CSR NO. 7152

CIRM EFFECTIVELY ALLOCATE ITS REMAINING \$3.54 BILLION TO MAKE THAT IMPACT? SO THAT'S WHAT STARTED US. WE THEN DEFINED THE IMPACT GOALS. WE ARE DEFINING THE QUESTIONS THAT WILL LEAD US TO THE DATA. AND THEN WE WILL BE ABLE TO MAKE THE RECOMMENDATIONS BASED ON THAT DATA, ULTIMATELY LEADING TO THOSE IMPACT GOALS.

NOW, IN TERMS OF TIMING, RIGHT NOW, AS YOU CAN SEE -- I DON'T KNOW. DO I HAVE A LITTLE -- I CANNOT DO ANYTHING HERE. IT'S OKAY. I'LL JUST DO IT WITH MY WAVES. SO THE 3-26-24 SCIENCE SUBCOMMITTEE WAS A COUPLE OF DAYS AGO. OUR TEAM PRESENTED THIS FRAMEWORK TO THE SCIENCE SUBCOMMITTEE. IT WAS VERY WELL RECEIVED. WE HAD SOME QUESTIONS, BUT THERE WERE NO MODIFICATIONS OF THIS FRAMEWORK AT THE TIME.

THE PLAN COULD BE TO -- I THINK CLAUDETTE SCARED SCOTT. THE PLAN COULD BE TO GET THIS FRAMEWORK TO CONTINUE WITH THE QUESTIONS. AND BETWEEN NOW AND JUNE, WE COULD BE, LIKE, DEVELOPING THE QUESTIONS AND THE DATA, AND WE COULD BE HAVING INTERACTIONS WITH THE SCIENCE SUBCOMMITTEE, FOUR, FIVE, WHATEVER IS NEEDED, IN ORDER TO COME WITH AN UPDATE AT THE BOARD MEETING IN JUNE. OBVIOUSLY THIS IS A VERY SHORT TIMELINE FOR JUNE FOR US TO HAVE A

BETH C. DRAIN, CA CSR NO. 7152

RECOMMENDATION, BUT WE CAN PROVIDE AN UPDATE TO THE BOARD THEN.

AT THAT TIME THERE IS ALSO GOING TO BE AN UPDATE ON THE FLOW CONTROL EVALUATION THAT DR. SAMBRANO IS LEADING WITH THE TEAM. AND WE WILL BE PROVIDING AN INTERIM RESEARCH BUDGET AT THE JUNE. THE REASON WE ARE THINKING OF AN INTERIM OR WE ARE PROPOSING AN INTERIM BUDGET IS BECAUSE IF WE ARE MAKING RECOMMENDATIONS THAT WILL CHANGE THE WAY THAT WE DO OUR PROGRAMS, AND IT'S COMING IN SEPTEMBER, IT DOESN'T MAKE ANY SENSE TO DO A FULL BUDGET, TO PROPOSE A FULL BUDGET BY THEN. HOWEVER, THE OPERATIONAL BUDGET WE WILL BE PROPOSING IT A PRIORI IN JUNE.

NOW, THE RECOMMENDATIONS WILL COME IN SEPTEMBER. AND WITH THOSE RECOMMENDATIONS, OUR MADAM VICE CHAIR ASKED IF WE COULD BE COMING WITH A CONCEPT AS WELL AND CHANGES AT THAT TIME, THAT THE IDEA COULD BE YES, IT'S A LITTLE PACKED, BUT THE IDEA COULD BE THAT WE COULD BE DOING IT THEN.

SO BETWEEN NOW AND THEN, WE WILL BE COLLECTING DATA, ANALYZING, AND INTERACTING WITH THE BOARD IF THE BOARD AGREES WITH THE PLAN.

AND WITH THAT, I WOULD JUST LIKE TO LEAVE IT FOR QUESTIONS UNLESS J.T. HAS ANYTHING ELSE TO

BETH C. DRAIN, CA CSR NO. 7152

ADD THAT I MIGHT HAVE FORGOTTEN.

DR. THOMAS: NOPE. ALL GOOD. THANK YOU, ROSA. ROSA, IF YOU WOULD JUST MENTION SARA'S ROLE HERE.

DR. CANET-AVILES: SARA TAYLOR IN THE PAST HAS BEEN ESSENTIAL IN THE PROJECT MANAGEMENT OF THIS WHOLE ENDEAVOR. SO I WANT TO THANK SARA AS WELL, WHO IS THE PROJECT MANAGER IN OUR TEAM. THANK YOU, SARA.

DR. THOMAS: THE ONLY THING I'D LIKE TO ADD BEFORE WE GET TO Q AND A IS THESE DISCUSSIONS THAT THE WORKING GROUP HAS HAD, WHICH DEAL WITH VERY MEATY ISSUES, WHICH THERE ARE ALWAYS DIFFERENCES OF OPINION, I WANT TO REPORT TO THE BOARD THAT THE GROUP HAS ACTED EXTREMELY COLLABORATIVELY, UNIFORMLY SUPPORTIVELY, AND ARE ALL ON THE SAME PAGE IN TRYING TO MAKE THIS TRANSITION HERE GO AS SMOOTHLY AS POSSIBLE. SO I WANTED EVERYBODY TO KNOW THAT.

DR. CANET-AVILES: THANK YOU, J.T.

CHAIRMAN IMBASCIANI: MR. JUELSGAARD.

MR. JUELSGAARD: YES, ONE OBSERVATION AND THEN ONE QUESTION, ROSA. SO THE FIRST IS YOU TALK ABOUT A REMAINING BUDGET OF 3.54 BILLION; BUT AS YOU TAKE AWAY THE NEURO RESEARCH AND THE ACCESS AND AFFORDABILITY, TRULY WE'RE LEFT WITH 1.40 BILLION OR

BETH C. DRAIN, CA CSR NO. 7152

AREAS OUTSIDE OF THAT, RIGHT?

DR. CANET-AVILES: 2.45.

MR. JUELSGAARD: 2.45. OKAY. MY MATH IS NOT RIGHT THEN.

DR. CANET-AVILES: THAT IS THE EXACT NUMBER IN THE DOCUMENT.

MR. JUELSGAARD: I MISSED A DECIMAL POINT. THE QUESTION IS SO WE HAVE THIS PAUSE THAT'S GOING ON RIGHT NOW IN NEW APPLICATIONS. AND THERE WILL COME A DAY WHEN WE WILL DECIDE THAT THERE ARE GOING TO BE APPLICATIONS THAT WE WILL ACCEPT AND THAT WE WON'T. THAT'S MY SUSPECTED OUTCOME. WE'RE GOING TO NARROW THE FIELD, SO TO SPEAK, RIGHT.

SO ARE WE GOING TO HAVE THIS INTERIM PERIOD WHEN WE SAY, OKAY, WE'RE GOING TO START ACCEPTING APPLICATIONS AND IT'S GOING TO BE AN ALL COMERS APPROACH TO A DAY WHEN WE SUDDENLY NARROW THE FIELD? IF THAT'S THE CASE, DOES THAT MAKE SENSE TO DO IT THAT WAY? OR SO THAT MEANS IF IT DOESN'T, THEN WE THEN HAVE TO ACCELERATE THIS TIMELINE OR WE HAVE TO CONTINUE THE PAUSE BEYOND WHATEVER, THE END OF MAY OR END OF JUNE, WHATEVER WE SAID, TILL WE CATCH UP WITH WHERE WE WANT TO GO. SO HOW ARE WE THINKING ABOUT THAT? ARE WE WORRIED ABOUT THAT?

DR. CANET-AVILES: WE HAD THE SAME

BETH C. DRAIN, CA CSR NO. 7152

QUESTION INTERNALLY. I THINK THAT'S A VERY FAIR QUESTION TO ASK. I THINK IT'S ALSO ABOUT MESSAGING, AND I SHOULD PROBABLY LEAD TO OUR PRESIDENT BECAUSE HE --

DR. THOMAS: SO, STEVE, OUR THINKING ON THIS IS REMEMBER THAT BY THE TIME WE GET TO JUNE, AGAIN AT WHICH POINT IT IS CERTAINLY OUR HOPE THAT THE BOARD DECIDES THAT'S THE TIME TO REINSTITUTE RECEIPT OF APPLICATIONS, THAT WE WILL HAVE COMPLETED DR. SAMBRANO'S REVIEW AND UPDATE OF PROCESSES THAT WILL BE IN PLACE FOR THE REVIEW PROCESS WHICH WILL GOVERN WHAT COMES IN AT THAT POINT.

HAVING SAID THAT, IF WE ARE NOT TO START GETTING APPLICATIONS BACK AT THAT POINT, WE'RE GOING TO GO ANOTHER THREE MONTHS OFF THE MARKET, WHICH I DON'T THINK IS SOMETHING THAT WE WOULD RECOMMEND. WE HAVE, FOR EXAMPLE, A NUMBER OF PROGRESSION EVENT APPLICATIONS THAT WE WOULD LIKE TO ATTEND TO SOONER RATHER THAN LATER. AND ALTHOUGH THE TIMING OF THIS IS A LITTLE BIT UNUSUAL, I THINK IT'S SOMETHING THAT WILL WORK. IT WILL BE STILL AT THAT POINT ALL COMERS THROUGH THE REPRIORITIZING VOTE IN SEPTEMBER, BUT WE BELIEVE THAT THAT'S THE BEST COURSE RATHER THAN BEING OUT OF THE MARKET, SO TO SPEAK, FOR ANOTHER THREE MONTHS.

BETH C. DRAIN, CA CSR NO. 7152

DR. CANET-AVILES: COULD WE HAVE A COMPROMISE AND FOCUS ON THE -- OR ANOTHER WAY COULD BE TO FOCUS ON THE ONES -- TO LET IN THE ONES THAT ARE IN THE PIPELINE, WHICH MORE OF THEM ARE RARE DISEASES, AND THAT THEY ARE PART OF OUR PIPELINE AS ABLA CREASEY HAS BEEN A TALKING ABOUT?

DR. THOMAS: I THINK THE -- I WOULD SUGGEST THAT WE NOT MAKE ANY DECISIONS ON THIS TODAY, BUT THAT'S ABSOLUTELY A VERY VALID QUESTION TO BE REVISITED AS THE SCIENCE SUBCOMMITTEE MEETS IN THE NEXT FEW MONTHS AND THE BOARD MEETS IN JUNE.

CHAIRMAN IMBASCIANI: OKAY. I HAVE QUESTIONS FROM FIRST SHLOMO AND THEN FRED FISHER AND THEN ANNE-MARIE.

DR. MELMED: I THINK JUELS RAISES A VERY IMPORTANT POINT, WHICH CAN ACTUALLY BE BROADENED. DID YOU CONSIDER DURING THIS INTERIM PERIOD, WHICH MAY BE LONGER THAN ANY OF US WISH TO ANTICIPATE, FOR GOOD REASON, SHOULD WE CONSIDER HAVING AN EMERGENCY FUND? SO SOMEBODY HAS REALLY A HOT TOPIC. THEY'RE IN THE MIDDLE OF A CLINICAL TRIAL AND THINGS LOOK REALLY GOOD, THEY'RE ABOUT TO EMBARK ON A PHASE 3 OR THEY'RE ABOUT TO FINISH A PHASE 3 TRIAL. SHOULD WE HAVE AN EMERGENCY FUND SET ASIDE FOR SPECIAL CIRCUMSTANCES WHICH MEET CERTAIN VERY RIGOROUS

BETH C. DRAIN, CA CSR NO. 7152

CRITERIA?

DR. CANET-AVILES: WE COULD. WELL, I WAS GOING TO DELEGATE TO J.T.

DR. THOMAS: I'LL ANSWER THAT. SO WE CERTAINLY COULD CONSIDER THAT. THE ISSUE IS ONCE YOU START DOING THAT FOR SOMEBODY, YOU'RE OPENING THE DOORS.

DR. MELMED: WE SHOULD HAVE PREDETERMINED, RIGOROUS SCIENTIFIC CRITERIA WHICH WOULD JUSTIFY THAT.

DR. CANET-AVILES: BUT WE HAVE THE GRANTS WORKING GROUP, WHICH IS ANOTHER OF THE BOTTLENECKS THAT WE HAVE RIGHT NOW. SO WE WOULD BE IN THE SAME PREDICAMENT ALL OVER AGAIN. RIGHT NOW AS IT IS, WE HAVE A VERY -- I'M LOOKING AT MY COLLEAGUES. SO PLEASE SPEAK. BUT WE HAVE A VERY OVERLOADED SYSTEM, RIGHT. IF WE ADD ONE OF THESE THINGS, WE HAVE TO DO IT VERY WELL. AND TO DO IT WELL, YOU HAVE PUT THE INFRASTRUCTURE, THE MANPOWER, THE TIME, THE RESOURCES, AND THAT MAKES US RESHIFT THE PROCESSES WHICH ARE ALREADY OVERLOADED. SO I THINK IT COULD BE VERY HARD TO DO THIS.

DR. THOMAS: I THINK, SHLOMO, IT'S TOTALLY A GOOD QUESTION. AND IF OTHER MEMBERS OF THE BOARD WOULD LIKE TO REACT TO THAT, IT'S SOMETHING THAT WE

BETH C. DRAIN, CA CSR NO. 7152

HAVE THOUGHT ABOUT, BUT FOR THE REASONS WE'RE RECOMMENDING STICKING TO THE PROCESS THAT WE HAVE IN PLACE IN COMING BACK IN JUNE. BUT OTHER MEMBERS OF THE BOARD PLEASE COMMENT ON THAT IF YOU WOULD.

CHAIRMAN IMBASCIANI: I HAVE FRED FISHER TO COMMENT.

DR. FISHER: SO, FIRST, I JUST WANT TO REINFORCE J.T.'S COMMENTS AT THE TOP. BUT WE ARE FORTUNATE TO HAVE THE STAFF THAT WE HAVE. AND, J.T., YOU'VE DONE A GREAT JOB OF TRANSITIONING INTO YOUR ROLE AND, AS PART OF THAT, REALLY BRINGING THE STAFF TOGETHER IN A WAY THAT WE CAN ALL BE PROUD OF. AND I'M PERSONALLY GRATEFUL FOR THE EXPERTISE THAT EXISTS WITHIN THE STAFF.

I HAD TWO OTHER. I THINK I'M A CONSERVATIVE WHEN IT COMES TO THE PAUSE AND THE DEVELOPMENT OF A NEW PROCESS. WE'RE SORT OF A VICTIM OF OUR OWN SUCCESS IN TERMS OF GOING VERY QUICKLY INTO A PERIOD WHERE IT'S NO LONGER A QUESTION OF WHETHER OR NOT PEOPLE KNOW ABOUT CIRM AND CIRM FUNDING. WE'RE GETTING INUNDATED WITH PROPOSALS. AND THE INFRASTRUCTURE REQUIRED TO DEAL WITH THAT IS EXTRAORDINARY. AND I'M NOT SURE THAT WE HAVE IT YET, BUT WE DEFINITELY NEED IT JUST TO PROCESS THE APPLICATIONS THAT WE HAVE.

BETH C. DRAIN, CA CSR NO. 7152

SO I'M NOT A FAN OF DIVERTING FUNDS OR CHANGING THE TIMELINE AT THIS POINT FOR THE PAUSE. IN FACT, IF IT WAS NECESSARY FOR THE PAUSE TO CONTINUE TO ALLOW YOUR PROCESS TO COME TO A CONCLUSION THAT THE BOARD COULD ULTIMATELY VOTE ON, I WOULD BE IN FAVOR OF THAT. WE HAVE TO TAKE THE LONG VIEW WHEN IT COMES TO THE KINDS OF CHANGES THAT ARE BEING PROPOSED BECAUSE CIRM WILL BE HERE FOR A WHILE LONGER. AND I THINK WE OUGHT TO MAKE SURE THAT WHATEVER WE DO GOING FORWARD IS THE RESULT OF A THOUGHTFUL AND DELIBERATIVE PROCESS THAT WE CURRENTLY HAVE UNDER WAY, AND WE SHOULD LET IT COME TO ITS NATURAL CONCLUSION.

THE LAST COMMENT IS OF THE THREE SLIDES THAT YOU SHOWED ON ONE PAGE, THE FIRST SLIDE, THE ONE THAT SHOWED PUBLICATIONS, ACTUALLY SAW A DIP IN THE PRIOR TWO YEARS, IN THE LAST TWO YEARS.

DR. CANET-AVILES: MY HUSBAND SAW THAT TOO LAST NIGHT. I HAVE TO LOOK IT UP. SO THANK YOU, DOUGLAS. IT WAS COVID. IT WAS THE YEARS OF COVID BECAUSE IT WAS '20 TO '22, WHICH IS WHEN A LOT OF THE LABS COULD NOT DO RESEARCH.

DR. FISHER: IT'S LESS TO DO WHY THE DIP, AND COVID IS AN EASY EXPLANATION, AND MORE TO DO WITH THE EXTENT TO WHICH WE RELY ON PUBLISHED DATA

BETH C. DRAIN, CA CSR NO. 7152

TO INFORM OUR GRANTMAKING PROCESS. AND IT'S UNCLEAR TO ME, AS SOMEONE WHO HAS BEEN INVOLVED IN COUNTLESS GRANT APPLICATION REVIEWS, THAT THE EXISTENCE OR LACK THEREOF OF PUBLICATIONS HASN'T REALLY BEEN SOMETHING I'VE BEEN AWARE OF. BUT IT OCCURS TO ME THAT AS PART OF THE PROCESS, THERE'S A QUESTION ABOUT WHETHER OR NOT OR TO WHAT EXTENT HAVING PUBLISHED DATA SUPPORTING THE WORK THAT WE'RE ABOUT TO FUND SHOULD BE PART OF THE PROCESS THAT YOU ULTIMATELY RECOMMEND. THANK YOU.

DR. CANET-AVILES: THANK YOU, FRED. THAT'S A VERY GOOD QUESTION. SO THE LAST -- DO YOU MIND PUTTING THE SLIDE BACK. IT'S NO. 7.

SO THE LEFT GRAPH WAS ABOUT PUBLICATIONS, BUT THE OTHER TWO GRAPHS ARE DELINEATING CLINICAL TRIALS FOR GENE AND CELL THERAPIES. SO YOU HAVE A GOOD POINT THERE, THAT IF WE RELY ONLY ON ACADEMIC PUBLICATIONS, THAT'S NOT RATIONAL. THE ONLY REASON WE ADDED THIS INFORMATION WAS TO SHOW THAT THE LANDSCAPE OF REGENERATIVE MEDICINE IN GENERAL IS BASICALLY EXPLODING, HAS BEEN EXPLODING OVER THE PAST YEARS.

AND ONE OF THE THINGS IS RESEARCH, WHICH WE CAN ONLY MEASURE WHEN IT'S NOT RESEARCH THAT HAS ALREADY LED TO A DEVELOPMENT CANDIDATE GOING INTO

BETH C. DRAIN, CA CSR NO. 7152

CLINICAL TRIALS. WE CAN ONLY MEASURE BY THE ACTIVITY OF PUBLICATIONS, BUT WE ALSO NEED TO MEASURE -- NOT THIS ONE ACTUALLY. IT'S THE ONE WITH THE GRAPH. THIS ONE.

BUT THE OTHER ONE WAS THE GENE THERAPY PIPELINE AND THE NON-GENETICALLY MODIFIED CELL THERAPY PIPELINE. AND IT WAS SHOWING THE PRECLINICAL, THE PHASE 1 CLINICAL TRIALS, PHASE 2, PHASE 3, AND THEN PREREGISTRATION. SO THAT'S ANOTHER ONE OF THE MEASURES.

NOW, YOUR POINT COMES TO REINFORCING THE FACT THAT OUR PROCESS NEEDS TO BE BASED ON EMPIRICAL DATA AND FACTS. AND THAT WE WILL BE COMING TO YOU AT THE SCIENCE SUBCOMMITTEE TO FIGURE OUT IF THAT'S THE DATA THAT MAKES SENSE OR NOT BECAUSE WE DON'T WANT TO COME WITH A JUSTIFICATION AND THEN HAVE TO DISCUSS AGAIN THE DATA THAT WE NEED TO COLLECT TO JUSTIFY THAT RECOMMENDATION. BUT THANK YOU. THAT'S A VERY WELL-MADE POINT.

CHAIRMAN IMBASCIANI: THANK YOU. DR. DULIEGE.

DR. DULIEGE: SO, J.T., NICE TO HAVE YOU BACK FULL SPEED AHEAD AT THE HELM THIS TIME OF CIRM. GREAT.

AND, ROSA, YOUR PRESENTATION WAS EXCELLENT

BETH C. DRAIN, CA CSR NO. 7152

IN TERMS OF STRATEGIC THINKING. BUT ALSO IT FEELS THAT WITH YOU THE CIRM TEAM ENTIRELY IS ENERGIZED AND BETTER ALIGNED. THIS COMES THROUGH. THIS IS VERY REAL, A VERY REAL IMPRESSION.

CONGRATS FOR TAKING A STEP TO PAUSE, AND WE REALLY DO THAT IN OUR LIFE. WE TEND TO GO AND MOVE AND MOVE. AND TAKING AN HONEST INTENTIONAL PAUSE TO REFLECT ON STRATEGIC DIRECTION IS AN EXCELLENT AND COURAGEOUS THING TO DO. AND I UNDERSTAND THAT THE OUTCOME OF THAT IS PROBABLY AROUND JUNE. IS THAT THE TIME FRAME?

SO REALLY MY MAIN QUESTION OF OTHERS, BUT THE MAIN QUESTION IS WHEN YOU TALK ABOUT RECOMMENDATIONS FOR STRATEGIC PRIORITIES, IS IT SOMETHING LIKE THE CIRM WILL RECOMMEND THAT EITHER WE FOCUS ON A PARTICULAR TECHNOLOGY OR A FEW AREAS -- DISEASE AREAS, MEDICAL AREAS THAT COULD IMPROVE THE OUTCOME? IS THAT THE KIND OF PRACTICAL RECOMMENDATION THAT YOU INTEND TO MAKE AT A HIGH LEVEL, NOT TO YOU TO COMMIT RIGHT NOW.

DR. THOMAS: ANNE-MARIE, EXCELLENT QUESTION. THAT'S SOMETHING THAT'S GOING TO BE DISCUSSED AS WE GO DOWN THE ROAD. AGAIN, THIS IS ABOUT TODAY JUST THE PROCESS. SO WE ARE NOT PREPARED TO DISCUSS ANYTHING SUBSTANTIVE LIKE THAT.

BETH C. DRAIN, CA CSR NO. 7152

BUT I ASSURE YOU WE WILL AT THE APPROPRIATE TIME.

DR. CANET-AVILES: I TALK A LOT AND HE'S
VERY --

DR. DULIEGE: DON'T SAY THAT, ROSA. THAT
IS NOT TRUE. J.T. CAN TALK A LOT AS WELL.

DR. THOMAS: IS THAT NECESSARY?

DR. CANET-AVILES: I'M MORE EXCITABLE.

DR. DULIEGE: THAT IS NOT CORRECT, ROSA.
THANK YOU. ESSENTIALLY WAIT AND SEE, ANNE-MARIE,
RIGHT?

CHAIRMAN IMBASCIANI: THANK YOU. THE
CHAIR RECOGNIZES DR. LEVITT.

DR. LEVITT: SO THIS IS A QUESTION FOR
YOU. THERE'S A CONVERGENCE OF LOTS OF THINGS GOING
ON, RIGHT. AND FOR ANY ORGANIZATION, IT DOESN'T
STOP AND PAUSE AND SAY, OKAY, WE'RE GOING TO DEAL
WITH ONE THING AT A TIME. THINGS ARE DONE IN
PARALLEL, BUT THERE NEEDS TO BE SOME CONVERGENCE AT
SOME TIME. SO WHAT I'M PARTICULARLY INTERESTED IN,
WE HAVE A SEARCH GOING ON FOR THE PRESIDENT AND CEO.
AND WE HAVE THIS PLANNING, WHICH IS GOING TO BE
MOVING AT A RELATIVELY FAST RATE, HOW DO YOU SEE
THESE INFORM EACH OTHER BECAUSE THE CANDIDATES
LOOKING AT THIS JOB ARE GOING TO WANT TO HAVE A
SENSE OF THE BREADTH OF WHAT THEIR RESPONSIBILITIES

BETH C. DRAIN, CA CSR NO. 7152

AND IMPACT ARE GOING TO BE. THAT'S WHAT ANYONE WOULD WANT TO KNOW ABOUT.

AND SO HOW IS THIS GOING TO BE COMMUNICATED AND UTILIZED, AND ARE YOU OR YOUR TEAM TALKING TO THE FOLKS WHO ARE DOING THE SEARCH ABOUT HOW TO FIGURE OUT TO MARRY TO SOME EXTENT OR TO PARTNER TO SOME EXTENT THE JOB DESCRIPTION THAT WE HAVE AND HAVE APPROVED FOR THE PRESIDENT AND CEO AND THIS EFFORT?

DR. CANET-AVILES: SO WE ARE NOT CURRENTLY TALKING TO THE COMMITTEE LEADING THIS EFFORT, NOT CURRENTLY. WE'VE TALKED BEFORE. BUT I THINK ONE OF THE ESSENTIAL PARAMETERS DURING THE INTERVIEW OF THIS NEW -- ONE OF THE ESSENTIAL CRITERIA SHOULD BE THAT THE PERSON EMBRACES WHAT THE LEADERSHIP TEAM HAS BEEN DOING. SO I DON'T THINK WE NEED MORE VISION. THERE'S A LOT OF VISION. WHAT WE NEED IS DOING, RIGHT, AND WE NEED SOMEBODY -- SORRY. MARIA.

CHAIRMAN IMBASCIANI: THANK YOU, ROSA. IT MAY HAVE BEEN UNFAIR TO PUT THE BURDEN OF THAT QUESTION ON YOU ACTUALLY. THANK YOU.

I JUST WANT TO REMIND THE BOARD THAT WE IN A SENSE ADDRESSED THIS ISSUE EARLY ON IN SAYING THAT WE WERE NOT GOING TO, MY WORDS NOW, TREAD WATER FOR THE SIX MONTHS, THE CRUCIAL TIME PERIOD WHEN WE

BETH C. DRAIN, CA CSR NO. 7152

STARTED THE PROCESS, THAT THINGS HAD TO EVOLVE. WE WERE FACED WITH ALL OF THE DIFFICULTIES THAT DR. SAMBRANO BROUGHT TO US AND FLOW AND DOLLARS AND WORK, THE ONUS OF THE BURDEN ON YOUR STAFF, THAT WE HAD TO ADDRESS THESE ISSUES, ISSUES THAT OUR INTERIM PRESIDENT HAS GOT SECURELY IN HAND. AND WE'RE PROGRESSING.

YES, ANY PERSON SERIOUSLY INTERESTED IN THE JOB OF PRESIDENT WILL WANT TO ASK SERIOUS QUESTIONS ABOUT WHAT AM I GETTING MYSELF INTO TO ADDRESS THESE THINGS, BUT WE ARE MOVING FORWARD.

DR. CANET-AVILES: I THINK THE IMPLICIT QUESTION DR. LEVITT BRINGS IS IS THE NEW PERSON GOING TO THROW WHAT WE ARE DOING RIGHT NOW BECAUSE THIS IS A LOT OF WORK. AND IF WE ARE GOING TO THROW IT, THEN MAYBE WE NEED TO THINK ABOUT.

DR. LEVITT: THE QUESTION WAS NOT TO QUESTION THE PROCESS THAT WE'VE HEARD ABOUT IN THAT. I THINK THOSE OF US ON THE SCIENCE SUBCOMMITTEE ENTHUSIASTICALLY SUPPORT IT. AND FROM THE COMMENTS THAT I'VE HEARD, THE BOARD IS ENTHUSIASTIC ABOUT THIS, AND WE RECOGNIZE, AND YOU HAD THE DATA UP THERE, EARLY 2023, THAT THERE ARE CHALLENGES THAT WE HAVE AS AN ORGANIZATION. AND SOMEBODY SAID, I FORGET WHO IT WAS, WE'RE REAPING WHAT WE SOW. SO WE

BETH C. DRAIN, CA CSR NO. 7152

HAVE, AS ALL ORGANIZATIONS DO, HAVE TO MAKE ADJUSTMENTS.

MY QUESTION WAS IN THE CONTEXT OF TRYING TO MAKE SURE I UNDERSTOOD THAT THERE WAS GOING TO BE SOME COMMUNICATION OR SOME WAY OF SOME STRATEGY THAT WOULD BE USED TO BE ABLE TO COMMUNICATE THE ONGOING ACTIVITY AND PROCESS, NOT TO HALT IT OR HINDER IT OR SLOW IT OR SPEED IT UP OR ANYTHING ELSE. THAT'S REALLY UP TO THE TEAM TO MANAGE FROM MY PERSPECTIVE. BUT TO RAISE THIS ISSUE BECAUSE WE DO HAVE AN ONGOING SEARCH, AND IT'S REALLY IMPORTANT THAT WE HAVE AN UNDERSTANDING OF HOW TO COMMUNICATE WHAT THE TEAM IS DOING IN THAT CONTEXT. THE QUESTION FOR YOU AND THE TEAM NOT FOR HIM.

VICE CHAIR BONNEVILLE: GEORGE WANTS TO ANSWER THAT.

CHAIRMAN IMBASCIANI: GEORGE.

DR. BLUMENTHAL: THANK YOU. ACTUALLY I THINK THAT'S A VERY FAIR QUESTION TO ASK ABOUT THIS PROCESS AND HOW IT INTERACTS WITH THE PRESIDENTIAL SEARCH. AND I THINK THE ANSWER IS, FIRST OF ALL, WE DO LIVE IN A COMPLEX WORLD WHERE MULTIPLE THINGS HAPPEN AT THE SAME TIME. SO WE HAVE TO LEARN TO DEAL WITH IT. AND I THINK THE INTERACTION CAN BE IN MULTIPLE WAYS BETWEEN THE SEARCH AND THIS PROCESS AS

BETH C. DRAIN, CA CSR NO. 7152

IT PROCEEDS.

IN PARTICULAR, OUR GOAL, AS YOU WILL HEAR LATER ON IN THE MEETING FROM KIM, IS TO ACTUALLY BRING TO THE BOARD IN JUNE OUR RECOMMENDATIONS FOR THE NEXT PRESIDENT OF CIRM. SO THAT'S THE TIME SCALE THAT WE'RE STILL LOOKING AT FOR THE PRESIDENTIAL SEARCH.

SO I ANTICIPATE THAT WITH LUCK WE WILL BE MAKING THAT DECISION AT THE BEGINNING OF THE SUMMER BEFORE THIS PROCESS IS COMPLETED. AS A RESULT, I THINK IT'S IMPORTANT, AS WE INTERVIEW CANDIDATES AND AS WE INTERACT WITH CANDIDATES FOR THE POSITION, THAT WE MAKE THEM AWARE OF THE PROCESS SO THAT THEY UNDERSTAND WHAT'S GOING ON AND THAT THEY CAN -- THIS CAN BE A PART OF THE SEARCH PROCESS ITSELF TO SEE HOW WELL THEY CAN WORK WITH OR WITHIN THIS PROCESS.

BUT I WOULD GO A LITTLE BIT FURTHER THAN THAT AS WELL TO POINT OUT THAT THE NEXT LEADER OF CIRM WILL BE SOMEONE WHO HAS TO IMPLEMENT WHATEVER WE DECIDE AS A BOARD. AND IT IS A BOARD DECISION ULTIMATELY FOR WHAT WE DO. SO I REALLY DO HOPE THAT WE CAN USE THE TIME BETWEEN THE APPOINTMENT OF THE NEXT PRESIDENT AND THE TIME WHEN THE BOARD NEEDS TO MAKE A FINAL DECISION TO GET SIGNIFICANT INPUT FROM OUR NEW LEADER OF THE ORGANIZATION SO THAT HE OR SHE

BETH C. DRAIN, CA CSR NO. 7152

WILL FEEL THAT THEY HAVE AN INVESTMENT IN THE SUCCESS OF THIS NEW PLAN THAT WE'RE PUTTING TOGETHER.

SO I THINK THAT THIS CAN ACTUALLY BE ACCOMPLISHED IN A VERY POSITIVE WAY, BUT IT IS -- I THINK THE QUESTION THAT WAS RAISED IS A PERFECTLY FAIR ONE. WE ALWAYS KEEP IN MIND THE FACT THAT WE'RE DOING A PRESIDENTIAL SEARCH AT THE SAME TIME THAT WE'RE DOING THIS REALLOCATION PROCESS. SO I THINK THAT THEY CAN INTERACT, BUT I THINK IT'S IMPORTANT THAT THE NEXT PRESIDENT OF CIRM FEEL THAT THEY HAVE AN IMPORTANT ROLE TO PLAY IN IMPLEMENTING THIS.

CHAIRMAN IMBASCIANI: THANK YOU, GEORGE. DR. BARRETT.

DR. BARRETT: I JUST WANT TO ADD TO GEORGE. I AGREE THAT THE QUESTION IS A PERFECTLY FAIR ONE. AS I WILL REPORT LATER, I THINK THE TYPE OF CANDIDATES THAT WE'RE CURRENTLY ENTERTAINING WILL BE VERY WELL QUALIFIED TO ENGAGE WITH THIS. AND THERE ARE A CERTAIN NUMBER OF BOUNDARY CONDITIONS, AND THIS IS A DATA-DRIVEN PROCESS. SO I FEEL IT IS HIGHLY UNLIKELY THAT ANYBODY COMING INTO THE POSITION WOULD SAY THIS IS ALL WRONG. LET'S THROW IT ALL OUT. THEY MAY WANT TO ASK QUESTIONS. THEY

BETH C. DRAIN, CA CSR NO. 7152

MAY WANT TO HAVE INPUT AND SUGGESTIONS, BUT I REALLY THINK THE CHANCES FOR THEM SAYING THIS IS ALL COMPLETELY WRONG, LET'S START OVER IS ALMOST ZERO.

AND I THINK THE ONLY THING I WILL ADD TO WHAT GEORGE SAID IS THAT THE ONLY THING THAT'S CONSTANT IS CHANGE. WE ARE ALWAYS GOING TO BE CONSIDERING CHANGE. WE HAVE TO BE NIMBLE. WE HAVE TO KEEP THE BUSINESS OF THE INSTITUTION MOVING FORWARD. SO I APPLAUD THE STAFF FOR WORKING SO ACTIVELY ON THIS. I THANK YOU, PAT, FOR RAISING THIS ISSUE, BUT I THINK WE HAVE A WAY FORWARD TO MAKE SURE THAT THESE ALIGN.

DR. LEVITT: I APPRECIATE THE COMMENTS. AND I WOULD -- GEORGE SAID SOMETHING THAT'S REALLY IMPORTANT. IT'S VERY ATTRACTIVE WHEN ONE IS LOOKING AT A SENIOR ADMINISTRATIVE POSITION, IF ONE IS A CANDIDATE, TO SEE THAT THERE IS AN UNBELIEVABLY TALENTED TEAM, WHICH WAS ARTICULATED ALREADY TODAY AND WE KNOW THAT, THAT'S ATTRACTIVE. SO IT WASN'T TO -- IT WAS TO MAKE SURE THAT WE ARE KEEPING THIS ON THE FRONT OF OUR FRONTAL LOBES -- AS A NEUROSCIENTIST I HAVE TO SAY THAT -- AND THAT WE PAY SOME ATTENTION TO THIS BECAUSE I THINK IT'S IMPORTANT TO POINT OUT AND ONE THAT IS A POSITIVE VARIABLE IN TERMS OF ATTRACTING THE VERY BEST.

BETH C. DRAIN, CA CSR NO. 7152

THANKS.

CHAIRMAN IMBASCIANI: THANK YOU, PAT. I HAVE FRED FISHER ON THE LINE.

DR. FISHER: I AM. AND AS A MEMBER OF THE SEARCH COMMITTEE, I CAN TELL YOU THAT MY OWN PRIORITY IS TO FIND SOMEONE WHO'S NOT GOING TO BELIEVE THAT THEY HAVE AN INVITATION TO COME IN AND FIX EVERYTHING THAT'S WRONG. THIS ORGANIZATION IS NOT IN THAT KIND OF SHAPE WHERE IT NEEDS A NEW CEO TO RESET THE TABLE ON WHAT THE ORGANIZATION IS DOING. SO THERE WILL BE NO INVITATION BY THIS PERSON TO COME IN AND FIX EVERYTHING OR CHANGE EVERYTHING. AND, FRANKLY, IF THE PERSON COMES INTO THE POSITION THINKING THEY'RE GOING TO DO THAT UNILATERALLY, THEN WE'VE CHOSEN THE WRONG PERSON FOR THE JOB, WHICH I DON'T EXPECT TO HAPPEN.

SO THE CEO THAT WE'RE GOING TO HIRE IS SOMEBODY WHO KNOWS HOW TO WORK WITH A VERY HIGH PERFORMING TEAM IN A VERY HIGH PERFORMING ORGANIZATION THAT HAS A VERY HIGH PROFILE AND ESTEEM AND WHAT THEY CAN CONTRIBUTE TO THAT, NOT WHAT THEY CAN CHANGE ABOUT THAT. THANKS.

CHAIRMAN IMBASCIANI: THANK YOU, FRED, FOR THE SUCCINCT REMARKS.

I DON'T SEE ANYONE ELSE AT THIS POINT

BETH C. DRAIN, CA CSR NO. 7152

WISHING TO MAKE A COMMENT ON THIS. MR. PRESIDENT.

DR. THOMAS: THANK YOU VERY MUCH, ROSA.
CONGRATULATIONS AGAIN TO EVERYBODY WORKING ON THIS.
THIS IS A HUGE LIFT. AND AS WE SAID, AND AS YOU SAW
HERE FROM THE PRESENTATION, WE'RE GETTING IT DONE.
SO OKAY.

SO NEXT, AS I SAID, I WANTED TO MOVE ON TO
HIGHLIGHT ONE OF OUR GREAT PROGRAMS, WHICH IS GOING
TO BE A PRESENTATION BY DR. SHEPARD ON THE COMPASS
PROGRAM WHICH IS NOW A YEAR INTO IT, AS WELL, AS I
MENTIONED, A SHORT, MOST ENJOYABLE VIDEO, VERY
SHORT, MOST ENJOYABLE VIDEO ON THE EDUCATION
PROGRAMS IN GENERAL. KELLY.

DR. SHEPARD: CAN EVERYONE HEAR ME?

MR. TOCHER: YES, KELLY. WE CAN HEAR YOU.

DR. SHEPARD: OKAY. THANK YOU. GOOD
MORNING, MR. CHAIR, MADAM CHAIR, MEMBERS OF THE
BOARD, CIRM TEAM, AND MEMBERS OF THE PUBLIC. IT'S
MY PLEASURE TO COME HERE TODAY AND GIVE YOU AN
UPDATE ON THE STATE OF OUR NEWEST EDUCATION PROGRAM,
THE COMPASS PROGRAM. I'M GOING TO ASK SOMEBODY TO
ADVANCE THE SLIDES FOR ME TODAY. I'M SORRY I
COULDN'T THERE IN PERSON.

BUT LET ME JUST BEGIN BY GIVING A BRIEF
BIT OF CONTEXT AROUND WHERE THE COMPASS PROGRAM

BETH C. DRAIN, CA CSR NO. 7152

FITS. SO COMPASS WAS ONE OF FOUR CORE EDUCATION PROGRAMS THAT CIRM IS ACTIVELY SUPPORTING. THIS TIMELINE SHOWS CIRM'S ACTIVITIES RANGING FROM THE PASSAGE OF PROPOSITION 71 BACK IN 2004 TO PRESENT. THREE OF THESE PROGRAMS WERE INITIATED UNDER PROPOSITION 71 AND RE-SUPPORTED UNDER PROPOSITION 14 WITH SOME UPDATES. THESE INCLUDE, ACROSS THE TOP, THE CIRM SCHOLARS PROGRAM WHICH SUPPORTS REGENERATIVE MEDICINE TRAINING AND FELLOWSHIPS FOR PREDOCTORAL, POST-DOCTORAL, AND CLINICAL FELLOWS.

THE BRIDGES PROGRAM WHICH SUPPORTS UNDERGRADUATE AND MASTER'S LEVEL STUDENTS IN VARIOUS CALIFORNIA STATE UNIVERSITIES AND COMMUNITY COLLEGES AROUND THE STATE WHO DO FULL-TIME HANDS-ON PAID INTERNSHIPS AS GUESTS AT PARTNERING INSTITUTIONS WHICH ARE MAJOR REGENERATIVE MEDICINE RESEARCH INSTITUTES AND BIOTECHNOLOGY COMPANIES.

AND OUR SPARK PROGRAM WHICH SUPPORTS HIGH SCHOOL INTERNSHIPS IN REGENERATIVE MEDICINE LABORATORIES FOR HIGH SCHOOL STUDENTS AROUND THE STATE.

IN LATE 2022 WE LAUNCHED THE FIRST NEW EDUCATION PROGRAM THAT WAS DEVELOPED UNDER PROPOSITION 14. AND IT'S SPECIFICALLY CREATED TO COMPLEMENT THESE EXISTING PROGRAMS AND EXTEND OUR

BETH C. DRAIN, CA CSR NO. 7152

INVESTMENTS IN CREATING A DIVERSE REGENERATIVE
MEDICINE WORKFORCE FOR CALIFORNIA AND THE WORLD.
NEXT SLIDE.

SO BRIEFLY, COMPASS IS AN ACRONYM FOR
CREATING OPPORTUNITIES THROUGH MENTORSHIP AND
PARTNERSHIP ACROSS STEM CELL SCIENCE. THE OBJECTIVE
OF ALL COMPASS AWARDS IS TO PREPARE A DIVERSE
UNDERGRADUATE STUDENT CADRE FOR CAREERS IN
REGENERATIVE MEDICINE THROUGH THE CREATION OF NOVEL
RECRUITMENT AND SUPPORT MECHANISMS THAT IDENTIFY AND
FOSTER UNTAPPED TALENT. SO THIS IS TARGETING
STUDENTS WHO ARE A LITTLE BIT EARLIER IN THEIR
COLLEGE CAREERS, MAYBE HAPPEN TO CITE THEIR INTEREST
IN RESEARCH, BUT MAY NOT BE AWARE OF ALL THE
DIFFERENT TYPES OF OPPORTUNITIES AND CAREER PATHS
THAT WOULD BE AVAILABLE TO THEM WITH THE RIGHT KIND
OF CONNECTIONS AND THE RIGHT KIND OF TRAINING. SO
WE'RE TARGETING THOSE STUDENTS.

THE PROGRAMS ARE STRUCTURED BY INTEGRATION
WITHIN BACHELOR'S DEGREE PROGRAMS AT COLLEGES OR
UNIVERSITIES THAT HAVE EITHER INTERNALLY ACCESS TO
THEIR OWN REGENERATIVE MEDICINE-RELATED LABORATORIES
AND FACULTY OR BY PARTNERING WITH AN INSTITUTION
THAT CAN OFFER THOSE TYPES OF TRAINING
OPPORTUNITIES. MOST IMPORTANTLY, THESE PROGRAMS

BETH C. DRAIN, CA CSR NO. 7152

CREATE AND SUSTAIN A SUPPORTIVE, INCLUSIVE TRAINING ENVIRONMENT FOR THOSE STUDENTS. NEXT SLIDE PLEASE.

THE WAY THIS IS DONE IS THAT EACH COMPASS PROGRAM HAS SOME KEY ADMINISTRATIVE COMPONENTS.

FIRST AND FOREMOST, CREATING THE BEST TRAINEE EXPERIENCE POSSIBLE IS PROVIDING TWO OR IN SOME CASES THREE YEARS OF SUPPORT THROUGHOUT THEIR UNDERGRADUATE TIME, PROVIDING FOUNDATIONAL COURSES AND OPPORTUNITIES TO DO RESEARCH INTERNSHIPS EITHER OVER THE SUMMER OR PART TIME AS WHAT SUITS THEIR SCHEDULES BEST THROUGHOUT THE ACADEMIC YEAR.

ALL STUDENTS RECEIVE VERY STRATEGIC MENTORING BOTH AT THE INDIVIDUAL LEVEL AND AT THE COHORT LEVEL. NOW, ON THE LEFT AND RIGHT SIDE OF THIS BALANCE, AS YOU CAN SEE, ARE THE TWO KEY ADMINISTRATIVE COMPONENTS THAT ARE UNIQUE TO THE COMPASS PROGRAM. ONE IS THE FOCUS ON OUTREACH AND RECRUITMENT. THERE'S A DEDICATED ROLE IN THE LEADERSHIP OF EACH COMPASS PROGRAM WHO FOCUSES ON DEVELOPING INNOVATIVE NEW STRATEGIES TO IDENTIFY AND RECRUIT STUDENTS FROM UNDERREPRESENTED BACKGROUNDS AND DIVERSE INDIVIDUALS AND ANALYZING THE OUTCOMES OF THE PROGRAM ON A YEARLY BASIS AND ADAPTING PLANS AS NEEDED IN TERMS OF OUTREACH TO TRY TO INCREASE THE DIVERSITY OF OUR FUTURE WORKFORCE.

BETH C. DRAIN, CA CSR NO. 7152

OVER ON THE RIGHT SIDE, THERE'S ANOTHER KEY DEDICATED ROLE IN THESE PROGRAMS WAS DEVELOPING MENTORSHIP PRACTICES. THIS INCLUDES TRAINING OF ALL INDIVIDUALS WHO WILL SERVE AS MENTORS FOR THE STUDENTS AND DEVELOPING SPECIALIZED COHORT ACTIVITIES TO FOSTER AND PROMOTE THE SUCCESS OF THESE STUDENTS AS THEY PROGRESS THROUGH THEIR EDUCATION AND IN THE FUTURE. AND IT'S ALSO VERY IMPORTANT THAT THIS COORDINATOR DEVELOPS A WAY TO DISSEMINATE ANY NEW LESSONS AND OUTCOMES FROM THEIR PROGRAMS AND SHARE THEM BROADLY SO THAT OTHER INSTITUTIONS THAT MAY NOT HAVE THE BENEFIT OF HAVING THEIR OWN COMPASS PROGRAM CAN LEARN AND INCORPORATE SOME OF THESE PRACTICES INTO THEIR OWN PROGRAMS. NEXT SLIDE PLEASE.

SO AS OF THE END OF 2022, CIRM AWARDED 16 COMPASS PROGRAMS THROUGHOUT CALIFORNIA, WHICH YOU SEE DEPICTED ON THIS MAP HERE. YOU CAN SEE THAT THEY ARE HOSTED IN MANY LARGE RESEARCH UNIVERSITIES AS WELL AS SOME STATE COLLEGES AND EVEN IN TWO CASES COMMUNITY COLLEGES, WHICH ARE DEPICTED BY THE PURPLE DOTS, SOLANO COMMUNITY UP IN THE BAY AREA AND MIRACOSTA COMMUNITY COLLEGE DOWN IN THE OCEANSIDE AND SAN DIEGO AREA. NEXT SLIDE PLEASE.

SO OF THE 16 PROGRAMS, WE HAVE JUST

BETH C. DRAIN, CA CSR NO. 7152

RECEIVED THE YEAR ONE PROGRESS REPORTS FOR THE MAJORITY OF THEM. AND WE JUST WANTED TO GIVE YOU A REALLY HIGH LEVEL SNAPSHOT OF WHAT WE'RE SEEING TO DATE. SO IN THE FIRST YEAR WE SAW 116 COMPASS SCHOLARS APPOINTED. WE'RE ALREADY IN THE FIRST QUARTER OF YEAR TWO, AND THAT NUMBER HAS COME UP TO 161 ALREADY. OF THE STUDENTS THAT ARE ENROLLED IN OUR COMPASS PROGRAM, WE KNOW THAT 54 PERCENT OF THEM ARE FIRST GENERATION COLLEGE STUDENTS. AND THEIR AGES RANGE FROM 18 TO 44 YEARS OLD, AND ABOUT 60 PERCENT OF THEM IDENTIFY AS FEMALE.

ON THE LEFT HERE IS A PICTURE OF ONE OF OUR COMPASS SCHOLARS FROM THE YEAR ONE COHORT FROM SOLANO COMMUNITY COLLEGE, DEMARIO GAKE. NEXT SLIDE PLEASE.

JUST TO GO INTO A LITTLE BIT MORE DETAIL ABOUT SOME OF THE DIFFERENT ASPECTS OF DIVERSITY, OVER ON THE LEFT SLIDE, YOU SEE A BREAKDOWN OF THE COMPASS SCHOLARS REPORTED RACIAL AND ETHNIC DIVERSITY. THOSE ARE DEPICTED IN THE ORANGE BARS, AND THE COMPARATOR IN THE BLUE BARS IS THE AVERAGE OF THE UC UNDERGRADUATE CENSUS FROM FALL OF 2023. SO THESE NUMBERS ARE SMALL, AND THIS IS VERY EARLY DAYS; BUT, AS YOU CAN SEE, THE COMPASS STUDENTS ARE REFLECTING THE DIVERSITY, GENERALLY SPEAKING, OF THE

BETH C. DRAIN, CA CSR NO. 7152

CAMPUSES FROM WHICH THEY'RE DRAWN, AND IN SOME CASES, ESPECIALLY IN AFRICAN-AMERICAN AND HISPANIC CATEGORIES, THE LEVELS OF REPRESENTATION OF COMPASS SCHOLARS IS MUCH CLOSER TO WHAT IT IS IN THE STATE OVERALL. SO SO FAR WE ARE SEEING DIVERSITY IN TERMS OF RACE AND ETHNICITY.

ON THE RIGHT, IF YOU LOOK AT THE AGES OF APPOINTMENT, THIS IS SHOWING DIVERSITY IN TERMS OF AGE. NOT SURPRISINGLY, THE MINORITY OF THE STUDENTS ARE IN THEIR LATE TEENS OR EARLY TWENTIES, WHICH IS PROBABLY YOUR TYPICAL UNDERGRADUATE STUDENT AT THESE INSTITUTIONS. HOWEVER, WE ARE SEEING REPRESENTATION FROM STUDENTS WHO ARE OVER 30 AND IN SOME CASES OVER 40. NEXT SLIDE PLEASE.

AND THIS LAST SLIDE IS COMPARING THE DEMOGRAPHICS OF THE COMPASS COHORTS THUS FAR WITH THE AVERAGE UC FROM THE CENSUS THAT I CITED PREVIOUSLY. AND AS YOU CAN SEE, THE 54 PERCENT OF FIRST GENERATION COLLEGE STUDENTS WE'RE SEEING IN COMPASS IS A LITTLE BIT HIGHER THAN THE PROPORTION OF FIRST GENERATION COLLEGE STUDENTS IN THE UC'S ON AVERAGE. AND IN TERMS OF GENDER IDENTITY, WE'RE SEEING A SLIGHT INCREASE IN REPRESENTATION OF INDIVIDUALS IDENTIFYING AS FEMALE COMPARED TO UC. AND MY NEXT SLIDE PLEASE.

BETH C. DRAIN, CA CSR NO. 7152

AND THIS SLIDE IS JUST A COUPLE OF PICTURES THAT HAVE BEEN SENT TO US FROM PARTICIPANTS IN OUR COMPASS PROGRAM. AND I JUST INCLUDED THEM HERE TO GIVE YOU A VISUAL REPRESENTATION OF SOME OF THE HIGHLIGHTS. SO OVER ON THE LEFT, WE'RE SEEING COMPASS AND ALSO BRIDGES STUDENTS FROM CAL STATE SAN BERNARDINO WHO ARE ATTENDING THE 2023 INLAND EMPIRE CONSORTIUM. ONE OF THE NICE THINGS ABOUT THE COMPASS PROGRAM IS THAT THE STUDENTS ARE HAVING INTERACTIONS WITH STUDENTS FROM OUR BRIDGES PROGRAM AS WELL AS OUR CIRM SCHOLARS PROGRAM IN EVENTS LIKE THIS AND EVEN WITHIN THEIR OWN INSTITUTIONS AS PART OF THEIR COHORT ACTIVITIES.

THE SECOND TWO PICTURES WERE SENT TO ME BY DR. JIM DEKLOE, WHO IS THE PROGRAM DIRECTOR OF THE COMPASS PROGRAM AT SOLANO COMMUNITY COLLEGE. THESE ARE SOME STUDENTS FROM HIS FIRST AND SECOND YEAR COHORT. THERE'S DEMARIO AGAIN IN THE CENTER DONATING CELLS FOR A BE-THE-MATCH EVENT. THIS WAS AN OUTREACH EVENT THAT WAS ORGANIZED BY THE COMPASS STUDENTS AND WAS, ACCORDING FOR BE-THE-MATCH PARTNERS, ONE OF THE MOST SUCCESSFUL EVENTS THAT THEY'VE SEEN. THEY HAD AN UNPRECEDENTED NUMBER OF PEOPLE SHOWING UP TO DONATE TISSUES. AND THEY EVEN IDENTIFIED A MATCH AMONGST ONE OF THE PARTICIPANTS.

BETH C. DRAIN, CA CSR NO. 7152

AND OVER ON THE RIGHT, YOU WILL SEE A PICTURE OF THE SOLANO COLLEGE STUDENTS WITH THEIR MENTOR, MICHAEL SILVA, WHO HAPPENS TO BE A BRIDGES ALUMNUS. AND THEY'RE VISITING THE MUZZETTA THROWER ADULT EDUCATION CENTER AS PART OF THEIR COMMUNITY OUTREACH ACTIVITIES. AND THEY'RE SPEAKING TO THE ADULT STUDENTS THERE ABOUT REGENERATIVE MEDICINE AND THE POSSIBILITIES OF CIRM'S -- AND DESCRIBING THE IMPORTANCE OF CIRM'S MISSION. AND MY NEXT SLIDE PLEASE.

SO IN CONCLUSION, WE'VE JUST COMPLETED THE FIRST YEAR OF THE COMPASS PROGRAM. AND THIS SLIDE IS JUST KIND OF A SUMMARY THAT BRINGS EVERYTHING HOME, SHOWING OUR FOUR CORE EDUCATION PROGRAMS THAT ARE COMPLEMENTARY ALONG THE PIPELINE BEGINNING FROM HIGH SCHOOL WHERE WE ARE SUPPORTING INTERNSHIPS ALL THE WAY TO THE POST-DOCTORAL AND CLINICAL LEVEL. THE NUMBERS YOU SEE ARE THE NUMBERS OF ALUMNAE THAT HAVE COME FROM THESE PROGRAMS. OF COURSE, WE DON'T HAVE ANY ALUMNAE FROM COMPASS YET BECAUSE THEY'RE ALL ACTIVELY TRAINING FOR THEIR TWO OR THREE YEARS. BUT WE DO EXPECT TO ADD ANOTHER 300 STUDENTS TO THIS PROGRAM BY 2027.

SO THIS CONCLUDES THE FORMAL PART OF MY PRESENTATION, HIGHLIGHTING THE FIRST YEAR OF

BETH C. DRAIN, CA CSR NO. 7152

COMPASS. BUT BEFORE I GO, WE WANTED TO SHARE SOMETHING THAT INCLUDES SOME COMPASS STUDENTS, BUT IS A LITTLE BIT BROADER AND INCLUDES REPRESENTATION FROM SOME INDIVIDUALS FROM ALL OF OUR EDUCATION PROGRAMS. WE HAVE -- MAYBE WE CAN GO TO THE NEXT SLIDE, BUT BEFORE WE START THE VIDEO, JUST LET ME INTRODUCE IT.

SO WE WANTED TO SHARE WITH YOU A SPECIAL PROJECT THAT OUR TEAM HAS BEEN WORKING FOR THE BETTER PART OF A YEAR. THIS IS AN OUTREACH VIDEO THAT WAS THE BRAINCHILD OF DR. ROSA CANET-AVILES, A MULTI-TALENTED, GOOD AT EVERYTHING SHE DOES, WHO SUGGESTED THE POSSIBILITY OF OURSELVES, OUR TEAM, CREATING AN OUTREACH VIDEO TO RAISE AWARENESS OF THE DIFFERENT EDUCATIONAL PROGRAMS AND THE BENEFITS THAT THEY CAN OFFER AND THE IMPORTANCE OF BRINGING DIVERSE PERSPECTIVES INTO OUR WORKFORCE. AND I SHOULD MENTION THAT ROSA, THE IDEA WAS INITIATED IN A CONVERSATION WITH OUR OWN BOARD MEMBER YSABEL DURON AS WELL.

AND SO WE ALL WORK TOGETHER VERY COLLABORATIVELY AMONGST OUR TEAM. AND WHEN OUR COMMUNICATIONS TEAM CAME ON BOARD, WE WORKED WITH THEM AS WELL. AND WE PUT TOGETHER THIS VIDEO THAT HIGHLIGHTS THE SUCCESS AND ACCOMPLISHMENTS OF

BETH C. DRAIN, CA CSR NO. 7152

MULTIPLE TRAINEES FROM ACROSS OUR EDUCATION PROGRAMS. THERE ARE MANY PEOPLE INVOLVED. I WOULD LIKE TO GIVE A SPECIAL ACKNOWLEDGEMENT TO THE AFOREMENTIONED SARA TAYLOR WHO HELPED US WITH ALL THE DIFFERENT COMMUNICATIONS THAT WERE INVOLVED IN INVITING PEOPLE TO PARTICIPATE AND COORDINATING THEIR SCHEDULES.

AND THIS IS JUST A SNEAK PREVIEW. OUR COMMUNICATIONS TEAM IS WORKING WITH US TO DEVELOP AND THEY HAVE DEVELOPED A FORMAL LAUNCH PLAN WHICH WILL GO OUT IN THE NEXT COUPLE OF WEEKS, BUT WE DID WANT TO GIVE YOU GUYS THE FIRST GLIMPSE AT THE OUTREACH VIDEO. AND WE'RE VERY EXCITED TO SHARE THIS WITH YOU NOW. SO IT'S A COUPLE MINUTES LONG, AND I'LL BE QUIET NOW AND LET EVERYBODY WATCH. THANK YOU VERY MUCH.

(THE VIDEO WAS THEN SHOWN, BUT NOT REPORTED NOR HEREIN TRANSCRIBED.)

(APPLAUSE.)

CHAIRMAN IMBASCIANI: THANK YOU, DR. SHEPARD, AND THANKS FOR THE PRESENTATION. AND THAT WAS A VERY -- REALLY INSPIRING VIDEO YOU PUT TOGETHER. THANK YOU.

MR. PRESIDENT.

DR. THOMAS: THANK YOU, KELLY, AGAIN FOR

BETH C. DRAIN, CA CSR NO. 7152

ALL YOUR AND YOUR TEAM'S INCREDIBLY HARD WORK IN
PUTTING TOGETHER OUR WONDERFUL EDUCATION PROGRAM.

SO I'LL BRIEFLY CLOSE AGAIN HERE,
PRESIDENT'S PREROGATIVE, OPENING DAY, TO TALK ABOUT
A SPORTING EVENT. YOU'RE EXPECTING BASEBALL, AND
THAT'S NOT THE CASE. SO TWO WEEKS -- LET'S SEE, WAS
IT LAST WEEK? TEN DAYS OR SO AGO MR. TOCHER CAME UP
WITH A GREAT IDEA FOR A TEAM-BUILDING EXPERIENCE TO
FOSTER THIS COLLABORATION AND SUPPORT THAT WE'VE
BEEN DISCUSSING HERE AT THE MEETING. AND HE
DISCOVERED THAT WITHIN A COUPLE MILES OF OUR
HEADQUARTERS IS THIS GO-CARTING PLACE AND
RECOMMENDED THAT, TO DEVELOP THIS SENSE OF
CAMARADERIE, IT WOULD BE A GOOD IDEA TO GO OUT AND
HAVE THE TEAM GO-CART. SO THOUGHT, BOY, THIS IS A
GREAT IDEA. THIS IS REALLY JUST SORT OF FURTHER TO
THE THEMES WE'VE BEEN ESPOUSING, ET CETERA.

NOW, YOU SHOULD HAVE GOTTEN THE SENSE THAT
MAYBE IT WASN'T QUITE WHAT IT SEEMED WHEN IN THE
DAYS LEADING UP TO THE GO-CARTING EVENT MR. TOCHER
WAS SEEN STALKING IN THE HALLS, GUARANTEEING
VICTORY, TRASH TALKING, AND MUTTERING PHRASES LIKE
DUCKS ON THE POND, FISH IN THE BARREL, ET CETERA.
WE KIND OF LET IT GO. WE FIGURED THE TEAM WOULD
RISE TO THE OCCASION.

BETH C. DRAIN, CA CSR NO. 7152

SO WE GOT TO THE EVENT ITSELF, WHICH WAS A WEEK AGO TUESDAY. TWELVE INTREPID DRIVERS FROM THE CIRM TEAM DECIDED TO PUT THEMSELVES AT RISK OF GREAT BODILY HARM AND SUITED UP TO GO OUT TO THE COURSE. AGAIN, THIS IS MEANT TO BE A TEAM-BUILDING THING. NOW, OF COURSE, THIS IS A BUNCH OF VERY TYPE A PERSONALITIES. AND BY THE WAY, I SHOULD SAY IT WASN'T JUST THE 12 DRIVERS, MANY OF WHICH ARE HERE IN THE ROOM, IT WAS MANY MEMBERS OF THE TEAM WHO WERE THERE TO ROOT THEM ON IN THE SPIRIT OF SUPPORT. BUT WHEN THEY GOT OUT ON THE TRACK, OF COURSE, IT BECAME A VERY CUTTHROAT, NASTY, COMPETITIVE EXERCISE. AND IT WAS QUITE SOMETHING TO WATCH ACTUALLY.

THE FORMAT WAS THEY HAD THREE HEATS. IN THE FIRST HEAT YOU STARTED TO SEE PERSONALITIES EMERGE. DR. LOMAX, FOR EXAMPLE, SOMEHOW CONFUSING THIS EVENT WITH A CARNIVAL BUMPER CARS FORMAT, SYSTEMATICALLY ON THE FIRST HEAT TOOK OUT ABOUT HALF OF THE MEMBERS OF THE TEAM AT VARIOUS POINTS IN TIME, WHICH, BY THE WAY, ENDED UP GETTING HIM ULTIMATELY ONLY TENTH PLACE OUT OF 12, BUT WAS SOMETHING THAT WAS VIEWED WITH GREAT POSITIVITY BY LOCAL TORT LAWYERS WHO WERE IN ATTENDANCE AND PICKED UP A NUMBER OF CLIENTS.

BETH C. DRAIN, CA CSR NO. 7152

JANIE FROM THERAPEUTICS --

DR. CANET-AVILES: SHE'S MINE.

DR. THOMAS: SORRY. YES. MY MISTAKE.

SORRY. -- CAME TO PLAY BIG TIME. SHOWS UP IN LIKE A FORMULA ONE, LIKE, ONE-PIECE RACING SUIT. AND IF YOU WERE TO SEE HER OUT THERE AGGRESSIVELY ATTACKING THE COURSE, GOING AFTER THESE HAIRPIN TURNS LEAVING SCREECHES AND TIRE MARKS, TREAD, IN THE COURSE, YOU WOULD HAVE BEEN VERY PROUD OF HER VERY TYPE A AGGRESSIVE PERSONALITY.

THE FIRST HEAT WAS RUN. DOUG GUILLEN TOOK THE FIRST HEAT. SCOTT WAS NOT VERY HAPPY ABOUT THIS, BUT HE VOWED TO MAKE SURE THAT HE PICKED THINGS UP ON THE SECOND HEAT.

IN THE SECOND HEAT, AS IT TURNS OUT, LANA ENDED UP WINNING THE SECOND HEAT. MR. TOCHER AT THIS POINT WAS IN SECOND PLACE.

SO AS THE DRIVERS WENT OUT FOR THE THIRD HEAT, YOU WERE SEATED IN SEQUENCE IN THE STARTING BLOCKS, AND LANA WAS IN THE POLE POSITION. EMILY OF THE PATIENT ACCESS GROUP, WHICH IS NOW THE FRESHLY MINTED REBRANDED NAME OF WHAT WAS PREVIOUSLY KNOWN AS MEDICAL AFFAIRS, INNOCENTLY SAT IN THE SECOND CAR BEHIND LANA, AT WHICH POINT MR. TOCHER STORMS OUT TO HER AND YOU COULD SEE -- WE COULDN'T HEAR WHAT HE

BETH C. DRAIN, CA CSR NO. 7152

WAS SAYING, BUT YOU COULD SEE HIM LEANING OVER TALKING TO HER AND HER PUTTING HER HAND OVER HER FACE AND GETTING UP AND BEING FORCED TO GO TO ANOTHER CAR. AND, OF COURSE, BY THIS TIME EVERYBODY WAS IN THEIR CAR. SO THE ONLY THING LEFT WAS LAST PLACE. RIGHT. SO THE CROWD COLLECTIVELY GASPED. AND MARIA, BROACHING PROTOCOL, BROKE THROUGH THE FAN RACER BARRIER AND WALKED OUT AND IN A MIDSEASON DISPLAY OF FINGER POINTING EXCORIATION LAID INTO MR. TOCHER FOR HIS NONCHIVALROUS ACT.

AT THAT POINT THE THIRD HEAT COMMENCED, AND I'M NOT GOING TO DISCUSS IT IN GREAT DETAIL. IT LEADS THE SLIDE WE'RE GOING TO PUT UP ON THE SCREEN. NOW, AS YOU CAN SEE, LANA WON, BUT THAT'S ALL I'M GOING TO SAY.

(APPLAUSE.)

DR. THOMAS: THAT'S ALL I'M GOING TO SAY BECAUSE I'VE INVITED BOTH LANA AND SCOTT TO PRESENT THEIR PERSPECTIVES ON THE RACE. SO WITHOUT FURTHER ADO, I'LL TURN IT OVER -- I WANT TO POINT OUT, BY THE WAY, THE REASON WHY THIS SLIDE IS UP THERE, YOU MIGHT NOTICE, GENERALLY SPEAKING, THE FIRST PLACE WINNER HAS THE GOLD MEDAL. IF YOU NOTICE, MR. TOCHER, WHO IS IN SECOND PLACE, IS HOLDING THE GOLD MEDAL. AND LANA, WHO WON, HAS THE SILVER. WITH

BETH C. DRAIN, CA CSR NO. 7152

THAT, I'LL TURN IT OVER TO LANA AND SCOTT FOR COMMENT.

MS. MORALEZ: THANK YOU, J.T. I JUST HAVE A QUICK LITTLE SPEECH HERE THAT I WROTE UP. AND I WILL NEED BACKUP LATER BECAUSE I KNOW SCOTT IS GOING TO COME FOR ME.

BOARD MEMBERS AND FELLOW SPEED ENTHUSIASTS, BEFORE I DIVE INTO THE HEART-POUNDING SAGA OF OUR EPIC GO-CART SHOWDOWN, I WANT TO TAKE A MOMENT TO ACKNOWLEDGE THE BRILLIANT MINDS BEHIND THIS ADRENALINE-FUELED ADVENTURE. OUR VERY OWN BOARD GOVERNANCE TEAM HAD THE INGENIOUS IDEA TO KICK OFF A MONTHLY TEAM-BUILDING EVENT, AND WHAT BETTER WAY TO REV OUR ENGINES THAN WITH THE THRILLING PURSUIT OF GO-CART GLORY.

TODAY I STAND BEFORE YOU, NOT JUST AS A MEMBER OF BOARD GOVERNANCE, BUT AS UNDISPUTED CHAMPION OF THE OFFICE GO-CART CHALLENGE. THAT'S RIGHT. I CONQUERED THE TWISTS, TURNS, AND TURBO BOOSTS OF THE GO-CART TRACK, LEAVING ALL COMPETITORS, SCOTT IN PARTICULAR, QUIVERING IN MY FUMES AS I SCORCHED THE TRACK AND SECURED THE COVETED FIRST PLACE.

SCOTT, OH, SCOTT, LET'S NOT FORGET HIS VALIANT EFFORTS. YOU WERE INDEED A WORTHY OPPONENT.

BETH C. DRAIN, CA CSR NO. 7152

YOU GAVE YOUR ALL, WEAVING THROUGH THE TRACK WITH FINESSE AND DETERMINATION, BUT ULTIMATELY FALLING SHORT. DON'T WORRY, SCOTT. SECOND PLACE LOOKS GOOD ON YOU.

DESPITE THE RACERS REPRESENTING DIFFERENT DEPARTMENTS, WE CAME TOGETHER UNITED, LEAVING BEHIND OUR SPREADSHEETS AND EMAILS TO UNLEASH OUR INNER SPEED DEMON AS WE NAVIGATED THE HAIRPIN BENDS AND THE BATTLE FOR POSITIONS, FRIENDSHIPS WERE FORGED, ALLIANCES WERE MADE, AND RIVALRIES WERE BORN. IT WAS A THRILLING DISPLAY OF TEAMWORK, CAMARADERIE, HEALTHY COMPETITION, ALL INGREDIENTS FOR A MEMORABLE DAY OUT WITH OUR AWESOME CO-WORKERS. WHETHER WE CAME IN FIRST OR SECOND OR EVEN LAST, WHAT TRULY MATTERS IS THE UNFORGETTABLE EXPERIENCE WITH LAUGHTER SHARED ALONG THE WAY. CHEERS TO US, THE ULTIMATE OFFICE RACING DREAM TEAM.

(APPLAUSE.)

CHAIRMAN IMBASCIANI: I PRESUME SCOTT DOESN'T HAVE A COMMENT TO MAKE.

DR. THOMAS: OH, NO. YOU PRESUME INCORRECTLY.

MR. TOCHER: I'M A LITTLE OVERWHELMED. THE HITS JUST KEEP ON COMING. NO, I HAVE NO PREPARED REMARKS. I WILL SAY THAT AFTER SEVERAL

BETH C. DRAIN, CA CSR NO. 7152

YEARS OF WATCHING F-1 ON NETFLIX, WHICH IF YOU DON'T WATCH, IT'S ABSOLUTELY FASCINATING. I THINK ONE OF THE INTERESTING THINGS THAT I TOOK AWAY FROM THE FIRST SEASON EVENT WAS THAT THE DRIVERS WHO ARE ON THE SAME TEAM OFTENTIMES WERE THEIR WORST ENEMIES. THEY COMPETED FEROCIOUSLY. I THOUGHT THAT WAS ODD, AND IT WASN'T UNTIL MY EXPERIENCE HERE WITH GO-CARTING AGAINST LANA THAT THIS, IN FACT, COMES WITH THE SPORT AS SHE SPUN ME OUT IN THE FIRST HEAT FROM BEHIND LIKE ONE OF THOSE PIT MOVES THAT THE CHP DOES WHEN THEY'RE TRYING TO PULL OVER A DRUG RUNNER OR SOMETHING.

JUST IN ALL SERIOUSNESS, IT WAS A LOT OF FUN. IF YOU HAVEN'T DONE IT BEFORE, I HIGHLY RECOMMEND IT. AND I WAS APPRECIATIVE OF ALL THE FOLKS WHO CAME OUT WHO WERE NOT DRIVERS BUT SUPPORTED EVERYONE. AND AS J.T. SAID, IT'S SOMETHING THAT WE HOPE TO DO ON A REGULAR BASIS. AND IF ANY OF YOU ARE IN THE AREA, WE WILL LET YOU KNOW SO YOU DON'T MISS OUT EITHER. SO THANKS, J.T.

(APPLAUSE.)

CHAIRMAN IMBASCIANI: THANK YOU. I SEE FRED FISHER HAS HIS HAND UP. FRED.

DR. FISHER: YES, AS A LOYAL NETFLIX DRIVE TO SURVIVE ENTHUSIAST, WE ALL KNOW THAT THIRD PLACE

BETH C. DRAIN, CA CSR NO. 7152

MATTERS ONLY FOR THE FEW MOMENTS THAT THE THIRD PLACE DRIVER IS ON THE PODIUM. BUT I THINK IT WOULD BE -- WE WOULD BE REMISS NOT TO ACKNOWLEDGE WHO IT WAS THAT WAS ACTUALLY STANDING ON THE PODIUM IN THIRD PLACE AND MIGHT THAT PERSON HAVE SOME PERSPECTIVE TO LEND.

DR. THOMAS: YES. THAT WAS DOUG, WHO, AS I SAID, WAS IN FIRST AFTER THE FIRST HEAT AND VALIANTLY COMPETED, BUT WAS BETTERED ON THAT PARTICULAR DAY BY LANA AND MR. TOCHER. I DON'T KNOW IF, DOUG, YOU'RE NEAR A MICROPHONE SOMEPLACE. NO, OKAY. IN ANY EVENT, MR. CHAIRMAN, MADAM VICE CHAIR, THANK YOU VERY MUCH. THAT CONCLUDES OUR REPORT.

CHAIRMAN IMBASCIANI: THANK YOU, MR. PRESIDENT. AND CONGRATULATIONS, LANA.

I JUST WANTED TO DISPEL A RUMOR THAT LANA OWES PART OF HER SUCCESS TO THE, THIS IS A RUMOR NOW, THAT I TAUGHT HER HOW TO DRIVE. THAT'S NOT TRUE.

SO LET'S, IF WE CAN, SEGUE TO MORE MUNDANE MATTERS. THESE ARE ITEMS ON THE AGENDA, 6, 7, AND 9. THIS IS THE CONSENT CALENDAR. IT REPRESENTS THE MINUTES, WHICH I HAVE READ OVER. I DON'T FIND ANY CORRECTIONS TO THEM, BUT YOU ALL MIGHT. ITEM 7 IS CONSIDERATION OF APPOINTMENTS TO THE SCIENTIFIC

BETH C. DRAIN, CA CSR NO. 7152

MEMBERS OF THE GRANTS WORKING GROUP. IF YOU HAVE NOT READ THEM, THEY ARE EXTRAORDINARILY IMPRESSIVE BIOS. SO THERE ARE NINE APPOINTMENTS AND THREE REAPPOINTMENTS IN THAT ITEM.

AND THEN THE REGULARLY APPEARING APPROVAL TO REQUESTS TO ATTEND REMOTELY. SO IF ANYONE WOULD LIKE TO ABSTRACT ANYTHING FROM THE CONSENT AGENDA. I DO NOT SEE ANY HANDS. SO I'M GOING TO ASK FOR A MOTION TO APPROVE THE CONSENT AGENDA.

DR. BARRETT: MOVE APPROVAL.

DR. SOUTHARD: SECOND.

CHAIRMAN IMBASCIANI: WE HAVE A MOTION AND A SECOND. SO WE CAN CALL THE ROLL ON THAT.

MR. TOCHER: I WILL CALL THE ROLL FOR THOSE ON THE PHONE. BUT ALL THOSE IN THE ROOM IN FAVOR SAY AYE. ANY OPPOSED? ABSTENTIONS? AND I'LL CALL THE ROLL FOR THOSE ON THE PHONE.

MOHAMED ABOUSALEM. I'LL COME BACK.

DEBORAH DEAS.

DR. DEAS: HERE.

MR. TOCHER: YSABEL DURON. I'LL COME BACK. FRED FISHER.

DR. FISHER: YES.

MR. TOCHER: LARRY GOLDSTEIN.

DR. GOLDSTEIN: YES.

BETH C. DRAIN, CA CSR NO. 7152

MR. TOCHER: RICH LAJARA.

MR. LAJARA: YES.

MR. TOCHER: JOYCE SACKY.

DR. SACKY: YES.

MR. TOCHER: MICHAEL STAMOS.

DR. STAMOS: YES.

MR. TOCHER: KAROL WATSON.

DR. WATSON: YES.

MR. TOCHER: KEVIN XU.

DR. XU: YES.

MR. TOCHER: KEITH YAMAMOTO.

DR. YAMAMOTO: YES.

MR. TOCHER: AND I'LL COME BACK TO MOHAMED
ABOUSALEM. STILL NOT HEARING YOU, MOHAMED. AND
YSABEL DURON.

DR. ABUSALEM: I'M TRYING AGAIN HERE.

MR. TOCHER: AH, WE HEAR YOU. THANK YOU.

DR. ABUSALEM: OKAY. THANKS.

MR. TOCHER: AND YSABEL. ALL RIGHT.
THANK YOU. THE MOTION CARRIES.

CHAIRMAN IMBASCIANI: THANK YOU. NOW,
WE'RE GOING TO MOVE TO THE NEXT --

THE REPORTER: A SHORT BREAK, MR.
CHAIRMAN?

CHAIRMAN IMBASCIANI: YES.

BETH C. DRAIN, CA CSR NO. 7152

MR. TOCHER: WE CAN TAKE A FIVE-MINUTE.

CHAIRMAN IMBASCIANI: WE CAN TAKE A
FIVE-MINUTE BREAK. THANK YOU.

(A RECESS WAS TAKEN.)

CHAIRMAN IMBASCIANI: OKAY. DO WE HAVE
ENOUGH PEOPLE BACK IN THE ROOM?

MR. TOCHER: WE WILL BY THE TIME THE VOTE
OCCURS. WE SHOULD GET GOING.

CHAIRMAN IMBASCIANI: THANK YOU. OKAY.
SINCE THE NEXT THREE ITEMS ARE ALL IN THE PURVIEW OF
OUR GOVERNANCE, I'M GOING TO GIVE CONTROL OF THE
MEETING NOW TO ONE OF THE CO-CHAIRS OF THE
GOVERNANCE SUBCOMMITTEE, PAT LEVITT.

DR. LEVITT: GOOD MORNING. I'VE ARGUED
WITH DR. GASSON THAT I'M THE VICE CHAIR, BUT SHE
KEEPS SAYING THAT I'M THE CO-CHAIR. I GUESS I'M THE
CO-CHAIR. AND SHE HAS DECIDED TO TAKE THE TRAINING
WHEELS OFF. HERE I GO.

WE HAVE THREE ITEMS TO COVER ON NOS. 10,
11, AND 12. TWO ARE FOR THE BOARD'S CONSIDERATION
AND APPROVAL, AND THE THIRD IS A DISCUSSION ITEM.

THE FIRST TWO, THE DOCUMENTS THAT DESCRIBE
THE REVIEW PROCEDURES AND JOB DESCRIPTIONS AND
SURVEY QUESTIONS FOR THE BOARD CHAIR AND VICE CHAIR.
I'LL CALL ON SUSAN WHITE, OUR CONSULTANT, IN A

BETH C. DRAIN, CA CSR NO. 7152

MOMENT, AND THE SECOND IS THE JOB DESCRIPTION FOR THE PRESIDENT AND CEO.

JUST TO REMIND EVERYBODY, THIS HAS GONE THROUGH A SUBSTANTIVE PROCESS THAT INVOLVED BOTH JUDY AND MYSELF MEETING FOR POINT 10 WITH SUSAN WHITE AND THEN BRINGING IT TO THE GOVERNANCE SUBCOMMITTEE WHERE THAT DOCUMENT AND THE DOCUMENT FOR THE PRESIDENT AND CEO JOB DESCRIPTION WAS EDITED LITERALLY LINE BY LINE, WORD BY WORD, AND PUNCTUATION BY PUNCTUATION. SO WE'LL GO THROUGH THIS PROCESS AND ASK IF THERE ARE ANY QUESTIONS BEFORE WE PUT THE TWO ISSUES TO A VOTE.

SO, SUSAN, YOU'RE ONLINE. I'M GOING TO CALL ON YOU TO DISCUSS THE REVIEW PROCESS FOR THE CHAIR AND VICE CHAIR OF THE BOARD.

MS. WHITE: THANK YOU SO MUCH. GOOD MORNING, EVERYONE. AND I WOULD SHARE MY SCREEN. IT IS TRUE THAT, AS PAT JUST SAID, THE JOB DESCRIPTIONS THEMSELVES HAVE BEEN REVIEWED. AND SO RATHER THAN GO INTO ANY DETAIL ON THOSE, I'LL JUST MENTION -- GO AHEAD AND GET TO THE PROCESS. THIS IS ONE OF THE JOB DESCRIPTIONS. WHERE WE STARTED ON THOSE, JUST SO THAT PEOPLE KNOW THERE IS GROUNDING, WE STARTED WITH THE JOB DESCRIPTIONS LOOKING AT PROPOSITION 14 PROVISIONS, WE LOOKED AT THE ICOC BYLAWS, AND WE

BETH C. DRAIN, CA CSR NO. 7152

LOOKED AT THE 2021 INTERNAL GOVERNANCE POLICY BEFORE VITO AND MARIA HAD A CHANCE TO REALLY REACT TO IT AND MAKE THEIR OWN EDITS AND THEN FOR BOARD GOVERNANCE TO GO THROUGH IT. SO THERE WAS GROUNDING IN EACH OF THOSE, BOTH OF THOSE JOB DESCRIPTIONS.

CERTAINLY, IF THERE'S QUESTIONS, BE HAPPY TO TAKE THOSE, OR WE CAN COME BACK TO THOSE AT THE END.

HOW ABOUT I JUMP RIGHT INTO THE PROCESS. AND LET'S GO AHEAD AND I'LL SHOW YOU THE PROCESS TIMELINE. SO WHAT WE'RE DOING FOR BOTH THE BOARD CHAIR AND THE VICE CHAIR IS WE'RE GOING TO BE LAUNCHING, ACTUALLY IF EVERYONE IS GOOD WITH IT TODAY, TOMORROW WE'RE GOING TO HAVE A CHANCE FOR VITO AND MARIA TO ACTUALLY GIVE A SELF-ASSESSMENT BECAUSE WE RECOGNIZED WHEN WE PUT TOGETHER THE SURVEY QUESTIONS THAT MOST OF YOU ON THE BOARD DON'T HAVE A CHANCE TO SEE THE BOARD CHAIR AND THE VICE CHAIR TRULY DOING WHAT THEY DO DAY-TO-DAY. AND SO WE WANTED TO GIVE THEM A CHANCE TO ASSESS HOW THEY'RE DOING ON ALL THE FACTORS THAT WE'RE ASKING THEM ABOUT. AND THOSE FACTORS ARE BASED ON THE JOB DESCRIPTIONS. AND SO THEY ARE GOING TO COMPLETE THEIR SELF-ASSESSMENTS BY EARLY NEXT WEEK.

THEN WHEN WE LAUNCH THE ACTUAL REVIEW

BETH C. DRAIN, CA CSR NO. 7152

PROCESS, WHICH WE WILL BE SENDING OUT LINKS TO SURVEY MONKEYS, YOU WILL ALSO HAVE ATTACHED TO THAT BOTH MARIA AND VITO'S SELF-ASSESSMENTS. SO IT WILL GIVE YOU A CHANCE TO EDUCATE YOURSELF ON WHAT THEY HAVE DONE AGAINST ALL THE THINGS THAT YOU'RE GOING TO BE ASKED TO ASSESS THEM ON.

APRIL THE 8TH IS THE DAY THAT -- LET ME GO AHEAD AND SHOW YOU THAT TIMELINE HERE. I'LL SCROLL DOWN. APRIL 8TH IS THE DAY THAT I WILL BE SENDING OUT AN EMAIL TO EVERYONE ON THE BOARD AS WELL AS THE DIRECT REPORTS OF THE BOARD CHAIR AND THE VICE CHAIR AS WELL AS --

MR. TOCHER: SUSAN.

MS. WHITE: YES, GO RIGHT AHEAD.

MR. TOCHER: SUSAN, THIS IS SCOTT. I DON'T KNOW IF YOU'RE TRYING TO SHARE THE TIMELINE. WHAT WE SEE RIGHT NOW IS A POSITION DESCRIPTION.

MS. WHITE: THANK YOU, SCOTT. I ACTUALLY HAVE THE TIMELINE ON MY SCREEN. SO I DON'T KNOW WHY IT HASN'T MOVED TO THAT. INTERESTING. I'M LOOKING AT THE TIMELINE. ARE YOU SEEING THE TIMELINE RIGHT NOW, OR ARE YOU SEEING THE JOB DESCRIPTION?

MR. TOCHER: WE STILL HAVE THE POSITION DESCRIPTION.

MS. MANDAC: SUSAN, I CAN SHARE IT FOR YOU

BETH C. DRAIN, CA CSR NO. 7152

IF YOU'D LIKE.

MS. WHITE: OH, THAT'D BE GREAT. WHY DON'T YOU GO AHEAD AND DO THAT. I'LL STOP MY SHARE IF YOU DON'T MIND, CLAUDETTE. THANK YOU.

MS. MANDAC: FOR ALL MEMBERS WHO ARE PHYSICALLY PRESENT, YOU DO HAVE COPIES OF ALL THESE DOCUMENTS IN FRONT OF YOU AT YOUR TABLES IN CASE IT'S EASIER TO VIEW THAT WAY.

MS. WHITE: THANK YOU SO MUCH. SO YOU CAN SEE VERY QUICKLY AS WE'RE LOOKING AT THE TIMELINE THAT EVERYONE FROM THE BOARD AND ALTERNATES WILL BE ASKED TO COMPLETE AN ASSESSMENT VIA SURVEY MONKEY OF BOTH THE CHAIR AND THE VICE CHAIR AS WELL AS THE DIRECT REPORTS, AS WELL AS J.T. AND ALSO THE VICE CHAIR HAS AN OPPORTUNITY TO WEIGH IN ON THE CHAIR'S AND CHAIR ON THE VICE CHAIR'S PERFORMANCE. SO HOPEFULLY IT'S GOING TO BE VERY INCLUSIVE.

WE'RE DOING IT BY SURVEY MONKEY AT THIS TIME. I WILL TELL YOU THAT WE'VE TRIED VERY HARD TO MAKE IT AS STREAMLINED AS POSSIBLE. SO APRIL THE 8TH, WHEN YOU RECEIVE YOUR EMAIL FROM ME, THAT WILL HAVE THE LINKS TO THE TWO SURVEY MONKEYS AND THE SELF-ASSESSMENTS. YOU WILL NOTICE THAT YOU ARE GOING TO HAVE UNTIL APRIL 19TH AND ACTUALLY A FEW EXTRA DAYS FOR THE WHITE WINDOW. YOU WILL HAVE TILL

BETH C. DRAIN, CA CSR NO. 7152

APRIL 24TH TO ACTUALLY FINISH IT.

YOU WILL NOTICE THAT WE'VE TRIED TO MAKE IT VERY STREAMLINED. FOR THE BOARD CHAIR, THERE'S GOING TO BE 18 QUESTIONS. FOR THE VICE CHAIR, THERE'S GOING TO BE 15 QUESTIONS. AND THEN THE ONLY COMMENTS WE'RE ASKING FOR, RATHER THAN ASKING FOR YOU TO COMMENT ON EVERY SINGLE QUESTION, INSTEAD AT THE END WILL BE A COMMENT BOX FOR YOU TO GIVE KIND OF A 3 PLUS OR 3 MINUS, MEANING THREE THINGS THAT YOU THINK WENT PARTICULARLY WELL WITH THEIR PERFORMANCE AND THREE THINGS, UP TO THREE THINGS WHERE YOU THINK THERE'S OPPORTUNITY TO IMPROVE OR TO THINK DIFFERENTLY.

IN THAT SECTION OF 3 PLUS, 3 MINUS, THERE IS NO LIMIT. YOU CAN ADD MORE COMMENTS IF YOU WANT CERTAINLY. SO IT'S OPEN TO YOU, BUT DON'T FEEL LIKE YOU HAVE TO ANSWER OR PROVIDE COMMENTS EVERY STEP OF THE WAY. SO APRIL 24TH, THAT IS THE CLOSEOUT DATE FOR INPUT. AND I WILL SIMULTANEOUSLY WITH YOU DOING THE SURVEY MONKEY RESPONSES, I AM GOING TO BE REACHING OUT TO THE INCUMBENTS IN THE JOB AS WELL AS THE CHAIRS AND CO-CHAIRS OF EACH OF THE COMMITTEES AND THE DIRECT REPORTS OF THE INDIVIDUALS SO THAT -- FOR INTERVIEWS IN HOPES THAT, IF THERE'S ANYTHING THEY'D LIKE TO VERBALLY SHARE, THAT THEY FELT LIKE

**133 HENNA COURT, SANDPOINT, IDAHO 83864
208-920-3543 DRAIBE@HOTMAIL.COM**

BETH C. DRAIN, CA CSR NO. 7152

THE CONFINES OF THE SURVEY MONKEY WAS NOT ENOUGH. JUST GIVES US A CHANCE TO GET A BROADER, MORE ROBUST PICTURE. SO I'LL BE DOING THOSE INTERVIEWS VIRTUALLY.

CERTAINLY IF OTHER PEOPLE WANT TO TALK TO ME, THEY'RE MORE THAN WELCOME TO. IN FACT, MY CONTACT INFORMATION WILL BE ON THE EMAIL THAT COMES OUT TO YOU. SO YOU'RE WELCOME TO LET ME KNOW YOU WANT TO TALK IN ADDITION TO FILLING OUT THE SURVEY.

IT IS IMPORTANT THAT WE GET EVERYONE TO RESPOND. WE'RE HOPEFUL THAT BY YOUR HAVING A CHANCE TO SEE THE SELF-ASSESSMENT, THAT IF ANYONE WAS RELUCTANT IN THE PAST TO RESPOND BECAUSE THEY DIDN'T FEEL LIKE THEY KNEW ENOUGH, WE'RE HOPING THIS TIME THAT THEY WILL FEEL COMFORTABLE AND CONFIDENT IN RESPONDING.

ONCE WE CLOSE EVERYTHING OUT, I'LL BE ANALYZING THE DATA AND COMPILING SUMMARIES, PERFORMANCE REVIEWS, FOR BOTH THE CHAIR AND THE VICE CHAIR. I WILL BE DELIVERING THAT TO THE CO-CHAIRS OF THE BOARD GOVERNANCE COMMITTEE BY MAY THE 21ST. YOU'RE GOING TO HAVE A CHANCE TO REVIEW IT, TAKE A LOOK AT IT, MAKE SURE IT HITS THE MARK. WE'RE GOING TO BE REVIEWING IT WITH THE BOARD GOVERNANCE COMMITTEE WHO WILL DO THE SAME THING. AND THEN THE

BETH C. DRAIN, CA CSR NO. 7152

PLAN IS FOR THE FULL BOARD AT YOUR JUNE ICOC MEETING TO THEN REVIEW BOTH OF THE PERFORMANCE REVIEWS BEFORE THEY'RE THEN DELIVERED TO BOTH VITO AND TO MARIA.

SO THAT IS WHAT THE TIMELINE LOOKS LIKE. APRIL 8TH IS A SIGNIFICANT DATE BECAUSE THAT'S WHEN YOU WILL HEAR FROM ME WITH THE SURVEY MONKEY LINKS AS WELL AS THOSE OF YOU WHO ARE BEING INVITED TO HAVE A VIRTUAL DISCUSSION WITH ME, APRIL 8TH THAT DATE. THE OTHER SIGNIFICANT DATE, APRIL 19TH, IS WHAT WE'RE ASKING FOR AS THE DEADLINE; BUT IF LIFE HAPPENS, YOU NEED TO MAKE IT APRIL 24TH, WE WILL LIVE WITH THAT. SO THOSE ARE THE IMPORTANT DATES FOR YOU.

A COUPLE OF NOTABLE THINGS I DID WANT TO MENTION ABOUT THE SURVEY SINCE I HAVE YOUR ATTENTION ON IT. BECAUSE IT'S SURVEY MONKEY, YOU'RE NOT ABLE TO GO IN AND START IT AND THEN COME BACK LATER AND FINISH IT. SO IT IS IMPORTANT THAT YOU DO IT AT ONE SITTING. BECAUSE IT'S SO STREAMLINED, IT'S REALLY YOUR PROVIDING RATINGS ON 18 QUESTIONS OR 15 QUESTIONS FOR VITO OR MARIA RESPECTIVELY, WE'RE HOPING IT'S GOING TO TAKE NO MORE THAN ABOUT 15 MINUTES WHEN YOU'RE ACTUALLY DOWN TO DO IT. SO HOPEFULLY IT WILL BE FAIRLY QUICKLY, BUT PLEASE

**133 HENNA COURT, SANDPOINT, IDAHO 83864
208-920-3543 DRAIBE@HOTMAIL.COM**

BETH C. DRAIN, CA CSR NO. 7152

DON'T THINK YOU CAN LEAVE IT AND COME BACK.

THE SECOND POINT I WANTED TO MAKE IS THAT WHATEVER YOU INPUT IS ABSOLUTELY CONFIDENTIAL. THE FACT IS WE DON'T KNOW WHO SUBMITS. WE KNOW HOW MANY SUBMIT OUT OF THE TOTAL POPULATION, BUT WE DON'T KNOW WHO SAYS WHAT. SO PLEASE KNOW IT WILL BE CONFIDENTIAL. AND ADDITIONALLY, WHEN I DO MY INTERVIEWS OR DISCUSSIONS WITH YOU VIRTUALLY, THOSE OF YOU WHO PARTICIPATE IN THAT, I WILL NOT ATTRIBUTE INDIVIDUAL COMMENTS TO ANY PERSON. SO THE GOAL IS FOR THEMES, AND THE GOAL IS TO MAKE SURE THAT IF SOMETHING IS MATERIAL, MEANING THAT THREE OR MORE PEOPLE ARE FEELING THAT WAY, THEN IT'S IMPORTANT THAT WE CAPTURE IT AND SHARE THAT FEEDBACK.

ALL RIGHT. MAYBE I SHOULD JUST OPEN IT UP TO SEE IF INDIVIDUALS HAVE QUESTIONS OR ANYTHING THAT YOU WANT.

DR. LEVITT: YEAH. SUSAN, THANKS VERY MUCH. ONE THING I WANTED TO REEMPHASIZE IS THE PARTICIPATION. WE'VE TRIED TO MAKE THIS A COMPREHENSIVE, BUT STREAMLINED APPROACH TO REVIEW. AND THIS IS -- THE FEEDBACK FROM THESE REVIEWS IS CRITICALLY IMPORTANT FOR THE CHAIR AND VICE CHAIR. SO WE'RE LOOKING FOR A HUNDRED PERCENT PARTICIPATION AND HOPE THAT THE BOARD AND EXPECT THAT THE BOARD

BETH C. DRAIN, CA CSR NO. 7152

MEMBERS WILL DO THAT.

SO WE HAVE ANY QUESTIONS?

DR. CLARK-HARVEY: THANK YOU. SORRY.

HAVE TO GET ALL MY STUFF TOGETHER. THANK YOU SO MUCH FOR THIS. I REALLY FEEL LIKE THE PROCESS HAS BEEN THOROUGH, AND YOU ALL HAVE PUT A LOT OF TIME INTO THIS. I DID CATCH A FEW THINGS THAT I'LL SHARE WITH STAFF IN THE BACKGROUND AROUND JUST TYPOS.

BUT A COUPLE OF THINGS THAT I NOTICED THAT IF YOU COULD HELP ME WITH A BIT, AND IT WAS IN EACH OF THE APPLICATIONS. SO THE FIRST -- I'M SORRY. THE PAPERWORK, NOT THE APPLICATIONS.

SO IN THE POSITION DESCRIPTION FOR THE VICE CHAIR, THERE ARE SEVERAL THINGS CALLED OUT IN TERMS OF RESPONSIBILITIES AND DUTIES. HOWEVER, IN THE PERFORMANCE MANAGEMENT REVIEW FORM, THAT WASN'T -- ALL THE THINGS WEREN'T NECESSARILY CONSISTENT. FOR EXAMPLE, IN THE BOARD GOVERNANCE SECTION, THERE WAS INFORMATION LIKE IN 1.2 THAT TALKS ABOUT SUPERVISING THEIR BOARD GOVERNANCE STAFF. WONDERFUL. GREAT. YOU SHOULD. HOWEVER, I'M NOTICING THAT THAT'S NOT NECESSARILY DETAILED IN THE POSITION DESCRIPTION.

ALSO IN SECTION 2, EXTERNAL REPRESENTATION, MAINTAINING RELATIONSHIPS, COMMUNITY

BETH C. DRAIN, CA CSR NO. 7152

ORGANIZATIONS, ET CETERA, THAT'S ALSO NOT NECESSARILY CALLED OUT IN THE POSITION DESCRIPTION.

SO I GUESS WHAT I'M CALLING FOR IS JUST SOME CONSISTENCY THERE.

CONVERSELY, IN THE BOARD CHAIR'S DESCRIPTION, THERE ARE THINGS IN THE POSITION DESCRIPTION THAT ARE NOT IN THE PERFORMANCE MANAGEMENT REVIEW FORM. FOR EXAMPLE, IN SECTION 1 THERE'S NOT MUCH OR ANYTHING REALLY AROUND SUPERVISION OF THE PRESIDENT AND THE EXECUTIVE ASSISTANT; BUT IN THE POSITION DESCRIPTION, IT'S CALLED OUT THAT THAT PERSON HAS THOSE RESPONSIBILITIES.

SO I THINK JUST ANOTHER READ THROUGH TO MAKE SURE THAT ALL OF THE REQUIREMENTS AND THE THINGS THAT WE WERE SEARCHING FOR IN THE POSITION DESCRIPTION ARE ACCURATELY REFLECTED IN THE REVIEW SO THAT THAT PERSON FAIRLY CAN BE EVALUATED ON THOSE THINGS. AND IF THERE ARE THINGS, AS I POINTED OUT IN THE VICE CHAIR, THAT ARE IN THE REVIEW, BUT NOT IN THE POSITION DESCRIPTION, I JUST THINK IT'S SOMETHING TO -- I KNOW IT'S PICKY, BUT I THINK CONSISTENCY IS REALLY IMPORTANT. AND IT'S ONLY FAIR TO THE INDIVIDUAL THAT'S BEING EXPECTED TO DO THOSE DUTIES THAT THEY BE ACCURATELY REFLECTED IN BOTH

BETH C. DRAIN, CA CSR NO. 7152

PLACES. I HOPE THAT MAKES SENSE. IF NOT, I CAN EXPOUND MORE.

DR. LEVITT: SO CAN I ASK YOU QUESTION? FOR THE BOARD CHAIR, 1.2, PARTNERS EFFECTIVELY WITH AND HOLDS CIRM PRESIDENT AND CEO ACCOUNTABLE TO FRAME STRATEGIC ISSUES, SET ORGANIZATION GOALS, AND MEASURE RESULTS, IS THAT NOT ADDRESSED, THAT THE RELATIONSHIP BETWEEN THE BOARD CHAIR JOB DESCRIPTION AND THE PRESIDENT AND CEO?

DR. CLARK-HARVEY: PARTLY. AND I THINK THAT IN THE CALL-OUT IN THE -- LET ME FIND IT, SORRY, EXACTLY WHERE THE INCONSISTENCY WAS. BUT I THINK IN THE POSITION DESCRIPTION IT CALLS IT OUT, BUT IT'S NOT FULLY CALLED OUT IN BOARD FUNCTIONS IN 1.2 SO I WON'T TAKE MUCH MEETING TIME HERE, BUT HAPPY TO HAVE A FOLLOW-UP CONVERSATION OR GET SOME CLARIFICATION. IT'S JUST A SUGGESTION TO BE A LITTLE BIT MORE DETAILED. I'LL LEAVE IT AT THAT.

DR. LEVITT: OKAY. ANY OTHER QUESTIONS? ANNE-MARIE.

DR. DULIEGE: YES. ULTIMATELY AFTER THAT, THE NEXT STEP WILL BE THE TWO CO-CHAIRS WILL DELIVER THE REVIEW INDIVIDUALLY AND CONFIDENTIALLY TO THE CHAIR AND THE CO-CHAIR; IS THAT RIGHT, OF THE CIRM?

DR. LEVITT: YES.

BETH C. DRAIN, CA CSR NO. 7152

DR. DULIEGE: OKAY. GREAT. THANK YOU.

DR. LEVITT: SO WITH SOME MINOR RECOMMENDATIONS, SCOTT, WHAT IS YOUR SUGGESTION THAT WE DO IN TERMS OF THIS PROCESS?

MR. TOCHER: I WOULD ASK FOR A VOTE TO APPROVE THE SURVEY QUESTIONS AND JOB DESCRIPTIONS. AND THE TEAM WILL REACH OUT TO LEONDRA TO ADDRESS HER CONCERNS.

DR. LEVITT: WITH THAT IN MIND, WITH THAT CONSTRUCT IN MIND, CAN I HAVE A MOTION TO -- CALLING A MOTION TO APPROVE THE JOB DESCRIPTIONS AND THE REVIEW MATERIALS?

DR. ABOUSALEM: I'LL MAKE THE MOTION.

DR. MALKAS: SECOND.

MR. TOCHER: THANK YOU. WE HAVE THE MAKER MOHAMED ABOUSLEM AND LINDA MALKAS IS THE SECOND.

DR. LEVITT: AND DO WE HAVE ANY FURTHER COMMENTS?

MS. DURON: PAT, YSABEL DURON HERE.

MR. TOCHER: YSABEL. GO AHEAD, YSABEL.

MS. DURON: WELL, PART OF ME DOESN'T KNOW THAT I WANT TO ACCEPT THESE IF THE CORRECTIONS ARE NOT MADE BECAUSE THOSE CORRECTIONS SOUND LIKE THEY'RE ACTUALLY QUITE IMPORTANT WHEN IT COMES TO ACCOUNTABILITY. SO I DON'T KNOW IF I CAN VOTE WITH

BETH C. DRAIN, CA CSR NO. 7152

LIMITED APPROVAL OR ABSTAIN. I JUST REALLY FEEL THAT ACCOUNTABILITY IS TOP OF THE LINE HERE. AND IF IT'S NOT WRITTEN IN AND IT'S NOT UNDERSTOOD AND IF IT'S NOT CLEAR, AND YOU'LL PLEASE PARDON ME IF I DIDN'T READ EVERYTHING WITH A FINE-TOOTH COMB AS LEONDRA DID, BUT I THINK THAT THAT'S HUGELY IMPORTANT. AND SO I DON'T KNOW IF WE NEED TO HOLD ON AND CAN DO THIS VOTE -- WELL, I GUESS WE HAVE TO DO IT IN A MEETING -- OR WHAT YOU CAN RECOMMEND TO ME SO I FEEL THAT I CAN ACCEPT THIS.

DR. CLARK-HARVEY: MAY I CLARIFY, MR. CHAIR? THANK YOU. I APPRECIATE THE CONSIDERATION.

LET ME BE CLEAR. THESE ARE MINOR EDITS. IT'S JUST MORE ABOUT CONSISTENCY, AND I DO FEEL THAT IF THIS WAS -- IF THE AMENDMENT WAS MADE TO VOTE ON THIS WITH MINOR GRAMMATICAL AND CONSISTENCY EDITS, THAT I WOULD BE FINE WITH THAT.

TO GIVE YOU AN EXAMPLE, IN SOME PLACES IT SAYS V-I-D-E. I THINK YOU MEAN TO SAY VICE. AND OTHER PLACES, THERE'S SOME -- I DIDN'T WANT TO BRING THOSE THINGS UP, BUT MY BIGGER POINT WAS CONSISTENCY. THAT CAN HAPPEN EASILY BECAUSE I THINK THE INTENT IS THERE AND THE SPIRIT IS THERE. SO PLEASE DON'T BE BELABORED, BUT I DID WANT TO DO MY DUE DILIGENCE TO ALLOW THAT SPACE TO MAKE EDITS

BETH C. DRAIN, CA CSR NO. 7152

AFTER THE VOTE, IF NEEDED. VERY MINOR.

DR. LEVITT: OKAY. BECAUSE WHAT YOU BROUGHT UP ARE THINGS THAT ARE IN A JOB DESCRIPTION AND NOT FULLY ARTICULATED IN THE REVIEW DOCUMENT OR VICE VERSA, THOSE ARE -- BUT THEY EXIST IN ONE OR THE OTHER DOCUMENTS, YOU'RE LOOKING FOR CONSISTENCY, NOT NECESSARILY A REWORK OF THE COMPONENT PARTS?

DR. CLARK-HARVEY: CORRECT. IT'S JUST CONSISTENCY. SORRY FOR BEING --

DR. LEVITT: DOES THAT HELP?

MS. DURON: YES. THAT IS CLARIFYING.
THANK YOU.

DR. LEVITT: OKAY. GREAT. THANK YOU VERY MUCH FOR YOUR COMMENT. SO COMMENTS FROM THE PUBLIC, SCOTT?

MR. TOCHER: I DON'T SEE ANY.

DR. LEVITT: OKAY. SO WE CAN GO TO A VOTE?

MR. TOCHER: THAT'S RIGHT. ALL THOSE IN THE ROOM IN FAVOR SAY AYE. ANY OPPOSED? ANY ABSTENTIONS? AND I'LL TAKE A ROLL CALL FOR THOSE ON THE PHONE.

MOHAMED ABOUSALEM.

DR. ABOUSALEM: YES.

MR. TOCHER: DEBORAH DEAS.

BETH C. DRAIN, CA CSR NO. 7152

DR. DEAS: YES.

MR. TOCHER: YSABEL DURON.

MS. DURON: YES.

MR. TOCHER: FRED FISHER.

DR. FISHER: YES.

MR. TOCHER: LARRY GOLDSTEIN. LET ME COME

BACK.

RICH LAJARA.

MR. LAJARA: YES.

MR. TOCHER: JOYCE SACKKEY.

DR. SACKKEY: YES.

MR. TOCHER: MICHAEL STAMOS.

DR. STAMOS: YES.

MR. TOCHER: KAROL WATSON.

DR. WATSON: YES.

MR. TOCHER: KEVIN XU.

DR. XU: YES.

MR. TOCHER: KEITH YAMAMOTO.

DR. YAMAMOTO: YES.

MR. TOCHER: LET ME COME BACK TO LARRY.

OKAY. GREAT. THANK YOU VERY MUCH. THE MOTION
CARRIES. THANK YOU, PAT.

DR. LEVITT: THANKS VERY MUCH, SCOTT.

SO THE ITEM NO. 11 FOR US TO CONSIDER IS,
AND YOU ALL HAVE IT AND RECEIVED IT BEFORE THE

BETH C. DRAIN, CA CSR NO. 7152

MEETING, THE JOB DESCRIPTION FOR THE PRESIDENT AND CEO. AND SO, SCOTT, WE CAN DO QUESTIONS, COMMENTS BEFORE WE DO A MOTION?

MR. TOCHER: SURE.

DR. LEVITT: I'M NOT GOING TO READ THROUGH THIS. THIS, AGAIN, WAS BROUGHT TO THE CO-CHAIRS AND THEN BROUGHT TO THE GOVERNANCE COMMITTEE, WENT THROUGH EXTENSIVE LINE-BY-LINE EDITING. WE WANT TO MAKE SURE THAT IT'S COMPREHENSIVE AND CLEARLY COMMUNICATED IN TERMS OF WHAT THE DOMAINS OF RESPONSIBILITY ARE. THERE ARE FIVE DOMAINS THAT INCLUDE STRATEGIC VISION, LEADERSHIP, COMMUNICATION, MANAGEMENT, ADMINISTRATIVE DUTIES, AND FINANCE. AND THEN SOME SPECIFIC ACTIVITIES THAT THEY WILL -- THAT THE INDIVIDUAL WILL ENGAGE IN DURING THEIR TENURE AS PRESIDENT AND CEO. VITO.

CHAIRMAN IMBASCIANI: ACTUALLY THANK YOU, PAT. IT'S MY DOCUMENT, BUT I HAVE ONE GRAMMATICAL ERROR I WANT TO CORRECT. AND THAT IS IN THE FIRST PARAGRAPH, POSITION DESCRIPTION, LINE FOUR, THE WORD "PROVIDE" FOR SYNCHRONIZATION OF SYNTAX SHOULD BE PROVIDES.

DR. CLARK-HARVEY: I WASN'T GOING TO CALL IT OUT, BUT SINCE YOU SAID IT.

CHAIRMAN IMBASCIANI: I WANTED TO BEAT YOU

BETH C. DRAIN, CA CSR NO. 7152

TO IT, LEONDRA.

DR. LEVITT: IT LOOKS LIKE EVERYBODY ON THE BOARD NEEDS A COPY OF "ELEMENTS OF STYLE." BEYOND THAT GRAMMATICAL CORRECTION --

MR. TOCHER: FRED FISHER HAS HIS HAND RAISED.

DR. LEVITT: FRED FISHER ONLINE. FRED, YOU'RE UP.

DR. FISHER: THANKS. JUST A QUICK THING TO POINT OUT. I THINK IN THAT SAME NEIGHBORHOOD THAT VITO WAS TALKING ABOUT, WHERE IT SAYS PROVIDE A STRATEGIC VISION FOR THE FUTURE, I FEEL LIKE THAT'S OVERSTATED. BUT THE ACTUAL WORK CONNECTED TO THE STRATEGIC PLAN AND STRATEGIC VISION IS WELL DESCRIBED LATER IN THE DOCUMENT. BUT -- AND I'M NOT SUGGESTING A REWRITE OR EDITING, BUT JUST POINTING OUT THAT SOME OF THIS NARRATIVE GOES, I THINK, ABOVE AND BEYOND WHAT WE'RE ACTUALLY LOOKING FOR. BUT THE NARRATIVE IS MUCH MORE CLARIFYING AND CORRECT LATER ON IN THE DOCUMENT. SO I'M JUST POINTING THAT OUT, BUT APPRECIATE THE WORK.

DR. LEVITT: SO I SAW THE SAME THING, AND I'M WONDERING IF WE SUBSTITUTED THE WORD, WE ELIMINATE THE WORD "PROVIDES" AND INSERT GUIDES A STRATEGIC VISION FOR THE FUTURE, WOULD THAT BE

BETH C. DRAIN, CA CSR NO. 7152

BETTER ALIGNED WITH WHAT COMES LATER IN THE DOCUMENT, GUIDE?

DR. FISHER: I THINK SO.

DR. LEVITT: OKAY.

DR. FISHER: CEO'S -- STRATEGIC VISION AND STRATEGIC PLAN HAS BEEN STATED BEFORE AS THE ROLE OF THE BOARD, NOT THE STAFF. THE ROLE OF THE STAFF IS TO SUPPORT THE CREATION OF THAT. THAT VISION AND THAT PLAN AND THE EXECUTION OF THAT PLAN, WHICH IS WELL DESCRIBED IN THE DOCUMENT, BUT, YES, ANYTHING THAT TELLS THIS PERSON WE'RE NOT LOOKING FOR YOU TO COME IN AND RESET THE VISION OF THE ORGANIZATION. THAT'S WELL ESTABLISHED AND DOES NOT NEED TO BE TINKERED WITH AT THIS TIME.

DR. LEVITT: OKAY. SO MAYBE IF WE SUBSTITUTE PROVIDES, WHICH IS IMPLIED IN THAT, IS THAT THAT INDIVIDUAL IS GOING TO PROVIDE THE STRATEGIC VISION AS OPPOSED TO GUIDING THE STRATEGIC VISION, WHICH THEY WILL BE PART OF THAT PROCESS ALONG WITH THE TEAM. AND THEN IT ALIGNS BETTER WITH WHAT COMES LATER IN THE DOCUMENT.

DR. DULIEGE: I DON'T WANT TO WORDSMITH SO MUCH, BUT I LIKE THE GUIDE. AND, IN FACT, WE COULD EVEN SAY GUIDE EXISTING STRATEGIC VISION SO IT'S EVEN CLEARER THAT WE'RE NOT GOING. I WOULD SAY FOR

BETH C. DRAIN, CA CSR NO. 7152

THE CIRM. VISION IS ALWAYS FOR THE FUTURE. IT'S REALLY BACKWARD. SO I WOULD SAY GUIDE THE EXISTING STRATEGIC VISION OF THE CIRM AS A SUGGESTION.

DR. LEVITT: SCOTT, YOU WRITING THAT DOWN? GOOD POINT. VERY GOOD POINT.

MR. TOCHER: I'LL READ IT BACK WHEN YOU'RE READY.

DR. SACKY: ACTUALLY I HAVE A COMMENT. CAN YOU HEAR ME?

MR. TOCHER: JOYCE SACKY, YES.

DR. SACKY: THANK YOU. I WONDER IF ACTUALLY BEING AS SPECIFIC AS TO SAY GUIDES THE EXISTING STRATEGIC VISION MIGHT SEEM A LITTLE TOO RESTRICTIVE. WE DON'T KNOW WHAT IS -- WHAT CHANGES IN THE SCIENTIFIC WORLD IS AROUND THE CORNER. I LIKE THE WORD "GUIDES," BUT I'M A LITTLE CONCERNED THAT IF A CANDIDATE THINKS THAT WE HAVE A BAKED-IN STRATEGIC VISION AND THAT IT'S GOING TO BE UNBENDING TO ANY CRISES THAT OCCUR IN THE PUBLIC HEALTH AND SCIENTIFIC WORLD, THEY MIGHT THINK THAT THIS IS NOT A JOB FOR THEM.

SO I'M GOING TO SUGGEST THAT WE DON'T WORRY SO MUCH THAT A PERSON IS COMING IN AND WILL UPEND OR THROW AWAY THE EXISTING VISION, BUT HAVE A LANGUAGE THAT ALSO INVITES A BIT OF FLEXIBILITY IN

BETH C. DRAIN, CA CSR NO. 7152

INNOVATION. THAT WOULD BE MY SUGGESTION.

DR. LEVITT: I THINK THAT'S AN IMPORTANT POINT. AND I THINK IMPLICIT IN GUIDING THE STRATEGIC VISION RATHER THAN PROVIDING A STRATEGIC VISION, I THINK THAT'S AN IMPORTANT CHANGE. AND I THINK GUIDING STRATEGIC VISION, THAT IMPLIES THAT THERE'S A STRATEGIC VISION THAT EXISTS FROM MY PERSPECTIVE. AND I THINK THAT ADDING MORE MODIFIERS TO THAT IS NOT GOING TO BE HELPFUL TO THE SEARCH COMMITTEE IN PARTICULAR OR TO THE CANDIDATES WHO MAY BE INTERESTED IN THIS.

WE ALL IN AGREEMENT WITH THAT ONE?

DR. GASSON: YES.

DR. LEVITT: OKAY. GOOD. ANY OTHER COMMENTS OR QUESTIONS ABOUT THE JOB DESCRIPTION? IF NOT, CALL A MOTION.

MR. TOCHER: THE MAKER IS ANNE-MARIE AND THE SECOND IS LINDA MALKAS.

DR. LEVITT: OKAY. WE'RE OPEN FOR COMMENTS, OTHER COMMENTS. AND COMMENTS FROM THE PUBLIC? ARE THERE ANY?

MR. TOCHER: NO, DOES NOT LOOK SO.

DR. LEVITT: OKAY. SECOND PLACE TOCHER.

MR. TOCHER: GOOD NIGHT, EVERYONE. ALL RIGHT. AS AMENDED AND SHOWN A MOMENT AGO ON THE

BETH C. DRAIN, CA CSR NO. 7152

SCREEN, ALL THOSE IN THE ROOM IN FAVOR SAY AYE. ANY
OPPOSED? ANY ABSTENTIONS? I'LL TAKE ROLL OF THOSE
ON THE PHONE.

MOHAMED ABOUSALEM.

DR. ABOUSALEM: YES.

MR. TOCHER: DEBORAH DEAS.

DR. DEAS: YES.

MR. TOCHER: YSABEL DURON.

MS. DURON: YES.

MR. TOCHER: FRED FISHER.

DR. FISHER: A GRATEFUL YES.

MR. TOCHER: RICH LAJARA.

MR. LAJARA: YES.

MR. TOCHER: JOYCE SACKY.

DR. SACKY: YES.

MR. TOCHER: MICHAEL STAMOS.

DR. STAMOS: YES.

MR. TOCHER: KAROL WATSON.

DR. WATSON: YES.

MR. TOCHER: KEVIN XU.

DR. XU: YES.

MR. TOCHER: AND KEITH YAMAMOTO.

DR. YAMAMOTO: YES.

MR. TOCHER: GREAT. THANKS VERY MUCH,

PAT.

BETH C. DRAIN, CA CSR NO. 7152

DR. LEVITT: OKAY. THANKS VERY MUCH. SO WE'RE ON TO ITEM 12, DISCUSSION OF THE BOARD CHAIR'S PLAN FOR ONBOARDING THE NEW PRESIDENT AND CEO. AND THANK YOU, MR. CHAIR.

CHAIRMAN IMBASCIANI: THANK YOU, PAT. AND THANKS TO THE GOVERNANCE SUBCOMMITTEE FOR ACTUALLY ASKING ME TO THINK ABOUT THIS AND PUT THIS TOGETHER. MY THOUGHTS ARE REPRESENTED ON THIS PAGE. I REALLY WANT TO REASSURE THE BOARD THAT THE REQUEST, WHEN WE FIND OUR NEW PRESIDENT AND CEO, THAT THERE WILL BE A PLAN IN PLACE TO WELCOME THIS PERSON, HE, SHE, OR THEY, AND TO MAKE SURE THAT THEY UNDERSTAND EVERYTHING ABOUT OUR PROGRAMS, OUR PERSONNEL, THE FOUNDING LEGISLATION THAT SUPPORTS US, THEN AGAIN ALL OF OUR SPECIAL COMMITMENTS. BUT I WANT TO SAY AT THE VERY BEGINNING THAT THIS IS SUBJECT TO RADICAL CHANGE DEPENDING ON WHO WE SELECT. AND WHY DO I SAY THAT?

IT WILL DEPEND ON WHETHER OUR NEW PRESIDENT AND CEO COMES FROM INSIDE OR OUTSIDE OF CIRM. AND BY THAT I MEAN OUR CIRM UNIVERSE, ONE OF OUR -- A SUCCESSFUL APPLICANT MAY COME FROM SOMEWHERE WITHIN -- WELL, WE KNOW IT'S NOT GOING TO COME FROM THE BOARD ITSELF, BUT MAYBE FROM OUR ALPHA CLINIC OR OUR WIDE-FLUNG GRANTEE UNIVERSE. IT ALSO

BETH C. DRAIN, CA CSR NO. 7152

DEPENDS ON WHETHER THAT PERSON COMES FROM OUTSIDE CALIFORNIA AND DOESN'T UNDERSTAND THE PECULIARITIES OF OUR STATE OR POSSIBLY EVEN OUTSIDE THE UNITED STATES, IN WHICH CASE THAT PERSON MAY NOT EVEN UNDERSTAND FUNDAMENTAL ASPECTS ABOUT AMERICAN HEALTHCARE DELIVERY.

SO WHEN I SAY RADICALLY ALTERED, A LOT OF THINGS I SPELL OUT IN HERE, IF THEY'RE COMING FROM WITHIN CIRM, WILL ALREADY BE APPARENT TO THEM. THEY MAY HAVE PARTICIPATED IN SOME OF THESE PROCESSES.

SECONDLY, I SPELL OUT -- I'M GIVING YOU MAJOR THEMES HERE, WHO THE SUPPORT PEOPLE WILL BE IN THE ONBOARDING PROCESS. OF COURSE, AND I WELCOME THE TRUST FROM THE BOARD TO BE A PERSON, A PIVOTAL PERSON IN THAT ONBOARDING PROCESS, THE VICE CHAIR EQUALLY SO, IF NOT MORE SO, AND OUR INTERIM PRESIDENT TO THE EXTENT THAT J.T. AND MARIA CREATED AN ONBOARDING CURRICULUM THAT I AVAILED MYSELF OF EARLY ON LAST YEAR. I THANK THEM FOR THAT.

SO THERE WILL BE A LOT OF SUPPORT, NOT TO NEGLECT TO MENTION, THE CHAIRS, VICE CHAIRS, AND CO-CHAIRS OF ALL OF THE SUBCOMMITTEES OF THE BOARD. AND I'VE ALREADY GONE OVER THE CONTENT.

IF YOU TAKE A LOOK AT THESE SIX POINTS, INCLUDING NO. 6, DEPENDING ON WHEN WE SWEAR IN OUR

BETH C. DRAIN, CA CSR NO. 7152

NEW PRESIDENT, WE WILL BE AT SOME POINT IN OUR 2024 TO 2025 BUDGET, SO THEY'LL NEED A SORT OF IMMEDIATE UPDATING ON HOW THAT BUDGET HAS BEEN EXPENDED TO DATE.

IF THERE IS ANYTHING THAT YOU THINK IS SUPERFLUOUS OR HAS BEEN NEGLECTED TO BE MENTIONED, I THINK NOW IS THE OPPORTUNITY TO ADVISE ME ON HOW TO IMPROVE THIS DOCUMENT. THANK YOU.

DR. LEVITT: SO WE HAVE OPPORTUNITY FOR DISCUSSION. ANYBODY ONLINE? OKAY. SO NO DISCUSSION ONLINE. I THINK WE'RE ALL SET.

MR. TOCHER: THAT'S RIGHT. YOU DON'T NEED TO VOTE ON THIS.

DR. LEVITT: WE DON'T NEED TO VOTE ON THIS. SO THANK YOU ALL VERY MUCH FOR YOUR INPUT. AND WE'RE MOVING FORWARD RAPIDLY AND APPROPRIATELY. THANK YOU. SO, MR. CHAIR, IT'S YOUR MEETING.

CHAIRMAN IMBASCIANI: YES. THANK YOU. THANK YOU, PAT. GREAT JOB.

WE'RE GOING TO NOW MOVE ON TO 13, 14, AND 15. THE CONSIDERATIONS OF THE APPLICATIONS FOR THE VARIOUS PROGRAMS. I'M GOING TO INVITE DR. SAMBRANO TO THE PODIUM. SO WE'RE GOING TO START WITH INFRASTRUCTURE 7 PROGRAM FIRST.

BUT BEFORE GIL STARTS, VICE CHAIR.

BETH C. DRAIN, CA CSR NO. 7152

VICE CHAIR BONNEVILLE: SO ONE THING IS THE WHOLE BOARD VOTES ON THIS. SO THAT'S A BIT OF A CHANGE. GENERALLY APPLICATIONS GO TO THE APPLICATION REVIEW SUBCOMMITTEE. BUT AT THE VERY BEGINNING WHEN THEY WERE PUTTING THE BYLAWS TOGETHER FOR THE ACCESSIBILITY AND AFFORDABILITY WORKING GROUP AND THE PRODUCT THAT CAME OUT OF THERE, IT WAS COMMENTED THAT THIS IS SOMETHING THAT THE WHOLE BOARD SHOULD VOTE, ANY PROGRAMS THAT CAME OUT OF THAT. SO JUST TO ESTABLISH THAT.

THIS IS ALSO THE FIRST TIME THE ACCESSIBILITY AND AFFORDABILITY WORKING GROUP MET AS A BODY TO REVIEW APPLICATIONS FOR A GIVEN PROGRAM. AND I WANT TO THANK THE INTERNAL TEAMS WHO WORKED REALLY HARD TO BRING ALL THE MEMBERS, SOME OF WHOM THIS IS THEIR FIRST EXPERIENCE WITH CIRM, UP TO SPEED ON THE REVIEW PROCESS AND THE INTERNAL SYSTEMS. SO, GIL, THANK YOU SO MUCH AND HAVE AT IT.

DR. SAMBRANO: OKAY. THANK YOU VERY MUCH. AND STILL MORNING. GOOD MORNING, EVERYONE. TIME HASN'T ESCAPED THAT QUICKLY. ALL RIGHT.

SO I WANT TO PRESENT TO YOU THE RECOMMENDATIONS FROM THE ACCESSIBILITY AND AFFORDABILITY WORKING GROUP RELATED TO THE PATIENT SUPPORT PROGRAM, THE CONCEPT OF WHICH THE BOARD

BETH C. DRAIN, CA CSR NO. 7152

APPROVED. AND JUST TO START OFF WITH, AS WE DO WITH OUR OVERALL MISSION, THIS IS CERTAINLY WHAT WE LOOKED TO IN ESTABLISHING THE PATIENT SUPPORT PROGRAM, CERTAINLY, CLEARLY A PART OF WHAT WE WANT TO DO, TO FACILITATE ACCESS TO PROGRAMS WHEN POSSIBLE.

SO WE HAVE REACHED AN AMAZING MILESTONE, AND SOME OF YOU MAY ALREADY HAVE SEEN THIS. WE HAVE NOW SURPASSED A HUNDRED CLINICAL TRIALS THAT CIRM HAS SUPPORTED. OVER HALF OF THOSE ARE STILL ACTIVE. AS AN ESTIMATE OF APPROXIMATELY THE NUMBER OF PATIENTS THAT ARE ENROLLED IN OUR CIRM-FUNDED TRIALS, THERE WAS A SURVEY DONE OF ABOUT 200 PATIENTS OVER THE FISCAL YEAR 22/23. SO JUST TO GIVE YOU AN IDEA OF THE NUMBER OF PATIENTS THAT THESE CIRM-FUNDED TRIALS GIVE AN OPPORTUNITY FOR PARTICIPATION IN.

AND OF THOSE PATIENTS, THE TREATMENT SITES REPORT TO US THAT 30 TO 50 PERCENT REQUIRE SUPPORT SERVICES IN SOME FORM.

AND, OF COURSE, RELATED TO THIS, WITH THE PASSAGE OF PROPOSITION 14, PROPOSITION 14 VERY SPECIFICALLY TRIES TO ADDRESS THE ACCESS AND AFFORDABILITY ELEMENT IN PART THROUGH THE PATIENT ASSISTANCE FUND. SO ANY ROYALTY REVENUES THAT ARE

BETH C. DRAIN, CA CSR NO. 7152

RECEIVED THROUGH INTELLECTUAL PROPERTY AGREEMENTS, MEANING ANY SUCCESSFUL PRODUCT DEVELOPMENT THAT HAPPENS THROUGH CIRM-FUNDED PROJECTS, GOES INTO AN INTEREST BEARING ACCOUNT THAT'S INTENDED TO OFFSET COSTS OF PROVIDING TREATMENTS AND CURES TO PATIENTS IN NEED. AND SPECIFICALLY IT ADDRESSES THE REIMBURSEMENT OF PATIENT-QUALIFIED COSTS FOR CLINICAL TRIALS.

AND SO WITH THAT, THEN LOOKING AT THE OVERALL BARRIERS THAT EXIST IN CLINICAL TRIAL PARTICIPATION AND WAYS IN WHICH WE CAN TRY TO MITIGATE THOSE, THERE ARE THREE BASIC AREAS THAT ARE HIGHLIGHTED HERE. ONE BEING AN INFORMATIONAL ONE BEING THAT PATIENTS OR PROVIDERS MAY NOT KNOW THAT A TRIAL EXISTS AND THAT THE PATIENT MAY NOT KNOW HOW TO CONNECT WITH A TRIAL SITE. THERE ARE LOGISTICAL ISSUES: CONSENTING, SCREENING, ENROLLMENT, AND OTHER PROCESSES THAT REQUIRE MULTIPLE STEPS, MAY BE CHALLENGING FOR PATIENTS TO DO WITHOUT SOME COORDINATION OR ASSISTANCE. AND, OF COURSE, THERE'S THE FINANCIAL BARRIER: TRAVEL EXPENSES, MEALS, ACCOMMODATIONS, AND CHILDCARE, OR OTHER OUT-OF-POCKET EXPENSES MAY MAKE IT DIFFICULT FOR PATIENTS TO PARTICIPATE IN A TRIAL. AND THIS IS PARTICULARLY TRUE FOR THOSE THAT ARE FROM

BETH C. DRAIN, CA CSR NO. 7152

UNDERSERVED COMMUNITIES THAT, EVEN IF THEY ARE REIMBURSED FOR THE COST, MAY NOT BE ABLE TO INITIALLY PROVIDE ANY OF THE COSTS UP FRONT.

SO WITH THESE BARRIERS IN MIND, WE SOUGHT TO THEN CREATE A PATIENT SUPPORT SERVICES PROGRAM THAT WOULD UTILIZE THE PATIENT ASSISTANT FUND TO PROVIDE TO PATIENTS. SO I WANT TO USE THIS SLIDE JUST TO CLARIFY THAT THERE ARE TWO SOURCES OF FUNDING THAT SUPPORT THE PROGRAM OVERALL. THERE'S THE PATIENT ASSISTANCE FUND CREATED UNDER PROP 14 THAT BRINGS IN FUNDS FROM ROYALTIES. AND SO CURRENTLY THAT FUND IS AT ABOUT 15.6 MILLION. IT HAS THE CAPACITY TO INCREASE OVER TIME. BUT AT THE MOMENT IT'S APPROXIMATELY THAT AMOUNT.

SEPARATE FROM THAT, WE ARE THEN SUPPORTING A PATIENT SUPPORT AWARDEE, PROGRAM AWARDEE, WITH 2.5 MILLION. SO THIS IS COMING FROM OUR RESEARCH FUNDS. AND SO THOSE RESEARCH FUNDS WILL SUPPORT THE INFRASTRUCTURE THAT ALLOWS US TO THEN DISBURSE THAT PATIENT ASSISTANT FUND MONEY TO PATIENTS. SO WHAT THIS WILL DO IS IT WILL BE A PROGRAM THAT'S SUPPORTED BY THE CIRM PROGRAM BUDGET IN ORDER TO IMPLEMENT THE DESIGN, PLANNING, AND OPERATIONAL EXPENSES OF THAT PROGRAM. AND THAT'S THE FOCUS OF WHAT THIS REQUEST FOR APPLICATIONS THAT WENT OUT,

BETH C. DRAIN, CA CSR NO. 7152

WHAT THE FOCUS OF THE APPLICATIONS THAT WE HAVE FOR APPLICANTS TO APPLY FOR, AND WHAT WAS REVIEWED BY THE AAWG.

ALL RIGHT. TO FOCUS IN ON THIS PATIENT SUPPORT PROGRAM, IT IS DESIGNED SPECIFICALLY TO ADDRESS THE BARRIERS THAT I PRESENTED TO YOU EARLIER. IT WILL ADDRESS THE INFORMATIONAL, LOGISTICAL, COORDINATION, AND FINANCIAL ELEMENTS TO THE ACTIVITIES LISTED UNDER EACH OF THOSE THAT ARE EXPECTED AND ALLOWABLE UNDER THE AWARD. THE AWARDEE WOULD HELP US MAINTAIN A PATIENT SUPPORT CENTER, TO DIRECT PATIENTS TO CLINICAL TRIALS, TO COORDINATE WITH SPONSORS TO VERIFY AUTHORIZATION OF PARTICIPATION IN THOSE TRIALS, DETERMINE IF THE PATIENT IS ELIGIBLE FOR FINANCIAL SUPPORT, TO HELP US MANAGE REFERRALS, COORDINATE VISITS ON BEHALF OF THE PATIENTS, AND ALSO ADMINISTER THE PATIENT ASSISTANT FUNDS TO COVER THE TRAVEL EXPENSES, MEALS, ACCOMMODATIONS, AND SO ON FOR INDIVIDUAL PATIENTS. BUT ALSO, IMPORTANTLY, TO DEVELOP AN ACCOUNTING SYSTEM TO FACILITATE THOSE DISBURSEMENTS, REPORT THEM TO CIRM AND ENSURE THAT THERE'S NONDUPLICATION OF COST OR EXPENSES GIVEN SOME OF THOSE COSTS COVERED BY THE CIRM-FUNDED TRIAL UNDER THE CLIN2 AWARD.

**133 HENNA COURT, SANDPOINT, IDAHO 83864
208-920-3543 DRAIBE@HOTMAIL.COM**

BETH C. DRAIN, CA CSR NO. 7152

SO THOSE ARE THE HIGHLIGHTS OF THE PROGRAM AND WHAT IT DOES.

SO THE SUCCESSFUL AWARDEE IN IMPLEMENTING THIS PATIENT SUPPORT PROGRAM WOULD GO THROUGH THREE PHASES THE WAY WE HAVE ORGANIZED THIS. WE WOULD EXPECT THE AWARDEE TO HAVE A START-UP PHASE OF LIKELY A FEW MONTHS, MAYBE ABOUT SIX MONTHS. THE START-UP PHASE IS FOR THE PROGRAM PLANNING, DEVELOPMENT OF THE OPERATIONAL SYSTEM, ESTABLISHING BUSINESS RULES, SOP'S AND PROGRESS FLOWS, AND TESTING OF THE PROGRAM. THE IDEA BEHIND THIS IS THAT THE AWARDEE IS NOT NECESSARILY GOING TO KNOW ALL THE DETAILS OF INTERACTION THAT CIRM HAS WITH ALL OF ITS CLINICAL TRIAL AWARDEES OR THE ALPHA CLINICS, FOR EXAMPLE. SO THERE IS A NEED FOR US TO WORK WITH THE AWARDEE TO HELP ESTABLISH THE APPROPRIATE SET OF REQUIREMENTS THAT ARE NEEDED IN ORDER TO HAVE A SUCCESSFUL PROGRAM. SO THERE IS AN EXPECTED INTERACTION THAT HAPPENS WITH CIRM WITH THE AWARDEE IN ORDER TO SET THAT UP.

THEN WE'LL FOLLOW THE LAUNCH OF THE PATIENT SUPPORT PROGRAM. THAT'S THE PHASE 1 IMPLEMENTATION. DURING THIS TIME OF LAUNCH, WE EXPECT THAT THE AWARDEE HAVE METRICS AND CONDUCT GAP ANALYSIS TO REPORT BACK TO CIRM ON HOW OVERALL THE

BETH C. DRAIN, CA CSR NO. 7152

PROGRAM IS GOING, AND FOR THEN TO WORK WITH CIRM TO DETERMINE HOW TO MAKE ADJUSTMENTS THAT MAY THEN IMPACT ON THE PHASE 2 PART, WHICH IS EXPANSION OF THE PATIENT FINANCIAL AND LOGISTICAL SUPPORT SERVICES AS NEEDED.

OKAY. IN TERMS OF QUALIFICATIONS FOR COMING IN AND APPLYING FOR THE PSP PROGRAM, WE WERE LOOKING FOR ANY FOR-PROFIT OR NON-PROFIT ORGANIZATION THAT HAS AT LEAST FIVE YEARS OF EXPERIENCE IN A PATIENT SUPPORT PROGRAM OR SERVICES. AN APPLICANT MUST BE ABLE TO INITIATE THE SERVICES WITH 120 DAYS OF THE FINAL CONTRACT. THAT MEANS INITIATING THE START PHASE, NOT LAUNCH THE PROGRAM NECESSARILY, WITHIN THE 120 DAYS. THE APPLICANT MUST HAVE A CALIFORNIA LOCATION AND MUST PROVIDE EVIDENCE OF ADHERING TO THE BEST PRACTICES FOR PATIENT SUPPORT PROGRAMS.

SO IN TERMS OF REVIEWING THE APPLICATIONS THAT CAME TO CIRM, AS I MENTIONED, THERE WERE FOUR APPLICATIONS THAT CAME IN. AND ALSO AS MENTIONED BY MARIA BONNEVILLE, THIS IS THE FIRST TIME THAT THE AAWG HAS ENGAGED IN A REVIEW OF APPLICATIONS. SO WE ADOPTED THE GRANTS WORKING GROUP REVIEW PROCESS GENERALLY THAT WE UTILIZE AND ADOPTED IT FOR AAWG. AND SO WE WENT THROUGH THESE SAME THREE PHASES OF

BETH C. DRAIN, CA CSR NO. 7152

APPLICATION SUBMISSION, ASSESSING ELIGIBILITY OF THE APPLICATIONS THAT CAME IN, THOSE THAT WERE ACCEPTED WENT THROUGH THE MERIT REVIEW BY AAWG, A RECOMMENDATION WAS MADE BY THE AAWG WHICH WE ARE BRINGING TO YOU TODAY FOR FINAL DECISION BY THE FULL BOARD.

THE COMPOSITION OF THE AAWG INCLUDES AAWG MEMBERS THAT HAVE BEEN APPOINTED BY THE BOARD TO SERVE IN THIS CAPACITY AS WELL AS MEMBERS WHO ARE ALSO PART OF THE ICOC. IN BOTH CASES THEY HAVE ESSENTIALLY THE SAME ROLE, UNLIKE GWG WHERE THE ROLES ARE A LITTLE BIT DIFFERENT. HERE BOTH TYPES OF MEMBERS PARTICIPATE IN THE TECHNICAL EVALUATION OF THE APPLICATION, AND THEY PROVIDE A SCORE ON ALL THE APPLICATIONS.

THE SCORING SYSTEM THAT WAS USED IS THE SAME THAT WE USE FOR INFRASTRUCTURE PROGRAMS, WHICH IS A SCORE OF 1, 2, OR 3. A SCORE OF 1 MEANS THAT THE APPLICATION RECEIVED EXCEPTIONAL MERIT AND WARRANTS FUNDING. A SCORE OF 2 MEANS IT NEEDS IMPROVEMENT, DOESN'T WARRANT FUNDING AT THIS TIME, BUT MAY BE RESUBMITTED IF AN APPLICATION HAS NOT BEEN APPROVED BY THE BOARD. AND IN THIS CASE I JUST WANT TO HIGHLIGHT THE FACT THAT WE'RE LOOKING TO FUND A SINGLE ENTITY, NOT MULTIPLE ONES. SO THIS

BETH C. DRAIN, CA CSR NO. 7152

BECOMES VERY IMPORTANT IN TERMS OF A SCORE OF 2.
THE SCORE OF 3 IS FOR THOSE THAT ARE -- APPLICATIONS
THAT ARE SUFFICIENTLY FLAWED THAT DO NOT WANT
FUNDING.

THE REVIEW CRITERIA THAT WERE UTILIZED BY
THE AAWG ARE BASED ON THESE FIVE QUESTIONS. DOES
THE APPLICATION OFFER A MEANINGFUL VALUE PROPOSITION
TO IMPROVE ACCESS AND RETENTION TO CIRM-FUNDED
CLINICAL TRIALS THROUGH ITS PROPOSED PATIENT SUPPORT
SERVICES? IS THE PROJECT WELL PLANNED AND DESIGNED?
IS IT FEASIBLE? AND DOES IT UPHOLD THE PRINCIPLES
OF DIVERSITY, EQUITY, AND INCLUSION?

AND THEN, OF COURSE, IN CONSIDERING DEI,
THIS IS JUST A NOTE THAT WAS MADE TO THE AAWG AND
ALSO APPLIES TO THE ICOC, THAT WE ARE STILL BOUND BY
PROP 209 IN TERMS OF OUR CONSIDERATION OF DEI WITHIN
APPLICATIONS. SO IT MEANS THAT, IN GENERAL,
REVIEWERS AND THE BOARD ARE FREE TO EVALUATE ALMOST
ANY ASPECT OF DEI THAT IS PERTINENT, BUT WE MUST
REFRAIN FROM CONSIDERING THE RACE, ETHNICITY,
NATIONAL ORIGIN, OR GENDER OF THE APPLICANT TEAM
PERSONNEL SPECIFICALLY. SO AS LONG AS WE DON'T DO
THAT, WE ARE GENERALLY OKAY.

AND SO THEN THAT BRINGS US TO THE SUMMARY
TABLE OF THE RECOMMENDATIONS OF THE AAWG. SO AS

BETH C. DRAIN, CA CSR NO. 7152

MENTIONED, FOUR APPLICATIONS WITH SIMILAR BUDGET REQUESTS. THE BUDGET ALLOWS FOR A FIVE-YEAR AWARD. THE OTHER THING THAT MAYBE I FORGOT TO MENTION WAS THAT THE 2.5 MILLION IS SET UP WITH MILESTONES AS WE DO WITH OUR OTHER PROJECTS. SO THE PHASES THAT YOU SAW WILL ALLOW US TO SET SPECIFIC MILESTONES SUCH THAT IF THEY DON'T MEET THOSE MILESTONES, THEN THE AWARD COULD BE TERMINATED AT THAT POINT.

SO FOR THE RECOMMENDATIONS, THERE WAS ONE APPLICATION THAT RECEIVED AN OVERALL SCORE OF 1. THE TOP ONE WHICH RECEIVED SEVEN VOTES FOR A SCORE OF 1, SIX FOR A SCORE OF 2. THE CIRM TEAM RECOMMENDATION IS TO FUND THAT APPLICATION. THE THREE OTHER APPLICATIONS RECEIVED A SCORE OF 2. THEY HAD A MAJORITY OF VOTES IN THE 2 CATEGORY, BUT ALSO HAD A NUMBER OF VOTES IN THE SCORE OF 3, MEANING DO NOT FUND. SO JUST WANT TO HIGHLIGHT THAT, AND I WILL TAKE ANY QUESTIONS.

VICE CHAIR BONNEVILLE: ARE THERE ANY BOARD MEMBER QUESTIONS? ANNE-MARIE.

DR. DULIEGE: EXCELLENT AS ALWAYS.

MS. DURON: SORRY. SORRY. IT'S YSABEL.

DR. DULIEGE: I'M SO SORRY.

VICE CHAIR BONNEVILLE: ANNE-MARIE HAD HER RAISED AS WELL, YSABEL.

BETH C. DRAIN, CA CSR NO. 7152

DR. DULIEGE: THAT'S OKAY. PLEASE GO AHEAD. BE MY GUEST, YSABEL. I'LL GO AFTER YOU.

MS. DURON: THANK YOU. I WAS A LITTLE LATE ON THE DRAW WITH MY MUTE BUTTON. SO THANK YOU, ANNE-MARIE.

VERY EXCITING, GLAD TO SEE THIS KICK OFF. I DO HAVE SOME CONCERNS AND HOPE THAT THEY CAN BE ADDED TO THE APPLICATION MATERIAL. ONE OF THOSE SHOULD BE ALL SERVICES MUST BE PROVIDED IN THE LANGUAGE APPROPRIATE TO THE PATIENT AND DON'T DEPEND ON THE FAMILY MEMBER TO INTERPRET BECAUSE EVEN THEY CAN MAYBE NOT UNDERSTAND AND WILL MISINTERPRET. SO IT SHOULD BE APPROPRIATE TO THE PATIENT.

THE MATERIALS PROVIDED SHOULD BE AT A LITERACY LEVEL THAT'S UNDERSTANDABLE TO THE PATIENT AND THE FAMILY.

AND THIRDLY, IF THERE IS CONSENT IN, YOU MUST, I WOULD MOTION -- MAYBE STEVE CAN HELP ME WITH THIS. HE ALWAYS DOES -- A MOTION THAT IF THERE'S CONSENT IN AND THAT THERE IS A STATEMENT WITHIN THE CONSENT IN THAT SAYS THEIR DATA WILL BE USED FOR FURTHER RESEARCH, THAT THEY HAVE THE OPPORTUNITY TO OPT OUT OR THAT NEEDS TO BE EXPLAINED TO THEM WHAT IT EXACTLY MEANS.

HAVING NOT SEEN ALL THE DOCUMENTS, GIL, I

BETH C. DRAIN, CA CSR NO. 7152

DON'T KNOW IF THESE ARE THERE. I DON'T KNOW IF I CAN ADD OR AMEND, BUT I DO THINK THESE ARE VERY PARTICULAR FOR THESE POPULATIONS WITH WHOM WE ARE TRYING TO ENGAGE.

DR. SAMBRANO: YSABEL, THANK YOU FOR THAT. I THINK THOSE ARE VERY IMPORTANT CONSIDERATIONS. THAT IS THE KIND OF DETAIL THAT WE WOULD EXPECT TO BE WORKING OUT WITH THE AWARDEE TO ENSURE THAT THEY IMPLEMENT THAT AS PART OF THEIR SOP'S AND ALL OF THE DIFFERENT ELEMENTS THAT THEY HAVE TO DEVELOP AS REQUIREMENTS IN PERFORMING AND IMPLEMENTING THIS PATIENT SUPPORT PROGRAM.

THE LEVEL OF DETAIL THAT WE WERE LOOKING AT FOR THE APPLICATIONS WAS ONE OF THEIR CAPABILITY, THUS DEMONSTRATING IN THEIR APPLICATION THAT THEY HAVE THE CAPABILITY TO PARTNER WITH CIRM, THAT THEY HAVE EXPERIENCE WITH THESE TYPES OF ACTIVITIES IN THE PAST, AND GIVE US CONFIDENCE THAT THEY WILL BE ABLE TO SUCCEED ONCE WE ESTABLISH THIS PROGRAM.

MS. DURON: GIL, I THINK I WOULD EVEN HAVE MORE CONFIDENCE IF I KNEW THIS STUFF WAS WRITTEN DOWN AND THEY KNEW THESE WERE THINGS THEY NEEDED TO MEET IN ORDER TO QUALIFY BECAUSE I THINK, TO ME, SOMETIMES IT'S CHECK THE BOX. OH, YES, WE CAN DO THAT. OH, YES, WE CAN DO THAT. BUT UNLESS THEY

BETH C. DRAIN, CA CSR NO. 7152

AGREE TO IT AND THEY CAN BE HELD ACCOUNTABLE FOR NOT RESPONDING CORRECTLY AT THE MILESTONE LEVEL, THEN WE CAN DO SOMETHING ABOUT IT AND NOT PRETEND THEY DIDN'T KNOW.

VICE CHAIR BONNEVILLE: YSABEL, THAT'S A CONSIDERATION, OF COURSE. AND I KNOW THAT THE TEAM WILL WORK WITH THE APPLICANT TO ENSURE THAT THIS OCCURS AND IS PART OF THE PROGRAM AND IS MILESTONED SO THAT IT IS CLEAR. WHAT WILL HAPPEN IS THE TEAM WILL WORK WITH THE APPLICANT MOVING FORWARD TO SET UP ALL THE BUSINESS RULES OF EVERYTHING THAT MUST BE PROVIDED. THE APPLICATION ALREADY EXPRESSED THAT THEY HAVE TRANSLATION SERVICES AVAILABLE IN, I'M NOT EXACTLY SURE HOW MANY LANGUAGES, BUT SEVERAL TO ADDRESS THE POPULATION OF CALIFORNIA.

SO THERE ARE THOSE DIFFERENT LEVELS THAT WILL BE WORKED OUT, AND WE WILL ENSURE THAT YOUR CONSIDERATIONS ARE MET.

MS. DURON: THANK YOU.

VICE CHAIR BONNEVILLE: I BELIEVE ANNE-MARIE IS NEXT.

DR. DULIEGE: FIRST OF ALL, GIL, AS I SAID, ALWAYS CLEAR, EXTREMELY PRECISE. ARE YOU SAYING THAT WE'RE REALLY AT THE END OF THE SELECTION PROCESS, WHICH IS GREAT, WHICH IS YOU HAVE A

BETH C. DRAIN, CA CSR NO. 7152

RECOMMENDATION? WE NEED TO MOVE ON AND NOW IMPLEMENT THE PROCESS. AND YOU'LL PROBABLY TELL US WHICH IS THIS GROUP AFTER EVERYTHING HAS BEEN VOTED TO PRESERVE SORT OF IMPARTIALITY; IS THAT CORRECT?

DR. SAMBRANO: YES.

DR. DULIEGE: GREAT. THANK YOU. REALLY GREAT.

TWO COMMENTS. ONE IS I COULDN'T HELP BUT NOTICING THAT YOU SAID THAT SO FAR CIRM SINCE ITS INCEPTION HAS FUNDED 103 CLINICAL TRIALS, WHICH IS REMARKABLE, AND ENROLLED 200 PATIENTS.

DR. SAMBRANO: IN THE FISCAL YEAR 22/23.

DR. DULIEGE: OKAY. THANK YOU. THAT REASSURES ME. I MISSED THAT POINT. IT IS NOT JUST A NUANCE HERE.

SO THEN MY QUESTION COMES TO THIS IS A WORK THAT IS GOING TO SUPPLEMENT AND HELP THE ALPHA CLINICS?

DR. SAMBRANO: YES. SO THERE'S -- YES. OUR EXPECTATION IS THAT THERE'S GOING TO BE A PARTNERING WITH THE ALPHA CLINICS WITH CIRM IN ORDER TO IMPLEMENT THE PROGRAM.

DR. DULIEGE: SO AT SOME POINT, NOT NOW, BUT COULD THERE BE SOMETHING BACK TO THE CIRM AS TO A CRITICAL EVALUATION OF THE ACHIEVEMENTS OF THE

BETH C. DRAIN, CA CSR NO. 7152

ALPHA CLINICS? AND WE HAVE HAD UPDATES REGULARLY. SO IT'S NOT THAT WE DON'T KNOW WHAT'S GOING ON AT ALL. BUT IT WOULD BE GOOD TO HAVE A LOOK THAT IS SOMEWHAT OF A CRITICAL LOOK. HOW MANY, HOW MUCH MILLIONS OF DOLLARS HAVE WE SPENT ON ALPHA CLINICS? WHAT HAS WORKED AND WHAT HASN'T WORKED? AND PARTICULARLY IN TERMS OF PATIENT ENROLLMENT, I TRUST THAT THEY WOULD DO A SUPER JOB IN TERMS OF CLINICAL TRIALS IMPLEMENTATION.

AND THE REASON WHY I'M SUGGESTING THIS IS BECAUSE IT WILL HELP US BETTER UNDERSTAND THE ADDED ROLE, WHICH WE KNOW, WHICH IS A REALITY OF THIS ENTITY, BUT JUST A CRITICAL FEEDBACK IN GENERAL IN THE FUTURE WOULD BE GREAT. THANK YOU.

DR. SAMBRANO: THANK YOU VERY MUCH.

VICE CHAIR BONNEVILLE: JUDY.

DR. CHOU: MAYBE MORE FOR CLARIFICATION THAN QUESTION. RUNNING A CLINICAL TRIAL, AND I UNDERSTAND THE REQUIREMENT ABOUT HAVING AT LEAST ONE CALIFORNIA SITE, BUT THEN WHEN WE FUND THIS PROGRAM, DO WE PARTICULARLY FUND THIS CALIFORNIA SITE OR IS ALL DISTRIBUTE TO ALL THE CLINICAL SITE?

AND THE SECOND QUESTION IS THEN WHEN SUPPORTING THE PATIENT, HOW MUCH OVERSIGHT WE HAVE. IS THAT REALLY IN THE FULL SPIRIT ACROSS ALL THE

BETH C. DRAIN, CA CSR NO. 7152

PATIENTS? OR THE SITE HAS THE RIGHT OR PROGRAM AWARDEE WILL HAVE THE RIGHT TO DECIDE WHICH PATIENT THEY WILL BE FUNDING OR SUPPORTING?

DR. SAMBRANO: RIGHT. SO IN TERMS OF THE CLINICAL SITE, SO WE WOULD WORK WITH THE APPLICANT. SO THEY MAY HAVE SITES WITHIN CALIFORNIA AS WELL AS OUTSIDE OF CALIFORNIA DEPENDING ON THE TRIAL. SOME ARE FULLY IN CALIFORNIA. SO THE EXPECTATION WOULD BE WE WOULD WORK WITH THE PATIENTS THAT QUALIFY FOR THAT TRIAL.

THE PATIENT SUPPORT PROGRAM WOULD, BASED ON THE BUSINESS RULES THAT ARE ESTABLISHED, DETERMINE WHETHER A GIVEN PATIENT INDIVIDUALLY QUALIFIES FOR A TRIAL OR NOT, WHETHER THEY CAN OR SHOULDN'T BE REIMBURSED, OR IF COSTS COULD BE COVERED, SAY, THROUGH THE CLIN2 AWARD THAT WE GAVE THE AWARDEE OR THROUGH THE PATIENT ASSISTANCE FUND. SO ALL OF THOSE RULES THAT ARE PERTINENT TO THAT SPECIFIC PATIENT WOULD COME INTO PLAY.

DR. CHOU: JUST TO BETTER UNDERSTANDING. SO THEN IF THE FUNDING GO TO THIS PARTICULAR AWARDEE, AND THEN THE SUPPORTING PROGRAM TO THE PATIENT OUTSIDE OF CALIFORNIA, WE ALSO PRETTY MUCH SUPPORTING THAT GIVEN --

DR. SAMBRANO: IT WOULD BE ONLY FOR

BETH C. DRAIN, CA CSR NO. 7152

CALIFORNIA PATIENTS.

DR. CHOU: OKAY. THANK YOU.

CHAIRMAN IMBASCIANI: FRED FISHER.

DR. FISHER: THIS REFLECTS AN ISSUE THAT HAS COME UP RECENTLY IN SEVERAL OF THE GRANT WORKING GROUPS WHERE THE QUESTION OF HOW MANY CALIFORNIA PATIENTS ARE BEING SERVED OR HAVE ACCESS TO A PARTICULAR CLINICAL TRIAL OR PROGRAM THAT WE'RE FUNDING VERSUS HOW MANY ARE OUT-OF-STATE. WE'VE HAD APPLICANTS PROPOSING ONE SITE IN CALIFORNIA OR FOUR SITES IN CALIFORNIA, BUT THEN SITES IN SIX OR SEVEN OTHER STATES.

AND SO AS PART OF THE PROCESS THAT THE STAFF ARE GOING THROUGH IN EVALUATING OUR FUND ALLOCATION METHODOLOGIES, I'D ASK THAT THE GROUP DOING THIS ASSESSMENT CONTEMPLATE IF THERE SHOULD BE SOME RATIO OF SUPPORT FOR INSIDE VERSUS OUTSIDE OF CALIFORNIA. ANYWAY, I THINK PEOPLE CAN SEE THE CHALLENGE OF EXPENDING THE MAJORITY OF FUNDS ACTUALLY ON OUTSIDE OF CALIFORNIA SITES AND OUTSIDE OF CALIFORNIA PATIENTS EVEN THOUGH THOSE PATIENTS MIGHT BE FORMER CALIFORNIANS. THAT'S NOT A CRITERIA.

VICE CHAIR BONNEVILLE: FRED, THIS FUND IS ONLY FOR PATIENTS WHO ARE TREATED IN CALIFORNIA.

BETH C. DRAIN, CA CSR NO. 7152

DR. FISHER: YEAH AND I GET THAT. I'M SIMPLY SUGGESTING THAT IN OTHER PROGRAMS WHERE THAT'S NOT THE CASE, THAT AS PART OF THE ASSESSMENT PROCESS THAT THE STAFF ARE GOING THROUGH, THE PRIORITIZATION PROCESS THAT THE STAFF IS GOING THROUGH, THAT THEY TAKE UP THE QUESTION.

VICE CHAIR BONNEVILLE: THANK YOU. STEVE.

MR. JUELSGAARD: SO JUST TO DOUBLE DOWN ON THIS ISSUE, JUST TO BE VERY, VERY CLEAR, AMONGST THE THREE TYPES OF COST, DIRECT, INDIRECT AND INFRASTRUCTURE COSTS, GENERALLY SPEAKING, WE'RE ONLY REIMBURSING DIRECT COST BECAUSE THAT'S THE ONLY WAY WE CAN TRULY SERVE CALIFORNIA PATIENTS AND WE IGNORE INDIRECT COSTS; THAT IS, OVERHEAD, GNA, ETC., OR BUILDING INFRASTRUCTURE COSTS WHICH IS DIRECT COSTS, RIGHT?

VICE CHAIR BONNEVILLE: IT IS FOR THINGS LIKE TRAVEL COST. THE TRAVEL, ROOM AND BOARD, DO THEY NEED A BABYSITTER FOR THE DAY.

MR. JUELSGAARD: THOSE ARE ALL DIRECT COSTS.

VICE CHAIR BONNEVILLE: YES.

MR. JUELSGAARD: OKAY. GOOD.

DR. SAMBRANO: YES. JUST FOR CLARITY, THAT'S ALL COMING FROM THE PATIENT ASSISTANCE FUND.

BETH C. DRAIN, CA CSR NO. 7152

THE AWARD THAT YOU'RE APPROVING NOW IS ACTUALLY FOR THE INFRASTRUCTURE THAT'S GOING TO DISBURSE THOSE FUNDS DIRECTLY TO THE PATIENT.

MR. FISCHER-COLBRIE: SORRY. I HAVE SEVERAL CLARIFICATION QUESTIONS AS WELL. FIRST OF ALL, OBVIOUSLY THERE'S BUDGET ALLOCATED FOR PHASE 1 OR PHASE 2 CLINICAL TRIALS FOR THIS KIND OF DIRECT SUPPORT. SO I WASN'T CLEAR IN MY HEAD HOW THIS FITS IN WITH THAT. THAT'S ONE QUESTION.

SECOND ONE IS I'M NOT SURE I UNDERSTAND HOW THE COSTS CORRELATE IN IRB APPROVAL THAT MIGHT BE RUNNING FOR SUPPORTING SOME OF THE COSTS AND HOW THIS WOULD FEED INTO AN IRB REVIEW AND APPROVAL.

AND SO THE THIRD THING IS IT'S CLEAR THIS IS FOR CALIFORNIA SITES, BUT JUST AS AN INJUNCTIVE ELEMENT TO THE DISCUSSION, THERE ALSO IS A PREVIOUS DISCUSSION ABOUT WHETHER IT'S FOR CALIFORNIA RESIDENTS AS OPPOSED TO PEOPLE FLYING IN, WE'RE INCURRING COST FOR THAT IN ANOTHER PART OF THE WORLD OR ANOTHER PART OF THE COUNTRY. SO THAT'S KIND OF A SEPARATE ELEMENT TO THE FOLLOW-UP. SO JUST SOME CLARIFICATION QUESTIONS.

DR. SAMBRANO: OKAY. I THINK SHYAM OR GEOFF, I THINK, WHO KNOW THE PROGRAM BEST, MAY BE BEST AT ADDRESSING THOSE QUESTIONS.

BETH C. DRAIN, CA CSR NO. 7152

DR. PATEL: YEAH. I COULDN'T FIND THE ON
BUTTON ON THE MICROPHONE. SORRY. I TOUCHED AND
MADE IT WORK.

SO I JUST WANT TO CLARIFY A COUPLE OF
THINGS, THEN I'LL GET TO MARK'S QUESTIONS. MARK, I
APOLOGIZE. I MISSED THE FIRST QUESTION, BUT I DID
CATCH THE OTHER TWO.

SO, FIRST OF ALL, JUST TO BE CLEAR, THE
\$2.5 MILLION IS AN AWARD TO THE AWARDEE FOR
ADMINISTRATIVE EXPENSES FOR THE SERVICES THEY'LL BE
PROVIDING IN TERMS OF INFORMATIONAL, LOGISTICAL, AND
FINANCIAL SUPPORT.

THE \$15.6 MILLION PATIENT ASSISTANCE FUND,
THAT IS VERY SPECIFICALLY DIRECTED TOWARDS
SUPPORTING COSTS OF CALIFORNIA PATIENTS AS SPECIFIED
BY PROPOSITION 14. SO I HOPE THAT HELPS ANSWER
THOSE QUESTIONS AROUND CALIFORNIA PATIENTS. AND IT
WOULD BE DIRECT COSTS FOR THAT AS WELL AS ANY
TRANSACTIONAL COSTS ASSOCIATED WITH THAT.

TO THE QUESTIONS THAT MARK RAISED, WITH
RESPECT TO THE IRB, SO RIGHT NOW IN A CLIN2 GRANT,
AN APPLICANT, A SPONSOR OF A TRIAL, WILL PROPOSE
PROVIDING SOME OF THE PATIENT SUPPORT IN THERE. AND
THAT IS WHAT IS BAKED INTO THE PROTOCOL. AND IN
MANY INSTANCES, THAT MAY NOT BE ENOUGH TO SUPPORT

BETH C. DRAIN, CA CSR NO. 7152

THOSE PATIENTS. AND IN THOSE INSTANCES, THE SITES ARE LOOKING AT OTHER WAYS TO BRING IN SUPPORT FOR THOSE PATIENTS.

SO THE WAY WE ENVISION THIS PATIENT ASSISTANCE FUND PROGRAM WORKING IS THAT, FIRST OF ALL, THE SPONSOR SUPPORT WOULD HAVE TO BE DEPLOYED FIRST, AND THEN THIS FUND WOULD THEN SUPPORT THOSE CALIFORNIA PATIENTS WHERE THEY HAVE THEIR NEEDS. AND IT WILL BE VERY TRANSPARENT IN THE TYPES OF SUPPORT THAT IT'S PROVIDING TO PROVIDE REASSURANCE TO THE IRB.

MR. FISCHER-COLBRIE: YEAH. SO THEN IT KIND OF GETS BLENDED, AND THEN IT'S A LITTLE TOUGH. IT'S LIKE THEY'RE PROPOSING A BUDGET FOR PATIENT ASSISTANCE. SO PRESUMPTIVELY THERE SHOULD BE SUFFICIENT DOLLARS BASED ON THE BUDGET PROPOSED IN THEIR GRANT. SO THEN THE -- THAT'S WHY I'M NOT CLEAR ABOUT, WELL, THEN IT MIGHT NOT BE ENOUGH. HOW DOES THAT GET DETERMINED? IS THAT EX POST FACTO? I'M JUST NOT CLEAR ABOUT HOW THAT WOULD GET ADMINISTERED. SO THAT'S WHY -- ONE OF THE SOURCES FOR MY CONFUSION AROUND THAT.

DR. PATEL: YEAH. SO ONE OF THE THINGS THAT WE CAN HIGHLIGHT ON THAT POINT IS THAT, AS GIL MENTIONED, THERE IS GOING TO BE THIS PLANNING PHASE.

BETH C. DRAIN, CA CSR NO. 7152

AND SO THE WAY THIS PROGRAM IS GOING TO BE ADMINISTERED AND THAT'S THE WAY THIS AWARD IS GOING TO BE MANAGED IS THAT INITIALLY CIRM IS GOING TO WORK HAND IN HAND WITH THE AWARDEE DURING THAT PLANNING PHASE TO GATHER DATA ON OUR TRIALS RIGHT NOW AND HOW PATIENT SUPPORT IS -- WHERE THE GAPS IN PATIENT SUPPORT ACROSS OUR TRIALS AS WELL AS GET DATA ON THE TRIALS THAT WE'RE ACTUALLY FUNDING. AND PART OF THAT THEN IS GOING TO FEED INTO CREATING THE BUSINESS RULES THAT WOULD ESTABLISH HOW THIS PARTICULAR PATIENT ASSISTANCE FUND IS GOING TO BE DEPLOYED AS WELL AS INFORMATIONAL AND LOGISTICAL ELEMENTS THAT THE AWARDEE WOULD BE PROVIDING.

AT THE END OF THAT, HAVING DONE A PILOT TEST OF THOSE SERVICES IS WHEN THIS AWARD WOULD GO INTO THE IMPLEMENTATION PHASE, AT WHICH POINT THEY WOULD HAVE ACCESS TO THE PATIENT ASSISTANCE FUND. SO UNTIL ALL OF THOSE THINGS HAVE BEEN WORKED OUT, NONE OF THE PATIENT ASSISTANCE FUND DOLLARS ARE ACTUALLY GOING TO BE DEPLOYED.

MR. FISCHER-COLBRIE: SO WE'RE INHERENTLY SAYING THAT IT'S HIGHLY LIKELY THAT THE BUDGET ALLOCATION SUBMITTED BY THE INSTITUTION FOR PATIENT ASSISTANCE AS BEING CURRENTLY DONE IS INSUFFICIENT, AND THERE NEEDS TO BE AN OVERLAY PROCESS TO REVIEW

BETH C. DRAIN, CA CSR NO. 7152

AND HAVE THE POTENTIAL TO GRANT ADDITIONAL DOLLARS;
IS THAT ACCURATE?

DR. PATEL: PART OF THAT WOULD BE FOR US
TO ASSESS WHAT IS THE MINIMUM LEVEL OF SUPPORT THAT
SOME OF THESE TRIALS SHOULD BE PROVIDING. AND SO
THAT'S DATA THAT WE'LL HAVE AS DOING THIS EXERCISE
OF GETTING ALL THE DATA ACROSS ALL THE TRIALS.

MR. FISCHER-COLBRIE: OKAY. AND THEN HOW
DOES THIS TIE IN WITH IRB REVIEWS AND ALLOCATION OF
DOLLARS?

DR. LOMAX: GOOD MORNING. THANKS. GEOFF
LOMAX. AND SO AS PART OF THE DEVELOPMENT OF THIS
PROGRAM, WE INTERVIEWED A NUMBER OF IRB'S. AND SO
THEIR GENERAL -- THE GENERAL DISPOSITION, ALTHOUGH
THERE WAS VARIANCE WITHIN THOSE DISCUSSIONS, IS THAT
TO THE EXTENT THERE'S A PROGRAM TO SUPPORT PATIENTS,
THAT THAT NEEDS TO BE PART OF THE PROTOCOL. THEY'D
REQUIRE THOSE PROGRAMS TO BE AVAILABLE TO ALL
PATIENTS. SO THAT'S ESSENTIALLY THE CLINICAL TRIAL
BUDGET AS OPPOSED TO THE SUPPORT PROGRAM PROVIDES
THAT BASELINE THAT THEY'RE COMFORTABLE WITH.

SO THAT WOULD BE -- THE BASIC SUPPORT
WOULD BE PART OF THE IRB APPROVAL. AND THEN I THINK
WHAT THE OPPORTUNITY WITH THIS PROGRAM IS IS THEY
WERE RECEPTIVE TO STATEMENTS LIKE PATIENT SHOULD NOT

BETH C. DRAIN, CA CSR NO. 7152

INCUR OUT-OF-POCKET COSTS FOR PARTICIPATING IN THIS TRIAL. THERE WILL BE THAT LEVEL OF SUPPORT. THEN THE QUESTION BECOMES ARE THERE VERY HIGH NEED PATIENTS THAT THEN YOU DO NEED TO DRAW UPON FUNDS FROM OTHER SOURCES. SO THAT'S SORT OF THE TYPES OF SCENARIOS THAT THEY WERE COMFORTABLE WITH.

SO IT ULTIMATELY DEPENDS ON THE IRB APPROVAL PROCESS HOW WE'RE REPRESENTING THE SUPPORT SERVICES. AND WHAT THEY'RE REALLY LOOKING FOR IS EQUITY ACROSS THE PATIENT POPULATION THAT'S GOING TO BE RECRUITED INTO THAT TRIAL.

MR. FISCHER-COLBRIE: YEAH. NO, I GET IT. PATIENT SUPPORT IS CRITICAL. THAT'S A FUNDAMENTAL STARTING POINT. I'M JUST STILL NOT LIKE A HUNDRED PERCENT CLEAR ABOUT FUNCTIONALLY HOW THAT WOULD WORK. IF IT'S ALSO A PHENOMENON THAT PEOPLE JUST ARE NOT DOING A GOOD JOB BUDGETING FOR THIS TO BEGIN WITH, ARE THERE OTHER MECHANISMS THAT MIGHT BE EMPLOYED TO HELP WITH THAT? BECAUSE WE'RE CREATING A WHOLE INFRASTRUCTURE TO BE AN OVERLAY KIND OF PHENOMENON.

DR. LOMAX: JUST TO THE EXTENT THAT IT GIVES YOU CONFIDENCE IN THE SORT OF GENERAL DIRECTION OF THIS PROGRAM, THOSE SORTS OF THINGS ARE HAPPENING NOW. THERE ARE PATIENTS IN IRB-APPROVED

BETH C. DRAIN, CA CSR NO. 7152

PROTOCOLS THAT ARE GETTING SUPPORT, BUT THEN THEY'RE RECEIVING ADDITIONAL SUPPORT, SAY, FROM NON-FOR-PROFIT OR OTHER ORGANIZATIONS THAT ARE HELPING SUPPORT THAT PATIENT. SO WE'RE TRYING TO EMULATE THAT LAYERING THAT YOU REFERRED TO. AND I THINK, AS SHYAM REFERRED TO, WE HAVE A SENSE OF THE FRAMEWORK; BUT UNTIL WE REALLY CAN ROLL UP OUR SLEEVES AND START TO WALK THROUGH THIS WITH OUR ALPHA CLINIC PARTNERS, IT'S HARD TO REALLY GET DOWN TO THE LEVEL OF DETAIL THAT I THINK WOULD GIVE THE MOST SATISFYING RESPONSE TO THE QUESTION THIS MORNING.

MR. JUELSGAARD: SO JUST TO FOLLOW UP ON WHAT MARK WAS TALKING ABOUT, WHEN YOU THINK ABOUT CLINICAL TRIALS WRIT LARGE, IT'S ONE THING TO HAVE A BUNCH OF CALIFORNIA-BASED CLINICAL TRIALS, BUT CERTAINLY MOST LARGER COMPANIES WILL DO CLINICAL TRIALS AND INVOLVE CENTERS ACROSS THE U.S. AND GLOBAL CENTERS OUTSIDE THE U.S. AND THE ISSUE OF EQUITY ACROSS -- WHEN DOING MULTIPLE CLINICAL TRIALS IN MULTIPLE JURISDICTIONS, THIS IS A BIT OF A STICKY WICKET, I THINK, FOR WHATEVER ORGANIZATION IS CONDUCTING THOSE CLINICAL TRIALS IF YOU HAVE A SPECIAL CIRCUMSTANCE FOR CALIFORNIA THAT'S DIFFERENT FROM WHAT YOU'RE WILLING TO PROVIDE IN SOME OTHER

BETH C. DRAIN, CA CSR NO. 7152

LOCALE.

SO I'M JUST MAKING THIS POINT. I'M NOT SUGGESTING -- IT'S JUST WE'RE GOING TO HAVE TO THINK ABOUT ALL THAT STUFF AS ALL THIS COMES TOGETHER BECAUSE THERE'S A LOT TO UNPACK IN ALL OF THIS FROM MY POINT OF VIEW.

DR. CHOU: CAN I HELP TO ECHO THAT IT'S REALLY HOW INITIALLY I ASKED THE QUESTION BECAUSE THAT HAS SOMETHING TO DO WITH THE IRB AND WITH ALL THE THINGS. THE INITIATIVE, THE INTENTION IS GREAT, BUT JUST NOT CLEAR ABOUT HOW WE ARE IMPLEMENTING THIS FUNDING AND SUPPORT.

VICE CHAIR BONNEVILLE: JOYCE, I THINK YOU HAVE A QUESTION.

DR. SACEY: YES. THANK YOU, MARIA. I JUST SENSE -- AGAIN, I AGREE AND ECHO COMMENTS THAT HAVE BEEN MADE EARLIER, THAT PATIENT SUPPORT IS CRITICAL. ADDRESSING ACCESS AND AFFORDABILITY ABSOLUTELY THE RIGHT APPROACH.

I GUESS MY QUESTION HAS TO DO WITH ASSUMING THAT THE GRANTEE HAS DONE THE APPROPRIATE BUDGETING AND ASKED FOR THE APPROPRIATE LEVEL OF BUDGET SUPPORT OR SUPPORT FOR PATIENTS OR WE HAVE TO DO THIS OVERLAY, HOW DO WE KNOW THAT WE ARE, IN FACT, HAVING THE RIGHT RESULTS THAT WE WERE GOING

BETH C. DRAIN, CA CSR NO. 7152

AFTER? I NOTICED THAT THERE WAS THIS SLIDE THAT APPROPRIATELY SORT OF CAUTIONED THAT IN SCORING THE DEI OR GIVING THE DEI SCORE, BECAUSE OF PROP 209, THAT WE NEED TO OR THE REVIEWERS NEED TO REFRAIN FROM CONSIDERING THE RACE, ETHNICITY, NATIONAL ORIGIN, OR GENDER OF THE RESEARCH TEAM. THAT I GET ENTIRELY.

BUT IF WE'RE GOING TO GIVE THIS ADDITIONAL FUNDING FOR THE PURPOSE OF ADDRESSING BARRIERS TO PARTICIPATION IN CLINICAL TRIALS, ARE WE THEN GOING TO EXPECT THE GRANTEE TO SHOW US THE FULL DEMOGRAPHIC PROFILE OF THOSE CLINICAL TRIAL PARTICIPANTS? BECAUSE IT SEEMS TO ME LIKE IF THEY CAN ONLY SAY, WELL, WE'RE GOING TO MAKE SURE THAT WE ADDRESS THE BARRIERS, BUT THEN WE DON'T REQUIRE THEM TO SHOW THE DATA THAT THEIR INTERVENTIONS ARE ACTUALLY WORKING, THEN PERHAPS WE'RE MISSING THE OPPORTUNITY TO SEE WHETHER THIS ADDITIONAL FUNDING SUPPORT IS ACTUALLY ACHIEVING THE GOAL THAT WE HAVE IN MIND.

DR. SAMBRANO: YES, THAT'S AN EXCELLENT QUESTION. AND IT IS PART OF WHAT WE DO WITH ALL OF OUR CLINICAL TRIALS IN PART OF THE FOLLOW-UP, WELL, ACTUALLY EVEN AT THE APPLICATION STAGE IS FOR THEM TO HAVE A DEI PLAN, BUT ULTIMATELY THE FOLLOW-UP IS

BETH C. DRAIN, CA CSR NO. 7152

TO ASK THE APPLICANT HOW THEY HAVE PROGRESSED AGAINST THAT DEI PLAN AS WELL AS WHAT THE DEMOGRAPHICS OF THE ENROLLMENT HAVE BEEN.

NOW, THE PROGRAM HERE, THE PATIENT SERVICES PROGRAM, WOULD HELP SUPPLEMENT THAT DATA THAT WE GET EITHER FOR THE REPORTING BACK BY THE APPLICANT OR DATA THAT THEY MORE COMPREHENSIVELY CAN COLLECT THAT WILL BOTH INFORM HOW THIS IS WORKING. SO I THINK THAT IS A CRITICAL PART OF INFORMING WHETHER THE IMPLEMENTATION OF A PATIENT SUPPORT PROGRAM IN THIS FASHION IS ACHIEVING THE GOALS OF TRYING TO ENCOURAGE IN FACILITATING PATIENT PARTICIPATION PARTICULARLY FROM COMMUNITIES THAT ARE UNDERSERVED.

DR. SACEY: THANK YOU.

VICE CHAIR BONNEVILLE: BEFORE I ASK FOR A MOTION, I JUST WANT TO MAKE SURE EVERYONE IS CLEAR. NONE OF THE PATIENT ASSISTANCE FUND DOLLARS THAT GO TO SUPPORT PATIENTS WILL GO OUT UNTIL ISSUES LIKE THIS ARE WORKED OUT WITH THE PROPOSED -- WITH THE AWARDEE. AND THINGS LIKE WHAT GETS COVERED THROUGH OUR CLINICAL TRIAL PROGRAM AND PATIENT ASSISTANCE VERSUS WHAT GETS COVERED UNDER THE PATIENT ASSISTANCE FUND, THOSE THINGS NEED TO GET WORKED OUT. THEY'RE NOT WORKED OUT YET. THEY HAVE TO GET

BETH C. DRAIN, CA CSR NO. 7152

WORKED OUT. WE HAVE TO HAVE ASSURANCES THAT
WHOMEVER THE AWARDEE IS CAN ACTUALLY DO THAT.

SO THE FIRST PHASE OF THIS IS THE
PLANNING, AND THAT MONEY WILL BE ALLOCATED SO THAT
THE AWARDEE AND OUR INTERNAL TEAM CAN WORK ALL OF
THOSE THINGS OUT. IF IT CAN'T GET WORKED OUT, WE
START ALL OVER AND WE PUT IT OUT TO AN RFA AGAIN AND
SEE WHAT COMES OF IT.

SO I JUST WANT TO MAKE SURE EVERYBODY
UNDERSTANDS THAT NONE OF THE DOLLARS THAT GO TO THE
PATIENTS WILL GO OUT UNTIL THIS HAS ALL BEEN WORKED
OUT.

J.T., WOULD YOU LIKE TO SAY SOMETHING?

DR. THOMAS: JUST A BRIEF COMMENT ON
PROCESS. AS WAS SUGGESTED HERE, THIS WAS THE FIRST
OF ITS KIND REVIEW BY THE AAWG. AND I WANT TO
CONGRATULATE MARIA ON RUNNING A GREAT MEETING IN
WHICH ALL OF THE MEMBERS OF THAT WORKING GROUP WERE
SINGULARLY ENGAGED AND REALLY GOT DOWN INTO THE
GRANULARITY OF ALL THE APPLICATIONS. AND JUST TO
REMINDE EVERYBODY, THE AAWG IS IN PART COMPOSED OF
TEN EXTERNAL MEMBERS WHO BRING DIFFERENT ELEMENTS OF
EXPERTISE TO THE TABLE, ALL CONNECTED TO THE ISSUES
OF ACCESSIBILITY AND AFFORDABILITY. SO THIS WAS A
BIG OPPORTUNITY FOR THEM TO WEIGH IN SUBSTANTIVELY

BETH C. DRAIN, CA CSR NO. 7152

ON THIS NEW PROGRAM. AND THEY WERE VERY MUCH ENGAGED. BUT I JUST WANTED TO SAY TO MARIA EXCELLENT JOB, AND THIS IS A GREAT RESULT. SO THANK YOU.

VICE CHAIR BONNEVILLE: THANK YOU, J.T. SO I HOPE WE CAN HAVE A MOTION TO FUND APPLICATION 15912.

MR. FISCHER-COLBRIE: SO MOVED.

DR. GASSON: SECOND.

VICE CHAIR BONNEVILLE: IS THERE ANY FURTHER BOARD COMMENT? IS THERE ANY PUBLIC COMMENT?

MS. MANDAC: WE HAD ONE ON THE SIGN-UP SHEET FOR PUBLIC COMMENT, MR. MIKE DE LAROCHE.

MR. DE LAROCHE: THAT'S OKAY.

MR. TOCHER: ALL THOSE IN THE ROOM IN FAVOR SAY AYE. THOSE OPPOSED? ANY ABSTENTIONS? AND I'LL POLL THE MEMBERS ON THE PHONE.

MOHAMED ABOUSALEM. SORRY, MOHAMED. NOT HEARING YOU AT THE MOMENT. I'LL COME BACK.

DEBORAH DEAS.

DR. DEAS: YES.

MR. TOCHER: YSABEL DURON.

MS. DURON: YES.

MR. TOCHER: FRED FISHER.

DR. FISHER: YES.

BETH C. DRAIN, CA CSR NO. 7152

MR. TOCHER: RICH LAJARA.

MR. LAJARA: YES.

MR. TOCHER: JOYCE SACKY.

DR. SACKY: YES.

MR. TOCHER: MICHAEL STAMOS. I'LL COME
BACK TO YOU, MICHAEL. I THINK WE'RE JUST HAVING A
LITTLE TROUBLE WITH YOUR AUDIO.

KAROL WATSON.

DR. WATSON: YES.

MR. TOCHER: KEVIN XU.

DR. XU: YES.

MR. TOCHER: KEITH YAMAMOTO.

DR. YAMAMOTO: YES.

DR. ABOUSALEM: HELLO.

MTR. TOCHER: YES. IS THAT MOHAMED?
SORRY, MOHAMED.

DR. ABOUSALEM: I'M SORRY. I'M HAVING
DIFFICULTY WITH SOUND. YES.

MR. TOCHER: GREAT. THANK YOU VERY MUCH.
I JUST WANT TO MAKE SURE. DID I GET KEITH
YAMAMOTO?

DR. YAMAMOTO: YES.

MR. TOCHER: GREAT. THANKS VERY MUCH.
AND ONE LAST TRY FOR MICHAEL STAMOS. I'M TOLD HE IS
NOT ON THE LINE ANYMORE. GREAT. THANKS VERY MUCH.

BETH C. DRAIN, CA CSR NO. 7152

THE MOTION CARRIES.

VICE CHAIR BONNEVILLE: THANK YOU, SCOTT.

CHAIRMAN IMBASCIANI: THANK YOU.

EVERYONE, WE'RE GOING TO ADJOURN FOR LUNCH IMMEDIATELY AFTER THE NEXT ITEM OF BUSINESS, WHICH IS AGENDA ITEM 14. GIL, IF YOU WOULD TAKE US THROUGH THE CLIN.

DR. SAMBRANO: SO FOR THE CLIN, DR. HAYLEY LAM IS GOING TO PRESENT THIS ONE.

CHAIRMAN IMBASCIANI: THANK YOU. HAYLEY.

DR. LAM: THANK YOU TO THE BOARD. I WILL BE TAKING YOU THROUGH THE CLINICAL AWARDS THAT IS UP FOR THE ARS TODAY.

AS ALWAYS, WE BEGIN WITH OUR MISSION, ACCELERATING WORLD-CLASS SCIENCE TO DELIVER TRANSFORMATIVE REGENERATIVE MEDICINE TREATMENTS IN AN EQUITABLE MANNER TO A DIVERSE CALIFORNIA AND WORLD.

THE CURRENT CLINICAL BUDGET STATUS IS AS FOLLOWS. THE BOARD HAS ALLOCATED 252 MILLION FOR THE CURRENT FISCAL YEAR AND ALREADY APPROVED 162 MILLION. AND UP FOR DISCUSSION TODAY IS A REQUEST OF JUST UNDER 6 MILLION.

THE SCIENTIFIC SCORING SYSTEM FOR THE CLINICAL PROGRAM IS A 1, 2, OR 3. A 1 IS A

BETH C. DRAIN, CA CSR NO. 7152

RECOMMENDATION FOR FUNDING. A 2 IS A DO NOT RECOMMEND AT THIS TIME, BUT THE APPLICANT CAN REVISE AND RESUBMIT. AND A 3 IS A DO NOT RECOMMEND FOR FUNDING, AND THE APPLICANT CANNOT RETURN WITH THE SAME PROJECT FOR AT LEAST SIX MONTHS.

THE REVIEW CRITERIA BY WHICH THE GROUP SCORES THE SCIENTIFIC ASPECT IS THESE FIVE CRITERIA. DOES THE PROJECT HOLD THE NECESSARY SIGNIFICANCE AND POTENTIAL FOR IMPACT? IS THE RATIONALE SOUND? IS THE PROJECT WELL PLANNED AND DESIGNED? IS THE PROJECT FEASIBLE? AND DOES THE PROJECT UPHOLD PRINCIPLES OF DIVERSITY, EQUITY, AND INCLUSION?

ADDITIONALLY FOR THE CLINICAL PROGRAM, WE HAVE THE DIVERSITY, EQUITY, AND INCLUSION SCORING. THIS IS SCORED BY THE GRANTING WORKING GROUP BOARD MEMBERS. AND THE SCALE FOR THIS IS FROM ZERO TO 10 WITH 6 AND ABOVE AN ACCEPTABLE RESPONSE.

THE COMPOSITION OF THE GRANTS WORKING GROUP IN CONTRAST TO THE AFFORDABILITY AND ACCESSIBILITY WORKING GROUP THAT YOU'VE JUST BEEN DISCUSSING IS COMPOSED OF THREE DIFFERENT TYPES OF PARTICIPANTS: THE SCIENTIFIC GRANT WORKING GROUP MEMBERS WHO EVALUATE THE DISEASE AREA, REGULATORY, AND MANUFACTURING AND PRODUCT DEVELOPMENT ASPECTS, AND PROVIDES A SCIENTIFIC SCORE FOR ALL

BETH C. DRAIN, CA CSR NO. 7152

APPLICATIONS. THE BOARD MEMBER GROUP, WHICH IS THE PATIENT ADVOCATE AND NURSE MEMBERS OF THE BOARD WHO SCORE ON THE DEI EVALUATION FOR ALL APPLICATIONS AND CAN PROVIDE A SUGGESTED SCIENTIFIC SCORE. AND FOR THE GRANTS WORKING GROUP, WE ALSO HAVE AD HOC SCIENTIFIC SPECIALISTS WHO COME IN AS NEEDED TO PROVIDE EXPERTISE IN SPECIFIC AREAS.

SO FOR YOUR CONSIDERATION TODAY IS THE CLIN1-14874. THE TITLE OF THIS PROGRAM IS "EXTRACELLULAR VESICLES FOR VENTRICULAR TACHYCARDIA" SO THIS IS A TREATMENT PROPOSED FOR ABNORMAL HEART RHYTHMS. AND THE GOAL OF THIS PROGRAM IS TO FILE AN IND. AND THE FUNDS REQUESTED ARE JUST UNDER 6 MILLION WITH NO CO-FUNDING REQUIRED FOR THIS PROJECT.

A LITTLE BIT OF BACKGROUND ON THIS PROJECT. HEART DISEASE IS THE LEADING CAUSE OF DEATH GLOBALLY RIGHT NOW, AND THE ABNORMAL HEART RHYTHM THAT THIS TREATMENT HOPES TO ADDRESS IS RESPONSIBLE FOR A SIGNIFICANT PORTION OF THAT MORTALITY. THE CURRENT STANDARD OF CARE IS AN ADMINISTRATION OF DRUGS OR ABLATION PROCEDURES. AND THEY'RE NOT ALWAYS EFFECTIVE. SO THE PROPOSED THERAPY MAY IDEALLY IMPROVE CARDIAC FUNCTION, SCAR VOLUME, AND GENERALLY MAKE THE HEART MORE STABLE.

BETH C. DRAIN, CA CSR NO. 7152

ADDITIONALLY, THE HOPE IS THAT THIS TREATMENT COULD BE EASIER TO DELIVER AND PERHAPS MORE STABLE THAN CELLULAR PRODUCTS WITH SIMILAR EFFECTS. AND THIS PROJECT IS WITHIN CIRM'S PURVIEW AS A THERAPY DERIVED FROM PROGENITOR CELLS.

SIMILAR CIRM PORTFOLIO PROJECTS, CURRENTLY WE HAVE A PHASE 1 CLINICAL TRIAL FOR AN EMBRYONIC STEM CELL-DERIVED CELL THERAPY FOR HEART FAILURE. AND THE APPLICANT TEAM, THIS CURRENT APPLICANT HAS NOT RECEIVED PRIOR CIRM FUNDING. HOWEVER, I WOULD JUST LIKE TO MENTION THAT THE APPARENT CANDIDATE FOR THIS WAS FUNDED PREVIOUSLY BY CIRM FOR A COMPLETELY DIFFERENT INDICATION.

SO FOR YOUR CONSIDERATION TODAY, THE GRANTS WORKING GROUP HAS RECOMMENDED THIS APPLICATION FOR FUNDING WITH 13 SCORES IN TIER I AND ONE IN TIER II WITH A DEI SCORE OF 7. AND THE CIRM TEAM CONCURS WITH THE RECOMMENDATION OF THE GRANTS WORKING GROUP FOR THE AWARD AMOUNT OF JUST UNDER 6 MILLION. SO I WOULD DEFER BACK TO THE ARS.

CHAIRMAN IMBASCIANI: THANK YOU, HAYLEY, FOR YOUR PRESENTATION. SINCE WE ONLY HAVE ONE ENTITY IN THIS GROUP, WE CAN ASK FOR A MOTION TO FUND.

DR. DULIEGE: I MOVE.

BETH C. DRAIN, CA CSR NO. 7152

CHAIRMAN IMBASCIANI: WE HAVE A MOTION ON THE FLOOR. WE'RE OPEN TO DISCUSSION FROM BOARD MEMBERS OF THE APPLICATION 14874.

THE REPORTER: I'M SORRY. WHO WAS THE SECOND?

MR. TOCHER: MARV SOUTHARD WAS THE SECOND.

CHAIRMAN IMBASCIANI: I DON'T SEE ANY COMMENTS. ADRIANA, PLEASE.

DR. PADILLA: HAYLEY, CAN YOU JUST REVIEW WHAT THE ISSUES WERE ON THE DEI SCORE OF 7 BECAUSE I CAN'T REMEMBER?

DR. LAM: SO, GENERALLY SPEAKING, THE SCORE WAS THAT THE APPLICANT ORGANIZATION IS WELL VERSED IN DIVERSITY, EQUITY, AND INCLUSION ASPECTS. SO I THINK THE GENERAL IDEA WAS THAT THERE COULD HAVE BEEN MORE CONCRETE PLANS ON SPECIFICS FOR WHAT THEY PLAN TO DO. BUT I'M PRETTY CONFIDENT THAT THE CIRM TEAM CAN WORK WITH THE APPLICANT OR HOPEFUL AWARDEE ON THIS DURING THE AWARD PROCESS.

CHAIRMAN IMBASCIANI: THANK YOU. I DON'T SEE ANY OTHER COMMENTS FROM BOARD MEMBERS. SO ARE THERE ANY MEMBERS OF THE PUBLIC THAT WISH TO COMMENT ON THIS APPLICATION? I'M BEING TOLD THERE ARE NONE. OKAY. WE MAY PROCEED.

MR. TOCHER: OKAY. ALL THOSE MEMBERS OF

BETH C. DRAIN, CA CSR NO. 7152

THE APPLICATION REVIEW SUBCOMMITTEE IN THE ROOM IN FAVOR SAY AYE. OPPOSED? ABSTENTIONS? I'LL POLL ON THE PHONE.

YSABEL DURON.

MS. DURON: YES.

MR. TOCHER: FRED FISHER.

DR. FISHER: YES.

MR. TOCHER: RICH LAJARA.

MR. LAJARA: YES.

MR. TOCHER: KAROL WATSON.

DR. WATSON: YES. SORRY I COULDN'T GET IT TO UNMUTE.

MR. TOCHER: NO PROBLEM. THANK YOU.

AND KEVIN XU.

DR. XU: YES.

MR. TOCHER: GREAT. THANKS VERY MUCH.

THE MOTION CARRIES.

CHAIRMAN IMBASCIANI: THANK YOU, SCOTT.

THE MOTION CARRIES, AND WE WILL TAKE A LUNCH BREAK, RECONVENING AT 12:45. ENJOY YOUR LUNCH. THANK YOU.

(A RECESS WAS TAKEN.)

CHAIRMAN IMBASCIANI: THANK YOU. I'D LIKE WELCOME ALL THE BOARD MEMBERS AND OTHERS BACK FROM THEIR LUNCH BREAK. WE'RE GOING TO TAKE UP WHERE WE LEFT OFF WITH THE CONSIDERATION OF AGENDA NO. 15,

BETH C. DRAIN, CA CSR NO. 7152

WHICH IS THE APPLICATIONS IN THE DISCOVERY PROGRAM.
DR. SAMBRANO WILL LEAD US AGAIN.

DR. SAMBRANO: THANK YOU. ONCE AGAIN, WE
START WITH OUR MISSION STATEMENT AND WHAT WE LOOK TO
WHEN WE SET UP THESE REVIEWS AND INSTRUCT OUR
REVIEWERS AS TO WHY WE ARE HERE AND WHAT OUR OVERALL
GOAL IS FOR THIS AGENCY AND FOR THE DISC-0
FOUNDATION AWARDS, WHICH REPRESENTS KIND OF THE
EARLIEST STAGE OF RESEARCH FUNDING THAT WE DO.

SO THE OBJECTIVE OF THIS PARTICULAR
PROGRAM IS THAT PROJECTS THAT APPLY TO DISC-0 NEED
TO CULMINATE IN A DISCOVERY OR TECHNOLOGY THAT WOULD
ADVANCE ONE OR MORE OF THE FOLLOWING: OUR
UNDERSTANDING OF BIOLOGY OF STEM CELLS THAT'S
RELEVANT TO HUMAN BIOLOGY AND DISEASE, GENETIC
RESEARCH RELEVANT TO HUMAN BIOLOGY OR DISEASE THAT
PERTAINS TO STEM CELLS OR REGENERATIVE MEDICINE, OR
THE DEVELOPMENT OF HUMAN STEM CELLS AS TOOLS FOR
BIOMEDICAL INNOVATION, OR THE GREATER APPLICABILITY
OF REGENERATIVE MEDICINE DISCOVERIES TO COMMUNITIES
REPRESENTING THE FULL SPECTRUM OF DIVERSITY.

WITH THAT IN MIND, HERE ARE JUST SOME
EXAMPLE ACTIVITIES THAT APPLICANTS CAN PROPOSE,
INCLUDING BASIC RESEARCH STUDIES, STEM CELL OR
GENETIC RESEARCH MECHANISMS, RESEARCH THAT ADDRESSES

BETH C. DRAIN, CA CSR NO. 7152

KEY BOTTLENECKS IN THE FIELD, SUCH AS TISSUE TARGETING, IMMUNOTOXICITY, OR TOXICITY IN THE DEVELOPMENT OF STEM CELL-BASED THERAPIES, STUDIES THAT HELP US BETTER UNDERSTAND HEALTHY VERSUS DISEASE HUMAN CELLS AND TISSUE, MECHANISTIC STUDIES OF DISEASE THAT ENABLE RATIONAL DESIGN OF STEM CELL-BASED TREATMENTS, THE INVESTIGATION OF STEM CELLS OR DERIVATIVES AS POTENTIAL TOOLS FOR THERAPY, OR OTHER INNOVATIONS THAT MAY BE USED IN RESEARCH, SUCH AS MODELING DISEASE, AND/OR GENERATION OF OMICS DATA THAT WILL EXTEND THE VALIDITY OF AND THE APPLICABILITY OF REGENERATIVE MEDICINE DISCOVERIES ACROSS UNDERSERVED RACIAL AND ETHNIC GROUPS.

THE PROGRAM ITSELF, IN TERMS OF WHAT THE AWARD OFFERS, THE APPLICATIONS NEED TO ADDRESS A KNOWLEDGE GAP OR A BOTTLENECK IN THE REGENERATIVE MEDICINE RESEARCH FIELD. AND SO THAT IS KEY IN BEING ELIGIBLE AND ALSO AN ELEMENT THAT IS REVIEWED BY THE GRANTS WORKING GROUP. AWARDS ARE FOR THREE YEARS AND UP TO ONE MILLION IN DIRECT PROJECT COSTS. SO IT DOES NOT INCLUDE THE INDIRECT OR FACILITIES COSTS. PROJECTS ARE LESS THAN -- PROJECTS THAT ARE LESS THAN THREE YEARS AND PROPOSE A BUDGET THAT'S GREATER THAN 400,000 PER YEAR ARE GOING TO REQUIRE STRONG JUSTIFICATION FOR THOSE AMOUNTS. AND THE

**133 HENNA COURT, SANDPOINT, IDAHO 83864
208-920-3543 DRAIBE@HOTMAIL.COM**

BETH C. DRAIN, CA CSR NO. 7152

AVAILABLE BUDGET FOR THIS CYCLE IS 22.5 MILLION.

THE COMPOSITION OF THE GRANTS WORKING GROUP, THIS IS SOMETHING THAT HAYLEY ALREADY SHOWED YOU. SO JUST VERY BRIEFLY, SAME COMPOSITION, SCIENTIFIC MEMBERS THAT WE PUT A PANEL TOGETHER BASED ON THE NEEDS OF THE SCIENTIFIC EXPERT FOR THE APPLICATIONS THAT WE HAVE BEFORE US, OUR GRANTS WORKING GROUP BOARD MEMBERS, BOTH OF WHOM PARTICIPATE IN THE POSITIVE SELECTION ASPECT, WHICH I'LL DESCRIBE SHORTLY, AND, OF COURSE, THE PARTICIPATION OF SPECIALISTS. PARTICULARLY FOR REVIEWS LIKE THIS, WE UTILIZE A LOT OF SPECIALISTS BECAUSE WE HAVE MANY APPLICATIONS AND ALSO THERE'S THE NEED TO FILL IN THOSE KNOWLEDGE GAPS WITH AS MANY REVIEWERS AS WE CAN.

SO I'LL DESCRIBE TO YOU THE POSITIVE SELECTION PROCESS. SO THIS IS PERFORMED WHENEVER WE HAVE A LARGE NUMBER OF APPLICATIONS THAT COMES IN THAT EXCEEDS THE CAPACITY OF THE GRANTS WORKING GROUP TO MANAGE IN A SINGLE REVIEW CYCLE. AND WHAT HAPPENS IN THE FIRST STAGE, THE GRANTS WORKING GROUP MEMBERS, THE PANEL ITSELF, INCLUDING THE PATIENT ADVOCATE MEMBERS AND NURSE BOARD MEMBERS, CONDUCT A PREREVIEW OF THESE APPLICATIONS AND SELECT WHICH ONES THEY WISH TO ADVANCE. AND THEY BASE THIS

BETH C. DRAIN, CA CSR NO. 7152

MOSTLY ON THE POTENTIAL IMPACT OF THE PROJECT AND THE LIKELIHOOD THAT IT ALIGNS WITH WHAT WE ARE LOOKING FOR UNDER THIS PROGRAM.

THE CIRM PRESIDENT AND THE CIRM TEAM EXAMINES NONSELECTED APPLICATIONS, THOSE THAT WERE NOT MOVED FORWARD BY THE GRANTS WORKING GROUP, TO DETERMINE IF THERE ARE ANY ADDITIONAL ONES THAT MIGHT MERIT A FULL REVIEW. AND THE REMAINDER THAT ARE NOT SELECTED BY EITHER GROUP ARE NOT CONSIDERED FURTHER.

FOR THIS PARTICULAR CYCLE, WE RECEIVED A TOTAL OF 158 APPLICATIONS. SO THAT IS THE LARGEST THAT WE HAVE RECEIVED FOR DISC-0 THUS FAR. AND A TOTAL OF 48 OF THOSE ADVANCED TO FULL DISCUSSION STAGE BY THE GRANTS WORKING GROUP.

THE SCORING METHOD THAT WAS USED BY THE GRANTS WORKING GROUP FOR THIS REVIEW WAS ON A SCALE OF 1 TO 100. THOSE THAT RECEIVE A SCORE OF 85 TO 100 ARE RECOMMENDED FOR FUNDING BECAUSE THEY HAVE EXCEPTIONAL MERIT. AND THOSE THAT SCORE BETWEEN 1 AND 84 ARE NOT RECOMMENDED FOR FUNDING. WE DO ENCOURAGE THE WORKING GROUP TO USE THE FULL SCALE AS BEST THEY CAN TO MAKE SURE THAT THEY REPRESENT THE RELATIVE MERIT OF THESE APPLICATIONS GIVEN THAT THEY'RE BEING COMPARED TO ONE ANOTHER. WE ALSO

BETH C. DRAIN, CA CSR NO. 7152

ADVISE THEM THAT, IF THEY CHOOSE TO SCORE BETWEEN 80 AND 84, AND THOSE THAT DO RECEIVE A SCORE BETWEEN 80 AND 84, THE APPLICATION IS NOT RECOMMENDED; BUT IF IT'S RESUBMITTED TO A FUTURE CYCLE, IT CAN THEN BYPASS THE POSITIVE SELECTION PROCESS THAT I DESCRIBED.

AND THE GRANTS WORKING GROUP USES THIS AS SORT OF A SURROGATE TIER II, IF YOU WILL, AS A MECHANISM FOR HAVING APPLICATIONS THAT THEY GENERALLY THINK ARE PROMISING, BUT HAVE SOME WORK TO DO STILL AND THEY WOULD LIKE TO SEE AGAIN. SO THOSE USUALLY GET A SCORE BETWEEN 80 AND 84.

THE REVIEW CRITERIA THAT ARE UTILIZED TO ASSIGN THAT SCORE ARE BASED ON THE FOLLOWING FIVE QUESTIONS. DOES THE PROJECT HOLD THE NECESSARY SIGNIFICANCE AND POTENTIAL FOR IMPACT? DOES IT HAVE A GOOD RATIONALE? IS IT WELL PLANNED AND DESIGNED? IS IT FEASIBLE, INCLUDING HAVING THE APPROPRIATE TEAM AND RESOURCES AVAILABLE TO CONDUCT THE WORK? AND DOES THE PROJECT UPHOLD THE PRINCIPLES OF DIVERSITY, EQUITY, AND INCLUSION?

AND THIS IS A TABLE THAT SUMMARIZES THE OUTCOME AND RECOMMENDATIONS FROM THE GRANTS WORKING GROUP. THERE WERE 11 APPLICATIONS THAT RECEIVED A SCORE OF 85 OR GREATER, AND THE TOTAL APPLICANT

BETH C. DRAIN, CA CSR NO. 7152

REQUESTS FROM THOSE 11 APPLICATIONS IS ABOUT 16.8 MILLION. AND THE FUNDS AVAILABLE ARE 22.5. SO THERE IS ADEQUATE BUDGET TO COVER THOSE 11. AND THERE WERE 37 THAT WERE NOT RECOMMENDED FOR FUNDING.

JUST A WORD ABOUT MINORITY REPORTS BECAUSE THAT IS SOMETHING THAT OFTEN COMES UP IN THESE REVIEWS. UNDER PROP 14 ANY APPLICATION THAT IS NOT RECOMMENDED FOR FUNDING, MEANING IT DOESN'T SCORE 85 OR GREATER, BUT WHICH HAS 35 PERCENT OR MORE OF ITS MEMBERS SCORING TO FUND THE APPLICATION MUST INCLUDE A MINORITY REPORT. AND SO THIS IS SOMETHING THAT'S NORMALLY INCLUDED WITHIN THE SUMMARY. AND ALTHOUGH IT'S COMMON TO HAVE ONE OR TWO MINORITY REPORTS, NONE OF THESE APPLICATIONS IN THIS PARTICULAR CYCLE QUALIFIED FOR A MINORITY REPORT. AND, THEREFORE, THERE ARE NO SPECIFIC RECOMMENDATIONS THAT WOULD BE RELATED TO THAT.

AND THEN THIS IS JUST A REMINDER OF BOARD MEMBERS THAT HAVE A CONFLICT OF INTEREST WITH AN APPLICATION. AND SO JUST BE MINDFUL OF SPEAKING OR VOTING ON THIS. I'M SURE SCOTT WILL REMIND US IF WE ARE NOT FOLLOWING THAT RULE.

ALL RIGHT. AND THEN SO WE CAN LEAVE THE SLIDE, AND WE CAN PUT UP THE SPREADSHEET WHICH SHOWS. AND SO THIS SPREADSHEET IS AVAILABLE TO YOU

BETH C. DRAIN, CA CSR NO. 7152

OR YOU SHOULD HAVE ACCESS ON BOARD EFFECT THE LIST OF APPLICATIONS, AND THEY ARE LISTED IN RANK ORDER. IT SHOULD SHOW IN GREEN THE 11 THAT ARE RECOMMENDED FOR FUNDING AND THOSE THAT FALL BELOW THAT.

SO OUR OVERALL TEAM RECOMMENDATION FOR THIS CYCLE IS TO FUND THOSE 11 APPLICATIONS AND TO NOT FUND THE REMAINDER. AND SO I WILL TURN IT BACK TO YOU.

CHAIRMAN IMBASCIANI: THANK YOU, GIL. SO AS IS OUR CUSTOM WITH THIS, I WILL ENTERTAIN FIRST A MOTION, AFTER PUBLIC COMMENT.

MR. TOCHER: YEAH. I THINK WE WERE GOING TO GO FIRST WITH PUBLIC COMMENT.

CHAIRMAN IMBASCIANI: EXACTLY. I WAS JUST GOING TO LAY OUT WHAT WE'RE GOING TO DO AFTER THAT AND THEN COME BACK TO THAT. THANK YOU, SCOTT.

WE'RE GOING TO ASK IF THERE'S ANYTHING IN THE GROUP RECOMMENDED NOT FOR FUNDING, IF YOU WOULD LIKE TO ELEVATE AND TAKE CARE OF THAT, AND THEN GO TO THE GROUP THAT'S FUNDED AND SEE IF YOU WANT TO UNFUND ANY OF THOSE. SO IN A SENSE I THINK WE'RE MOVING UP AGENDA 23 TO RIGHT NOW AND ASK IF THERE ARE MEMBERS OF THE -- FORGET WHAT I JUST SAID -- OPEN UP THE COMMENT TO THE PUBLIC AT THIS POINT BEFORE THE MOTION.

BETH C. DRAIN, CA CSR NO. 7152

MR. TOCHER: YES. TO BE CLEAR, THE PUBLIC, IF THERE'S ANY MEMBERS WHO WISH TO SPEAK TO THE PENDING DISC APPLICATIONS. FOR OTHER ITEMS NOT ON THE AGENDA, WE'LL COVER THAT LATER.

CHAIRMAN IMBASCIANI: YES. THANK YOU.

DR. TUSCANO: JOE TUSCANO. I'D LIKE TO HAVE SOME PUBLIC COMMENT IF NOW IS THE APPROPRIATE TIME.

CHAIRMAN IMBASCIANI: YES, IT IS.

MR. TOCHER: THANK YOU, DR. TUSCANO. AND YOU HAVE THREE MINUTES.

DR. TUSCANO: OKAY. YEAH. THIS IS JOSEPH TUSCANO, UC DAVIS CANCER CENTER. I'M THE PRINCIPAL INVESTIGATOR ON DISC-0 PROPOSAL 15700, "GENE-EDITED CD 19 CAR-T CELLS WITH SUPERIOR PROLIFERATION, AND SERIAL-KILLING." I THINK WE ALL KNOW THAT CELLULAR THERAPY AND CAR-TS ARE A REMARKABLE NEW THERAPY THAT HAVE PRODUCED CURES IN PATIENTS THAT OTHERWISE COULD NEVER ACHIEVE CURES. UNFORTUNATELY 60 TO 70 PERCENT OF PATIENTS WILL EVENTUALLY RELAPSE AND DIE OF THEIR DISEASE.

WHY IS THIS? IT'S PROBABLY DUE TO A LACK OF PERSISTENCE IN THE BODY, AND THIS IS LIKELY DUE TO A PROCESS CALLED REACTIVATION-INDUCED CELL DEATH THAT IS A NATURAL MECHANISM TO RID THE BODY OF

BETH C. DRAIN, CA CSR NO. 7152

AUTOREACTIVE T-CELLS.

WE'VE IDENTIFIED A HUMAN MODEL, NOT AN ANIMAL MODEL, BUT HUMAN MODEL WHERE THE REACTIVATION-INDUCED CELL DEATH IS DEFECTIVE. AND SO THESE YOUNG MEN, IT'S AN X-LINKED DISORDER WHERE THESE YOUNG MEN HAVE PERSISTENT ACTIVE T-CELLS. WE THOUGHT THIS WAS AS EXCELLENT MODEL. THE GENETIC DEFECT HAS BEEN IDENTIFIED. AND SO WHAT WE DID IS WE USED CRISPR TECHNOLOGY TO CREATE THIS IN OUR CAR-T CELLS. AND WHAT WE'RE ABLE TO SEE IS THAT THESE CELLS ARE PERSISTENT AND THEY ARE VERY ACTIVE AND THEY CAN UNDERGO SERIAL KILLING OF RE-INOCULATIONS WITH CANCER CELLS WHICH IS VERY, VERY PROMISING.

WHEN THIS WAS COMPARED TO STANDARD OF CARE CAR-T'S, IT WAS MUCH, MUCH MORE EFFECTIVE AT SERIAL KILLING AND PERSISTENCE. THIS IS A TECHNOLOGY THAT CAN BE APPLIED TO MANY DIFFERENT TYPES OF CELLULAR THERAPIES FOR MANY DIFFERENT MALIGNANCIES OR DISEASES.

WE APPRECIATE THE REVIEW COMMITTEE'S THOUGHTFUL AND THOROUGH REVIEW OF OUR PROPOSAL. WE RECEIVED AN EXCELLENT SCORE OF 83. JUST MISSED THE FUNDING LEVEL BY TWO POINTS. THERE WERE THREE PRIMARY CRITICISMS. ONE WAS BECAUSE THIS IS AN

BETH C. DRAIN, CA CSR NO. 7152

X-LINKED DISORDER, WILL THIS BE APPLICABLE TO FEMALE PATIENTS? WE'RE ABLE TO SHOW THAT SOME OF OUR DONORS WERE FEMALE. WE WOULD EFFECTIVELY KNOCK OUT THIS GENE IN THE FEMALE DONORS. AND THAT'S IN OUR REBUTTAL LETTER.

NO. 2, CAN THIS CAUSE OTHER MALIGNANCIES? THERE WAS A RECENT FDA WARNING FOR CELLULAR THERAPIES CAUSING T-CELL LYMPHOMAS. WE WILL TAKE PRECAUTIONS TO LOOK FOR OFF-TARGET INTEGRATION OF DNA SEQUENCES AS WELL AS AN INCORPORATED SUICIDE SWITCH, AS WELL AS A TARGET TO ALLOW ELIMINATION OF THESE CELLS IF THERE IS A PROBLEM.

AND THEN LASTLY, DOES THE APPLICATION APPROPRIATELY ADDRESS DIVERSITY, EQUITY, AND INCLUSION? AND THIS IS A STUDY WHERE WE USED DONOR CELLS, WHICH WE DID IN OUR PRELIMINARY DATA, AND WE HAVE 50 TO 60 DONORS AND WILL ENSURE WE UTILIZE A DIVERSE BACKGROUND.

WITH THAT, I WANT TO THANK THE REVIEW COMMITTEE FOR THEIR EXCELLENT REVIEW AND THE OPPORTUNITY TO SPEAK TODAY. WE HAVE ADDITIONAL DETAILS IN OUR REBUTTAL LETTER. AND I'D BE HAPPY TO TAKE ANY QUESTIONS.

CHAIRMAN IMBASCIANI: THANK YOU,
DR. TUSCANO.

BETH C. DRAIN, CA CSR NO. 7152

DR. TUSCANO: SORRY FOR THE BACKGROUND.
I'M IN CLINIC.

CHAIRMAN IMBASCIANI: YES, OF COURSE.

DR. BHADURI: I HAVE ADDITIONAL PUBLIC
COMMENT.

MR. TOCHER: PROCEED. YOU HAVE THREE
MINUTES.

DR. BHADURI: THANK YOU VERY MUCH. MY
NAME IS APARNA BHADURI, AND I AM AN ASSISTANT
PROFESSOR AT UCLA, AND I AM THE PRINCIPAL
INVESTIGATOR ON GRANT DISC-0 15764. AND I WOULD
LIKE TO ENCOURAGE FUNDING FOR MY PROPOSAL FROM TIER
II TO TIER I.

THIS PROPOSAL IS A STUDY TO GENERATE
DATA-DRIVEN IMPROVEMENTS IN ORGANOID MODELS TO MAKE
THEM MORE RESEMBLE THE DEVELOPMENTS THAT OCCUR IN
THE HUMAN BRAIN, ENABLING A MORE ACCURATE STUDY OF
NEURODEVELOPMENT DISORDERS.

IT IS A PRIORITY OF CIRM RIGHT NOW, AND IT
WAS ONE OF THE COMMENTS THAT THE PROJECT PLAN AND
TIMELINE DEMONSTRATE AN URGENCY THAT IS COMMENSURATE
WITH CIRM'S MISSION. OUR SCORE WAS 82, WHICH MISSED
THE FUNDING CUTOFF BY THREE POINTS. AND I'D LIKE TO
HIGHLIGHT THAT THIS FUNDING PROPOSAL IS URGENT
BECAUSE THIS PROJECT SEEKS TO PROVIDE CRITICAL

BETH C. DRAIN, CA CSR NO. 7152

IMPROVEMENTS IN CURRENT HUMAN BRAIN ORGANOID MODELS THAT, WITHOUT THESE IMPROVEMENTS, OUR ABILITY TO IDENTIFY AND TEST TREATMENTS FOR NEURODEVELOPMENTAL DISORDERS WHICH IMPACT 4.6 PERCENT OF CALIFORNIA CHILDREN WILL REMAIN SEVERELY LIMITED.

I'D LIKE TO HIGHLIGHT AND THANK THE REVIEWERS FOR THEIR POSITIVE COMMENTS AND CRITICISMS. OF THE CRITICISMS ABOUT THE PROJECT, ALL ARE ALREADY ADDRESSED IN THE APPLICATION. THESE ARE SPECIFICALLY IN FIGURES 3, 6, AND OTHER DETAILS ON PAGES 9 AND 13. AND THESE ARE DETAILS IN MY LETTER.

I'D LIKE TO HIGHLIGHT THAT NO CRITIQUES ARE OFFERED FOR THE SECOND AIM, AND THE NUMBER OF POSITIVE COMMENTS, INCLUDING THAT OVERALL THE PROJECT IS WELL DESIGNED, IT IS INVALUABLE DATA FOR THE FIELD OF STEM CELL NEUROBIOLOGY, AND THAT THE PROJECT ADDRESSES A MAJOR BOTTLENECK. THE PROJECT WILL OPEN DOORS FOR MULTIPLE LABORATORIES WITH DIFFERENT INTERESTS IN SUPPORT OF THE URGENCY OF THIS MISSION.

ADDITIONALLY, THE NATURE OF THE CRITIQUES IS SUCH THAT I AM CONFIDENT, IF ANY FURTHER CLARIFICATION IS REQUIRED, I CAN WORK DIRECTLY WITH PROGRAM OFFICERS AS THEY WERE MINOR DETAILS TO

BETH C. DRAIN, CA CSR NO. 7152

ENSURE ALL CONCERNS ARE ADDRESSED DURING EXECUTION OF THE PROJECT.

ENTHUSIASM FOR THE DIVERSITY, EQUITY, AND INCLUSION ASPECTS OF THE PROPOSAL WERE VERY STRONGLY RECEIVED. AND I BELIEVE THAT THIS WOULD IMPACT ESPECIALLY LOW INCOME AND UNDERREPRESENTED POPULATIONS TO WHOM NEURODEVELOPMENTAL DISORDERS ARE DISPROPORTIONATELY AFFECTED.

GIVEN THE POSITIVE RESPONSE AND LIMITED TECHNICAL CONSIDERATIONS, I WOULD ENCOURAGE THE BOARD TO FUND THIS RESEARCH IN THIS CURRENT ROUND OF APPLICATIONS BECAUSE IT WILL HAVE A MAJOR IMPACT TO PATIENTS WHO URGENTLY NEED NEW TREATMENTS, THE FIELD OF NEUROBIOLOGY, AND THE TAXPAYERS OF CALIFORNIA. THANK YOU VERY MUCH FOR YOUR CONSIDERATION.

CHAIRMAN IMBASCIANI: THANK YOU FOR YOUR COMMENTS, DR. BHADURI.

ARE THERE ANY OTHER PUBLIC COMMENTS BEING RECEIVED? THERE ARE NONE. OKAY.

THEN I'D LIKE TO ENTERTAIN FROM THE BOARD MEMBERS A MOTION IF THEY WOULD LIKE TO CONSIDER FUNDING ANY OF THE ONES THAT ARE PRESENTLY IN THE DO NOT FUND CATEGORY. ANNE-MARIE DULIEGE.

DR. DULIEGE: GIL, COULD YOU PLEASE RESPOND TO THE TWO COMMENTS THAT WE HAVE FOR EACH OF

BETH C. DRAIN, CA CSR NO. 7152

THESE TO THE EXTENT YOU REMEMBER THEM?

DR. SAMBRANO: SURE. SO I CAN RESPOND JUST VERY GENERALLY AND MAYBE GIVE YOU AN UNDERSTANDING OF KIND OF HOW WE APPROACH THIS PROCESS. SO THE APPLICATIONS THAT HAD PUBLIC COMMENT ALONG WITH SEVERAL OTHERS THAT SCORED BETWEEN 80 AND 84, THOSE ARE SCORES THAT THE GRANTS WORKING GROUP ARRIVED AT PRETTY DELIBERATELY WITH THE IDEA THAT THESE ARE PROMISING. SO NONE OF THESE ARE PROJECTS THAT WOULD HAVE FATAL FLAWS OR MAJOR ISSUES, BUT THAT THEY WOULD LIKE TO SEE AGAIN. THEY WOULD LIKE THE APPLICANTS TO ADDRESS THE CONCERNS AND COME BACK AT WHATEVER THE NEXT CYCLE IS.

BECAUSE THERE WERE NO MINORITY REPORTS, THAT'S BEEN KIND OF OUR GUIDING PRINCIPLE IN TERMS OF BRINGING A SPECIFIC RECOMMENDATION ON A GIVEN APPLICATION. WE DID NOT SPECIFICALLY LOOK AT THESE TO MAKE A RECOMMENDATION ON ANY OF THESE INDIVIDUAL APPLICATIONS OTHER THAN THEY FALL IN THIS CATEGORY OF 80 TO 84.

AND I KNOW THE APPLICANTS DID SUBMIT COMMENTS THAT ARE REBUTTALS TO THE GRANTS WORKING GROUP. AND GENERALLY WE VIEW THOSE AS ONES THAT SHOULD GO TO THE GRANTS WORKING GROUP ULTIMATELY OR SHOULD BE ADDRESSED WITH THE GRANTS WORKING GROUP

BETH C. DRAIN, CA CSR NO. 7152

SINCE THEY WERE THE ONES THAT ULTIMATELY HAD THE CONCERNS.

DR. DULIEGE: APPRECIATE IT. AND I THINK THAT'S ONE OF THE GREAT MANY QUALITIES OF THE REVIEW THAT YOU AND OTHERS HAVE ESTABLISHED OVER THE YEARS, WHICH IS TO BE VERY RIGOROUS AND FAIRLY SYSTEMATIC IN OUR APPROACH.

SO FOR PATIENTS AND RESEARCHERS, IT ALWAYS SEEMS URGENT. AND URGENCY IS SOMEWHAT A RELATIVE NOTION FOR SURE, BUT IT'S NOT TO BE TAKEN LIGHTLY. AND WHEN WILL BE NEXT OPPORTUNITY TO REAPPLY? IS IT IN A MONTH, THREE MONTHS, OR A YEAR?

DR. SAMBRANO: RIGHT. SO FOR THE DISC-0, WE OFFER IT ONCE A YEAR. SO THE NEXT DEADLINE WE'RE LOOKING AT WOULD BE AROUND NOVEMBER.

DR. DULIEGE: FOR THESE TWO --

DR. SAMBRANO: YES. FOR ANY OF THE APPLICANTS IN THIS CYCLE, IF THEY'RE GOING TO RESUBMIT, IT WOULD NOT BE TILL NOVEMBER.

DR. DULIEGE: AND A REVIEW BY EARLY NEXT YEAR, AND THAT MAKES A FULL YEAR REVIEW.

DR. SAMBRANO: ROSA, IF YOU HAVE A COMMENT --

DR. DULIEGE: THAT'S A LONG TIME.

DR. SAMBRANO: -- THAT MAY BE HELPFUL.

BETH C. DRAIN, CA CSR NO. 7152

DR. CANET-AVILES: I COULD ALSO SAY THAT SOME OF THE WORK, FOR EXAMPLE, FROM DR. BHADURI COULD GO INTO REMIND-L BECAUSE IT'S NEURODEVELOPMENT OR NEUROPSYCHIATRIC, AND THAT'S APPLICABLE TO THE SCOPE. SO IT'S NOT LIKE IT'S THE LAST CHANCE THAT THEY WILL HAVE. AND WE WILL BE DEVELOPING THE REMIND-X AS WELL.

DR. DULIEGE: IT'S THE WAY IT IS. AGAIN, ONE OF THE GOOD THINGS THAT HAS HAPPENED OVER THE YEARS IN SOME GRANTS, BUT I THINK IT'S THE CLINICAL GRANTS, THE REVIEW CYCLES ARE MUCH SHORTER, WHERE PEOPLE CAN REAPPLY WITHIN THREE MONTHS.

I HAVE TO SAY THAT I DIDN'T REALIZE IT WAS WITHIN A YEAR. AND THAT, FOR SURE, FOR RESEARCHERS AND PATIENTS, THIS IS SUPER LONG. THERE'S NO QUESTION ABOUT THAT. SO I DON'T KNOW IF THERE'S ANY WAY AROUND THAT, AND I'M NOT TRYING TO SUGGEST THAT WE CUT CORNERS HERE. BUT IF THERE ARE OTHER PATH THAT MIGHT HELP THESE RESEARCHERS HERE, THAT CERTAINLY WOULD BE A GOOD THING.

CHAIRMAN IMBASCIANI: DAVID.

DR. HIGGINS: I THINK A YEAR FOR RESEARCH THAT IS CLEARLY OVERALL RATED VERY HIGHLY, I THINK IT'S TOO LONG. SO I'D LIKE TO MAKE A MOTION TO ACCEPT THESE TWO THAT WE JUST DISCUSSED AND MOVE

BETH C. DRAIN, CA CSR NO. 7152

THEM FROM TIER II TO TIER I.

DR. DULIEGE: DAVID, I WOULDN'T WANT TO REEVALUATE THEM ON THE BASIS THAT TWO PEOPLE TOOK THE TIME, HAD ENOUGH PASSION ABOUT THE RESEARCH PROJECT TO INTERVENE. BUT IF WE THINK THAT OVERALL -- AND, AGAIN, IT'S NOT THE TIME TO REEVALUATE THE PROCESS. THE PROCESS IS THE PROCESS. IT HAS BEEN TESTED OVER THE YEARS. IT EXISTS FOR GOOD REASONS. WE REALIZE NOW THIS ONE TIER FOR DISCOVERY SEEMS LONG TO EVERYBODY AND FOR OTHERS.

DR. HIGGINS: THIS IS THE PROCESS THAT WE USE ACTUALLY. THE BOARD HAS ALMOST AT EVERY MEETING HAD THE OPPORTUNITY TO RAISE ONE FROM ONE TIER TO THE NEXT.

DR. CLARK-HARVEY: POINT OF ORDER. THERE'S A MOTION THAT'S BEEN MADE ON THE FLOOR. SO I THINK THERE'S SOME ACTION THAT NEEDS TO HAPPEN BEFORE DISCUSSION.

CHAIRMAN IMBASCIANI: THANK YOU, LEONDRA. THERE IS A MOTION ON THE FLOOR. I'M GOING TO ASK BEFORE WE HAVE FURTHER CONVERSATION, IS THERE A SECOND?

DR. SOUTHARD: I'LL SECOND.

CHAIRMAN IMBASCIANI: SO WE DO HAVE NOW THIS MOTION TO SPECIFICALLY ELEVATE TWO. I DON'T

BETH C. DRAIN, CA CSR NO. 7152

HAVE TO SAY THEIR NUMBERS 15700, 15764, TO BE FUNDED. SCOTT.

MR. TOCHER: ON POINTS OF ORDER, I JUST WANT TO REMIND THE MEMBERS WHO WERE IDENTIFIED ON GIL'S LAST SLIDE WHO HAVE CONFLICTS, UNFORTUNATELY AT THIS MOMENT IN THE DEBATE, BECAUSE THE CURRENT BUDGET EXCEEDS -- CURRENT BUDGET FOR QUESTS EXCEEDS THE PROGRAM BUDGET, ANY MEMBER WHO HAS A CONFLICT IN AN APPLICATION RIGHT NOW IS PRECLUDED FROM PARTICIPATING IN THE CONVERSATION OR THE VOTES AS TO ANY APPLICATION. SO A LITTLE LATER IN THIS CONVERSATION, WE MAY BE ABLE TO LIFT THAT RESTRICTION. BUT FOR NOW MEMBERS DURON, WATSON, BERNAL, AND FLOWERS, WE ASK YOU TO ABSTAIN FROM PARTICIPATING IN THE CONVERSATION.

CHAIRMAN IMBASCIANI: THANK YOU, MR. TOCHER. SO FURTHER CONVERSATION? YES.

MR. FISCHER-COLBRIE: POINT WELL TAKEN. DID I GET THE NUMBERS WRONG BECAUSE I THOUGHT WE WERE UNDER BUDGET?

MR. TOCHER: UNFORTUNATELY WE HAVE TO LOOK AT THE MOMENT AT THE ENTIRE SUBMISSION OF APPLICATIONS.

MR. FISCHER-COLBRIE: SORRY. MY APOLOGIES. THANK YOU.

BETH C. DRAIN, CA CSR NO. 7152

DR. FISHER: DO YOU SEE MY HAND RAISED?

CHAIRMAN IMBASCIANI: I DO NOW, FRED.

DR. BARRETT: JUST A POINT OF ORDER. SO THE TWO PROPOSALS THAT HAVE BEEN MENTIONED IN THE MOTION, I AM CONFLICTED ON ONE OF THEM. SO SHOULD I ALSO RECUSE MYSELF FROM FURTHER COMMENT?

MR. TOCHER: THAT'S RIGHT. I WAS SPEAKING PRIMARILY OF THE ARS MEMBERS, BUT ANY BOARD MEMBERS THIS APPLIES TO AS WELL.

CHAIRMAN IMBASCIANI: THANK YOU. FRED FISHER.

DR. FISHER: SO WE HAVE TO DRAW THE LINE SOMEWHERE, AND WE HAVE DRAWN THAT LINE. AND BY VIRTUE OF THE FACT THAT THESE PROPOSALS ARE IN FRONT OF US, THE ONES THAT MET THE CRITERIA FOR FUNDING AND THOSE THAT DIDN'T, THEY'RE ALL REALLY GOOD PROPOSALS. AND SO HOW FAR DOWN YOU SLIDE, WE JUST CAN'T MOVE THE NEEDLE. AND WHILE I APPRECIATE THE PLEA OF THE TWO APPLICANTS WHO DID NOT SCORE WELL, WE CAN'T DO THIS BASED ON TWO APPLICANTS SHOWING UP, MAKING THE CASE FOR THEIRS BECAUSE WE COULD HAVE HAD TEN APPLICANTS IN THE DO NOT FUND ALL MAKING VERY COMPELLING CASES FOR SUPPORT OF THEIR PROJECT.

AND I THINK THAT'S A CAN OF WORMS THAT WE BEST NOT OPEN. AND MAYBE AS THE PRIORITIZATION

BETH C. DRAIN, CA CSR NO. 7152

PROCESS CONTINUES, THAT WILL INFORM A DIFFERENT WAY OF GOING ABOUT THIS. BUT FOR NOW, THIS IS OUR WAY. AND GIVEN THAT, I THINK, THE APPROVED PROPOSALS ARE OVER BUDGET, IF I UNDERSTAND THAT CORRECTLY --

DR. SAMBRANO: NO.

DR. FISHER: -- WE OUGHT NOT TO BE EXACERBATING THAT PROBLEM.

CHAIRMAN IMBASCIANI: THANK YOU, FRED. NEXT SPEAKER IS VICE CHAIR BONNEVILLE.

DR. SAMBRANO: JUST FOR CLARITY, WE'RE NOT OVER BUDGET. SO IT'S 22.5 MILLION THAT'S AVAILABLE. IT'S 16.7, IF I RECALL, THE AMOUNT THAT THE 11 THAT ARE RECOMMENDED WOULD USE UP.

DR. FISHER: WE OUGHT TO PRESERVE WHAT'S LEFT IN SUPPORT OF OTHER APPLICATIONS THAT MAY COME FORWARD THAT SCORE AT 85 OR ABOVE.

VICE CHAIR BONNEVILLE: I ALSO WANT TO POINT OUT THERE'S AN APPLICATION THAT ACTUALLY DID NOT HAVE A LETTER THAT HAS SCORED HIGHER THAN THESE TWO. SO IF WE WERE GOING TO FUND ONE, WHY WOULDN'T WE FUND THE ONE THAT HAD THE HIGHER SCORE? SO YOU COULD LITERALLY HAVE A LOT OF PERMUTATIONS AROUND THIS. WE DON'T HAVE THE MONEY. WE HAVE AN EXPERT REVIEW GWG THAT MAKES THE RECOMMENDATIONS, AND I THINK, GIVEN THAT WE CAN'T FUND EVERYTHING THAT

BETH C. DRAIN, CA CSR NO. 7152

SCORES BETWEEN THE 80 AND THE 84, I THINK WE SHOULD JUST STICK TO THAT.

DR. DULIEGE: MARIA AND EVERYBODY, I'M CERTAINLY NOT TRYING TO CUT CORNERS. THE PROCESS EXISTS FOR A GOOD REASON AND SERVES A VERY GOOD PURPOSE. REGULARLY, HOWEVER, WE HAVE EVALUATED THE 84 BECAUSE BETWEEN MEAN AND MEDIANS, BINGO, THEY'RE EXACTLY THE SAME AND THEY END UP JUST SLIGHTLY ABOVE THE LINE WHERE THE MEDIAN ACTUALLY WOULD BE THE SAME.

I ALSO WANT TO REALLY APPLAUD THE DETERMINATION AND LEADERSHIP OF THESE TWO APPLICATION'S PI'S WHO TOOK THE TIME TO GO AND TELL US WHAT THEY FEEL AND WHAT THEY THINK. AND THAT'S THEIR ROLE. THAT'S ALSO OUR ROLE TO LISTEN TO THEM. AND IN THIS PROCESS, IN THAT PART OF THE DISCUSSION, IT MADE ME REALIZE THAT THIS IS ONLY A ONCE-A-YEAR REVIEW. I HAD EITHER NOT KNOWN THAT OR FORGOTTEN THAT. I WOULD SAY THERE'S ALWAYS A WAY TO DO THINGS BETTER, AND I'M JUST ASKING THE CIRM TO CONSIDER THIS SITUATION IN THE FUTURE HOW WE CAN IMPROVE THAT.

NOW, WE CANNOT MAKE REVIEWS EVERY TIME. AND, FINALLY, THE FACT THAT WE'E JUST AT BUDGET IS NOT IN FAVOR OF PUSHING THE BAR AND HAVING MORE

BETH C. DRAIN, CA CSR NO. 7152

PEOPLE BEING FUNDED BECAUSE WE DON'T WANT TO EXCEED THE BUDGET EITHER.

SO WITH THAT, I'M NOT MAKING A MOTION THAT WE SHOULD REVIEW THESE TWO APPLICATIONS. I JUST WOULD LIKE TO USE THAT AND CHANGE THE OUTCOME OF THESE TWO APPLICATIONS. I JUST WOULD LIKE TO USE THAT TO REFLECT ON HOW WE CAN MAKE THESE REVIEWS MORE FREQUENT.

CHAIRMAN IMBASCIANI: PAT LEVITT. THANK YOU.

DR. LEVITT: SO TWO THINGS. ONE IS THAT THERE'S THE SCORE COMPONENT AND THERE'S THE VOTE OF THE COMMITTEE THAT REVIEWED THESE GRANTS THAT VOTED YES OR NO TO FUND. AND THERE WAS AN OPPORTUNITY THERE TO AT LEAST SEE A SPLIT OF OPINION OR WHATEVER IT WAS; BUT IN TERMS OF THESE SCORES THAT ARE BELOW THE CUTOFF, THERE'S OVERWHELMING VOTES OF NO BY THE COMMITTEE THAT READ THE GRANTS. AND I'M AN ACTIVE SCIENTIST THAT SUBMITS GRANTS AND HAS VERY DISAPPOINTING REVIEWS THAT COME BACK AND WHY DIDN'T THEY SEE THAT.

SO I'M SYMPATHETIC AND I UNDERSTAND THAT IN THE PROCESS OF WHETHER WE NEED TO ADDRESS THE CYCLES IS ANOTHER ISSUE, BUT FOR ME, WHEN I LOOK AT THE NUMBER OF MEMBERS WHO REVIEWED THE GRANT AND

BETH C. DRAIN, CA CSR NO. 7152

SAID YES VERSUS NO IS AS IMPORTANT AS THE SCORE ITSELF. BECAUSE THEY'RE MAKING A FINAL DECISION ABOUT WHETHER THEY FEEL THAT IT MET THE CRITERIA FOR FUNDING. SO TO ME THAT'S A VERY IMPORTANT CRITERION THAT WE CAN'T IGNORE. SO I WOULD NOT WANT TO SEE A CHANGE AT THIS POINT IN TIME IN TERMS OF THE DECISIONS TO FUND AND MAYBE ADDRESSES AT A LATER TIME THE ISSUE AROUND THE PROCESS. THANK YOU.

DR. DULIEGE: I AGREE WITH YOU, PAT, AND THESE ARE POINTS WELL TAKEN.

CHAIRMAN IMBASCIANI: THE NEXT SPEAKERS WILL BE LEONDRA FOLLOWED BY KEITH YAMAMOTO.

DR. CLARK-HARVEY: THANK YOU. I AGREE WITH PUTTING THIS IN THE PARKING LOT AS A FUTURE AGENDA ITEM. I THINK IT SHOULD BE REVISITED.

AND ALSO I JUST HAVE A QUESTION. I'M SORRY IF I'M NOT TRACKING THIS WELL, BUT I'VE HEARD TWO DIFFERENT THINGS. I'VE HEARD THERE'S \$22 MILLION ALLOTTED. THESE APPLICATIONS TOTAL 16. BUT THEN I'VE ALSO HEARD WE DON'T HAVE THE MONEY. WHICH IS IT, AND ARE THOSE RELATED, OR AM I JUST MISHEARING?

DR. SAMBRANO: SO THE FIRST ONE IS CORRECT. THERE ARE 22.5 MILLION FOR THE CURRENT CYCLE. THE 11 APPLICATIONS THAT ARE RECOMMENDED

BETH C. DRAIN, CA CSR NO. 7152

TOTAL 16.7 MILLION. SO IF YOU WERE TO CHOOSE TO FUND ADDITIONAL ONES, YOU COULD FUND UP TO POTENTIALLY THREE MORE.

DR. CLARK-HARVEY: THANK YOU. I HEARD THE SUBSEQUENT COMMENT, WE DON'T HAVE THE MONEY. SO I'M NOT SURE WHAT THAT WAS IN RELATION TO, BUT IT SOUNDS LIKE THAT WAS INACCURATE.

DR. SAMBRANO: IT WAS INACCURATE.

DR. CLARK-HARVEY: RIGHT. OKAY. THANK YOU.

CHAIRMAN IMBASCIANI: I THINK THAT KEITH IS IN CONFLICT, SO HE'S NOT SPEAKING ON THIS ISSUE. AM I CORRECT ON THAT? THANK YOU.

SO ANY FURTHER COMMENT BY THE BOARD MEMBERS FIRST ON THIS STANDING MOTION? ANY MEMBER OF THE -- I'M SORRY.

DR. THOMAS: I'D JUST LIKE TO WEIGH A LITTLE BIT HERE. VERY SYMPATHETIC TO THE TWO APPLICANTS AS WELL AS TO DAVID AND MARV WITH RESPECT TO THE MOTION. HOWEVER, THERE'S A PRECEDENTIAL ISSUE HERE WHICH YOU DON'T WANT TO GET ON THE WRONG SIDE OF. OKAY. SO MY STRONG ADVICE TO YOU IS TO STICK TO THE COMMENTS THAT WE SHOULD NOT BE GOING BELOW THE 85.

CHAIRMAN IMBASCIANI: THE PUBLIC HAVING

BETH C. DRAIN, CA CSR NO. 7152

BEEN HEARD FROM ON THIS ISSUE, I THINK WE CAN
PROCEED TO A VOTE THEN, SCOTT.

MR. TOCHER: SO THE MOTION, JUST TO
REITERATE, IS TO MOVE APPLICATIONS DISC0-15711 AND
15764 UP TO THE FUND CATEGORY.

MARIA BONNEVILLE.

VICE CHAIR BONNEVILLE: NO.

MR. TOCHER: JUDY CHOU.

DR. CHOU: NO.

MR. TOCHER: LEONDRA CLARK-HARVEY.

DR. CLARK-HARVEY: NO.

MR. TOCHER: ANNE-MARIE DULIEGE.

DR. DULIEGE: NO.

MR. TOCHER: MARK FISCHER-COLBRIE.

MR. FISCHER-COLBRIE: NO.

MR. TOCHER: FRED FISHER. SORRY. WE'RE
HELPING HIM UNMUTE. FRED. OKAY. I'LL COME BACK TO
FRED.

DAVID HIGGINS.

DR. FISHER: I HAD TO UNMUTE MYSELF. I AM
A RESOUNDING NO. SORRY ABOUT THAT.

MR. TOCHER: THANK YOU VERY MUCH, FRED.

DAVID HIGGINS.

DR. HIGGINS: CONVINCED BY ONE OF MY
COLLEAGUES, I SAY AYE.

BETH C. DRAIN, CA CSR NO. 7152

MR. TOCHER: VITO IMBASCIANI.

CHAIRMAN IMBASCIANI: NO.

MR. TOCHER: STEVE JUELSGAARD.

MR. JUELSGAARD: NO.

MR. TOCHER: RICH LAJARA.

MR. LAJARA: NO.

MR. TOCHER: ADRIANA PADILLA.

DR. PADILLA: NO.

MR. TOCHER: LAUREN MILLER-ROGEN.

MS. MILLER-ROGEN: NO.

MR. TOCHER: MARV SOUTHARD.

DR. SOUTHARD: I'LL BE THE ONE YES.

MR. TOCHER: KEVIN XU.

DR. XU: NO.

MR. TOCHER: I'M SORRY. WAS THAT A NO,
KEVIN?

DR. XU: YEAH. NO.

MR. TOCHER: OKAY. GREAT. THANK YOU VERY
MUCH. THE MOTION FAILS.

CHAIRMAN IMBASCIANI: THANK YOU, SCOTT.

MR. TOCHER: MAY I MAKE A RECOMMENDATION?

CHAIRMAN IMBASCIANI: YES. WHAT TO DO
WITH THIS GROUP.

MR. TOCHER: YES. I THINK IT WOULD BE
APPROPRIATE AT THIS TIME TO ASK FOR A MOTION, AGAIN

BETH C. DRAIN, CA CSR NO. 7152

FROM SOMEONE WHO DOES NOT HAVE A CONFLICT ON THE ARS, TO NOT FUND THOSE APPLICATIONS IN THE SECOND TIER.

CHAIRMAN IMBASCIANI: OKAY.

MR. JUELSGAARD: SO MOVED.

VICE CHAIR BONNEVILLE: SECOND.

CHAIRMAN IMBASCIANI: WE HAVE A MOVEMENT FROM DR. JUELSGAARD AND SECOND FROM VICE CHAIR NOT TO FUND BELOW THAT LINE. DISCUSSION IS OPEN TO BOARD MEMBERS FIRST. I DON'T SEE ANY HANDS ON THE SCREEN. ANY COMMENTS FROM THE PUBLIC? NONE I'VE SEEN. SCOTT, I THINK WE CAN PROCEED TO THE VOTE.

MR. TOCHER: MARIA BONNEVILLE.

VICE CHAIR BONNEVILLE: YES.

MR. TOCHER: JUDY CHOU.

DR. CHOU: YES.

MR. TOCHER: LEONDRA CLARK-HARVEY.

DR. CLARK-HARVEY: YES.

MR. TOCHER: ANNE-MARIE DULIEGE.

DR. DULIEGE: YES.

MR. TOCHER: MARK FISCHER-COLBRIE.

MR. FISCHER-COLBRIE: YES.

MR. TOCHER: FRED FISHER. ONE MORE TIME, FRED. I WILL COME BACK TO YOU, FRED.

DAVID HIGGINS.

BETH C. DRAIN, CA CSR NO. 7152

DR. HIGGINS: YES.

MR. TOCHER: VITO IMBASCIANI.

CHAIRMAN IMBASCIANI: YES.

MR. TOCHER: STEVE JUELSGAARD.

MR. JUELSGAARD: YES.

MR. TOCHER: RICH LAJARA.

MR. LAJARA: YES.

MR. TOCHER: LAUREN MILLER-ROGEN.

MS. MILLER-ROGEN: YES.

MR. TOCHER: ADRIANA PADILLA.

DR. PADILLA: YES.

MR. TOCHER: MARV SOUTHARD.

DR. SOUTHARD: YES.

MR. TOCHER: KEVIN XU.

DR. XU: YES.

MR. TOCHER: GREAT. THANK YOU VERY MUCH.

THAT MOTION CARRIES. SORRY. FRED FISHER. OKAY.

LAST CALL FOR FRED.

THE MOTION CARRIES NEVERTHELESS.

SO AS A RESULT OF THAT MOTION, WE NOW HAVE A SITUATION WHERE MEMBERS WHO ARE IN CONFLICT, WHILE THEY CANNOT PARTICIPATE IN THE DISCUSSION WITH RESPECT TO THE APPLICATION WITH RESPECT TO THE APPLICATION WITH WHICH YOU'RE IN CONFLICT, YOU MAY PARTICIPATE IN DISCUSSIONS WITH RESPECT TO OTHER

BETH C. DRAIN, CA CSR NO. 7152

APPLICATIONS SHOULD THEY ARISE.

CHAIRMAN IMBASCIANI: GOOD. SO THE CHAIR WOULD NOW ENTERTAIN A MOTION WITH RESPECT TO THE 11 APPLICATIONS IN THE GROUP THAT WERE RECOMMENDED FOR FUNDING. IS THERE ANY APPLICATION IN THIS GROUP THAT YOU RECOMMEND NOT BE FUNDED? I DON'T SEE ANY COMMENT FROM THE BOARD. IS THERE COMMENT FROM THE PUBLIC. NO COMMENT BEING SEEN --

MR. TOCHER: WE DON'T HAVE A MOTION.

CHAIRMAN IMBASCIANI: WE DON'T HAVE A MOTION.

MR. FISCHER-COLBRIE: I MOVE THAT WE APPROVE THE GRANTS THAT ARE ABOVE THE THRESHOLD LINE.

MR. JUELSGAARD: SECOND.

CHAIRMAN IMBASCIANI: STEVE JUELSGAARD. THANKS.

COMMENT FROM BOARD MEMBERS ON THIS GROUP? NO COMMENT BEING SEEN AND NO COMMENT FROM THE PUBLIC, I THINK WE CAN CONCLUDE THIS WHOLE SESSION WITH A VOTE.

MR. TOCHER: FOR THE MEMBERS WHOSE NAMES I CALL THAT ARE IN CONFLICT WITH ANY APPLICATION, PLEASE GIVE YOUR ANSWER AND ADD EXCEPT WITH RESPECT TO THOSE APPLICATIONS IN WHICH I HAVE A CONFLICT.

BETH C. DRAIN, CA CSR NO. 7152

I'LL REMIND YOU IN CASE YOU FORGET.

DAN BERNAL.

MR. BERNAL: YES, EXCEPT FOR THOSE WITH WHICH I HAVE A CONFLICT.

MR. TOCHER: MARIA BONNEVILLE.

VICE CHAIR BONNEVILLE: YES.

MR. TOCHER: JUDY CHOU.

DR. CHOU: YES.

MR. TOCHER: LEONDRA CLARK-HARVEY.

DR. CLARK-HARVEY: YES.

MR. TOCHER: ANNE-MARIE DULIEGE.

DR. DULIEGE: YES.

MR. TOCHER: YSABEL DURON.

MS. DURON: YES, EXCEPT FOR THOSE WITH WHICH I HAVE A CONFLICT.

MR. TOCHER: MARK FISCHER-COLBRIE.

DR. FISCHER-COLBRIE: YES.

MR. TOCHER: FRED FISHER.

DR. FISHER: YES.

MR. TOCHER: ELENA FLOWERS.

DR. FLOWERS: YES, EXCEPT FOR THOSE WITH WHICH I HAVE A CONFLICT.

MR. TOCHER: DAVID HIGGINS.

DR. HIGGINS: YES.

MR. TOCHER: VITO IMBASCIANI.

BETH C. DRAIN, CA CSR NO. 7152

CHAIRMAN IMBASCIANI: YES.

MR. TOCHER: STEPHEN JUELSGAARD.

MR. JUELSGAARD: YES.

MR. TOCHER: RICH LAJARA.

MR. LAJARA: YES.

MR. TOCHER: LAUREN MILLER-ROGEN.

MS. MILLER-ROGEN: YES.

MR. TOCHER: ADRIANA PADILLA.

DR. PADILLA: YES.

MR. TOCHER: MARVIN SOUTHARD.

DR. SOUTHARD: YES.

MR. TOCHER: KAROL WATSON. KAROL, ARE YOU
STILL WITH US?

KEVIN XU.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. XU: YES.

2 MR. TOCHER: HOLD JUST ONE SECOND. GREAT.
3 THE MOTION CARRIES. THANK YOU.

4 CHAIRMAN IMBASCIANI: THIS IS GREAT.
5 THANK YOU VERY MUCH, BOARD MEMBERS, FOR ATTENDING TO
6 ALL THESE APPLICATIONS.

7 SCOTT, DON'T GO AWAY BECAUSE YOU'RE GOING
8 TO TAKE US INTO CLOSED SESSION.

9 MR. TOCHER: ALL RIGHT. WE'LL BE
10 PROCEEDING TO CLOSED SESSION FOR THE DISCUSSION OF
11 CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT,
12 PREPUBLICATION DATA, FINANCIAL INFORMATION, AND
13 CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER
14 PROPRIETARY INFORMATION RELATING TO BLA STATUS FOR
15 OUR CLIN PORTFOLIO PURSUANT TO HEALTH & SAFETY CODE
16 125290.30(F)(3)(B) AND (C).

17 CHAIRMAN IMBASCIANI: THAT SOUNDS LIKE AN
18 EYE CHART, BUT THANK YOU. OKAY. SO THE PEOPLE THAT
19 ARE NOT GOING TO BE PRESENT FOR THE CLOSED SESSION
20 SHOULD EXIT THE ROOM.

21 MR. TOCHER: YES, IN HOUSE TO DEPART THE
22 ROOM. AND MEMBERS OF THE BOARD WILL RECEIVE AN
23 INVITATION TO -- ON THE ZOOM, EXCUSE ME, WILL JOIN A
24 BREAKOUT ROOM, WHICH THEY SHOULD SEE ON THEIR
25 SCREENS NOW.

BETH C. DRAIN, CA CSR NO. 7152

1 (THE BOARD THEN WENT INTO CLOSED
2 SESSION NOT REPORTED NOR HEREIN TRANSCRIBED. THE
3 FOLLOWING WAS THEN HEARD IN OPEN SESSION AS
4 FOLLOWS:)

5 CHAIRMAN IMBASCIANI: ARE WE READY, BETH?
6 GOT IT, YES. THANK YOU.

7 I'D LIKE TO WELCOME EVERYONE BACK INTO
8 OPEN SESSION. AND WE ARE NOW UP TO AGENDA ITEM 18,
9 AND WE'RE GOING TO HAVE AN UPDATE FROM THE
10 PRESIDENTIAL SEARCH COMMITTEE. THIS WAS POSTPONED
11 FROM OUR FEBRUARY MEETING. DR. BARRETT.

12 DR. BARRETT: SO GOOD AFTERNOON AND THANK
13 YOU, MR. CHAIRMAN. I CAN BE FAIRLY BRIEF ON THIS,
14 BUT I HAVE POSITIVE NEWS TO REPORT ON BEHALF OF
15 DR. BLUMENTHAL AND MYSELF AS THE CO-CHAIRS OF THE
16 PRESIDENTIAL SEARCH COMMITTEE.

17 THE MOST IMPORTANT THING TO LET YOU KNOW
18 IS THAT THE PROGRESS AND THE PROCESS REMAIN ON TRACK
19 AND LARGELY ALIGNED WITH THE ORIGINAL TIMELINE THAT
20 WAS OUTLINED. AND WE REMAIN VERY CONFIDENT THAT WE
21 CAN IDENTIFY AN OUTSTANDING CANDIDATE BEFORE THE
22 SUMMER AS WAS ALREADY ALLUDED TO THIS MORNING.

23 WE'VE BEEN MEETING REGULARLY WITH OUR
24 SEARCH CONSULTANTS FROM SRI. AND THEY ARE
25 CONTINUING TO EXPAND THE POOL. THE POOL -- OR THE

BETH C. DRAIN, CA CSR NO. 7152

1 PROCESS IS NOT YET CLOSED. BUT EVEN AT THIS POINT,
2 WE CAN SAY THAT THE RESPONSE HAS BEEN EXTREMELY
3 ROBUST. THEY HAVE SPOKEN TO MORE THAN 300 PEOPLE.
4 THERE HAVE BEEN MORE THAN A HUNDRED APPLICATIONS,
5 AND THERE IS A MEANINGFUL PROPORTION OF THOSE
6 APPLICATIONS THAT LOOK LIKE THEY HAVE THE QUALITIES
7 THAT WE WOULD NEED IN THE NEXT PRESIDENT AND CEO.

8 THE POOL THAT WE HAVE THUS FAR, IN TERMS
9 OF THE MOST COMPETITIVE CANDIDATES, IS VERY DIVERSE
10 ACROSS A NUMBER OF DIFFERENT DIMENSIONS, INCLUDING
11 GENDER, THE SECTOR OF EMPLOYMENT. WE HAVE PEOPLE
12 FROM ACADEMIA, FROM BIOTECH, FROM BIOPHARMA, FROM
13 NON-PROFITS, FROM ADVOCACY ORGANIZATIONS. SO I
14 THINK THAT THE CONFIDENCE THAT WE HAVE WITH SRI
15 BEING ABLE TO SURFACE A LARGE NUMBER OF DIVERSE
16 CANDIDATES WAS WELL PLACED.

17 THEY HAVE REPORTED TO US THAT THERE HAVE
18 BEEN A FEW PEOPLE WHO HAVE DECLINED FURTHER
19 CONVERSATIONS BASED ON GEOGRAPHY AND NOT WANTING TO
20 RELOCATE TO THE BAY AREA. BUT ENCOURAGINGLY NOBODY
21 HAS SAID NO AS YET ON THE BASIS OF COMPENSATION. SO
22 WE'RE OBVIOUSLY IN A REASONABLY COMPETITIVE
23 POSITION, AND THEY SAID THAT THAT WAS TRUE BOTH OF
24 PEOPLE COMING FROM THE PRIVATE SECTOR AND FROM
25 ACADEMIA.

BETH C. DRAIN, CA CSR NO. 7152

1 THE CONSULTANTS AT OUR LAST MEETING, WHICH
2 WAS ACTUALLY -- FEELS LIKE IT WAS FOREVER AGO, BUT
3 WAS JUST THE DAY BEFORE YESTERDAY -- HAVE ASKED IF
4 WE CAN SLIGHTLY EXTEND THE PIECE OF THE TIMELINE
5 WHICH WAS DESIGNED FOR THEM TO DELIVER TO US THE
6 SO-CALLED LONG LIST OF INITIAL COMPETITIVE
7 CANDIDATES BY ONE TO TWO WEEKS. AND I WANT TO
8 STRESS THAT THIS IS NOT IN ANY WAY THAT THEY'VE BEEN
9 DRAGGING THEIR FEET OR THAT THERE AREN'T SUFFICIENT
10 CANDIDATES, BUT RATHER THAT THE CALIBER OF THE
11 PEOPLE THAT THEY'RE TALKING TO IS SUCH THAT THESE
12 ARE ALL BUSY PEOPLE WHO WEREN'T WAITING AROUND FOR A
13 PHONE CALL ABOUT A JOB. AND SO JUST GETTING ON
14 THEIR CALENDAR TO SCHEDULE CONVERSATIONS HAS BEEN
15 CHALLENGING.

16 SO I TAKE THAT, AND I THINK GEORGE DOES
17 TOO, AS A VERY POSITIVE SIGN AS WELL. IT REALLY IS
18 EXTREMELY ENCOURAGING.

19 AND I WILL REMIND EVERYBODY THAT THE
20 PROCESS THAT SRI IS PUTTING THESE PEOPLE THROUGH IS
21 REALLY QUITE RIGOROUS AND ACTUALLY IS DOING A LOT OF
22 THE INITIAL WORK FOR US. THERE IS A SERIES OF
23 CONVERSATIONS WITH THESE INDIVIDUALS, AND THEY ARE
24 ALSO BEING ASKED TO COMPLETE -- I'VE FORGOTTEN THE
25 PRECISE TERM FOR IT, BUT IT'S BASICALLY A HIGHLY

BETH C. DRAIN, CA CSR NO. 7152

1 STRUCTURED FORM OF A COVER LETTER WHERE THEY ARE
2 ENCOURAGED TO REFLECT ON THEIR EXPERIENCES AND THEIR
3 QUALIFICATIONS FOR THE VARIOUS ASPECTS OF THE ROLE.

4 AND MAYBE, SCOTT, YOU REMEMBER WHAT IT'S CALLED.

5 MR. TOCHER: I BELIEVE THEY CALL IT THE
6 COMPETENCY PROFILE.

7 DR. BARRETT: THE COMPETENCY PROFILE.

8 THANK YOU SO MUCH.

9 OF COURSE, WE WILL HAVE ACCESS TO ALL OF
10 THE APPLICATIONS; BUT BASED ON THE CALIBRATION
11 DISCUSSIONS WE HAVE HAD THUS FAR AND THE CV'S THAT
12 THEY'VE BROUGHT FORWARD TO SAY IS THIS THE RIGHT
13 SORT OF PERSON, I THINK THEY'RE DOING AN EXCELLENT
14 JOB.

15 WE ARE STILL NOT 100 PERCENT FIXED ON THE
16 NEXT STAGE OF THE PROCESS AFTER THE LONG LIST IS
17 DELIVERED IN PART BECAUSE WE DON'T KNOW THE LENGTH
18 OF THAT LIST. IF IT IS A MANAGEABLE NUMBER, THEN
19 MOST LIKELY WE WILL ASK THE ENTIRE SEARCH
20 SUBCOMMITTEE TO INTERVIEW THAT SET OF PEOPLE. AND I
21 WOULD SAY THAT THE MANAGEABLE NUMBER WOULD BE
22 SOMETHING AROUND EIGHT TO TEN CANDIDATES. IF IT IS
23 20 OR 30 CANDIDATES, OBVIOUSLY THAT'S WAY TOO MANY
24 FOR THE ENTIRE COMMITTEE TO INTERVIEW. I DON'T
25 THINK ANYBODY ON A COMMITTEE HAS 30 HOURS TO DEVOTE

BETH C. DRAIN, CA CSR NO. 7152

1 TO THIS PROCESS IN A VERY COMPRESSED SORT OF
2 SCHEDULE.

3 SO PROBABLY WHAT WE WILL DO IS ASK A
4 SUBSET OF THE SUBCOMMITTEE, INCLUDING PEOPLE IN THIS
5 ROOM, TO HELP US WITH SORT OF SHORT-LISTING THE LONG
6 LIST.

7 AND BASED ON THESE FIRST-ROUND INTERVIEWS,
8 WE EXPECT TO MAKE RECOMMENDATIONS TO THE FULL BOARD.
9 AND THE ONLY OTHER THING THAT I WILL SAY IS THE SORT
10 OF ELEPHANT IN THE ROOM IS THE ISSUE THAT PAT
11 BROUGHT UP AND THAT WE HAD A DISCUSSION ABOUT THIS
12 MORNING, THAT THIS IS HAPPENING IN THE CONTEXT OF
13 OTHER THINGS HAVING TO HAPPEN IN CIRM AT THE SAME
14 TIME. BUT I BELIEVE WE ARE VERY MUCH STILL ALIGNED
15 THAT THESE THINGS CAN HAPPEN IN PARALLEL, BUT THERE
16 WILL BE SUFFICIENT OPPORTUNITY FOR THE NEXT
17 PRESIDENT AND CEO TO ENGAGE WITH THE PROCESS OF
18 STRATEGIC PRIORITIZATION THAT WAS DISCUSSED THIS
19 MORNING.

20 AND, GEORGE, WOULD YOU LIKE TO ADD
21 ANYTHING?

22 DR. BLUMENTHAL: NO, I THINK YOU'VE
23 COVERED IT.

24 DR. BARRETT: I WILL SAY IT IS A GREAT
25 PLEASURE TO WORK WITH GEORGE AND SCOTT ON THIS

BETH C. DRAIN, CA CSR NO. 7152

1 PROCESS, AND I'M HONORED TO BE ONE OF THE CO-CHAIRS.

2 CHAIRMAN IMBASCIANI: THANK YOU VERY MUCH,
3 DR. BARRETT, FOR YOUR PRESENTATION AND FOR BOTH OF
4 OUR CO-CHAIRS FOR ALL THEIR WORK IN ORGANIZING THIS.
5 THANK YOU.

6 WE'RE GOING TO MOVE ON NOW TO A
7 PRESENTATION FROM OUR VICE PRESIDENT FOR
8 COMMUNICATIONS FOR THE COMM SUBCOMMITTEE.

9 VICE CHAIR BONNEVILLE: YSABEL, ARE YOU
10 STILL ON THE LINE, AND DID YOU WANT TO MAKE A
11 COMMENT OR DID YOU WANT ME TO?

12 MS. DURON: MARIA, YOU GO AHEAD.

13 VICE CHAIR BONNEVILLE: GREAT. THANKS.
14 AT OUR LAST COMMUNICATIONS SUBCOMMITTEE, WE
15 DISCUSSED THE IMPORTANCE OF UNDERSTANDING OUR ROLE
16 AS A COMMITTEE. AND AS WITH MANY OF OUR
17 SUBCOMMITTEES, WE'RE HERE TO SUPPORT THE INTEGRAL
18 TEAM WITH THEIR COMMUNICATIONS BY PROVIDING GUIDANCE
19 AND INPUT. AND WE'LL MEET QUARTERLY WITH THE TEAM,
20 AND THEY WILL HAVE A REPORT BACK TO THE BOARD AFTER.
21 BUT THE TEAM REPORTS INTO THE CEO AND PRESIDENT. SO
22 ULTIMATELY DECISIONS AROUND LOGOS, BRANDING,
23 MESSAGING FIRST GO THROUGH THE -- STARTS WITH THE
24 TEAM, GOES TO THE CEO/PRESIDENT, THERE IS
25 CONVERSATIONS WITH THE SUBCOMMITTEE, INPUT IS TAKEN,

BETH C. DRAIN, CA CSR NO. 7152

1 AND THEN ULTIMATELY THE DECISION IS MADE BY THE CEO.

2 AND I THINK THERE WAS A LITTLE CONFUSION
3 ABOUT THAT AFTER OUR LAST BOARD MEETING. AND SO WE
4 JUST WANTED TO CONVENE THE SUBCOMMITTEE. WE ALL
5 DISCUSSED THIS PROCESS. EVERYONE IS VERY
6 COMFORTABLE.

7 SO I WANT TO THANK KOREN AND HER TEAM FOR
8 BEING RESPONSIVE TO THE VARIOUS REQUESTS THAT HAVE
9 COME HER WAY AND TO THEIR WAY. AND, KOREN, IF YOU
10 WANT TO START.

11 MS. TEMPLE-PERRY: THANK YOU VERY MUCH,
12 MARIA, FOR THAT RECAP. AND THANK YOU, EVERYONE, FOR
13 THIS OPPORTUNITY FOR A QUICK UPDATE. SCOTT TOLD ME
14 TO BE QUICK.

15 SO AS MARIA MENTIONED, WE HAD A WONDERFUL
16 COMMUNICATIONS SUBCOMMITTEE MEETING TWO WEEKS AGO.
17 IT WAS VERY ENGAGING. IT WAS TWO HOURS, BUT WE HAD
18 A LOT OF WONDERFUL DISCUSSION. IN ADDITION TO WHAT
19 MARIA MENTIONED AROUND CLARIFYING THE MISSION OF THE
20 SUBCOMMITTEE, WE ALSO DISCUSSED WAYS FOR THE
21 SUBCOMMITTEE TO GET INVOLVED. SO THERE WERE A
22 NUMBER OF WONDERFUL IDEAS.

23 JUST QUICKLY, THERE WERE IDEAS AROUND
24 WRITING OP-EDS OR HAVING SUBCOMMITTEE MEMBERS WRITE
25 OP-EDS TO REALLY ILLUSTRATE CIRM'S IMPACT.

BETH C. DRAIN, CA CSR NO. 7152

1 ESPECIALLY ON THE HEELS OF OUR 20TH ANNIVERSARY,
2 IDEAS AROUND LEVERAGING THE BOARD'S NETWORK TO
3 SHOWCASE AND TO COMMUNICATE THE GREAT WORK THAT CIRM
4 IS DOING.

5 IN ADDITION, THERE WERE IDEAS, AND THIS
6 CAME UP QUITE FREQUENTLY, AROUND DEPLOYING A STRIKE
7 TEAM. ALTHOUGH I DID MENTION TO YSABEL THAT WE'D
8 PROBABLY NEED TO WORK ON THE BRANDING OF THAT A
9 LITTLE BIT, BUT IDEALLY OR IN GENERAL IT'S SORT OF
10 THIS IDEA OF HAVING A RESPONSIVE GROUP SPEAK ON
11 BEHALF OF CIRM WHENEVER REQUESTED THROUGHOUT THE
12 STATE OF CALIFORNIA. SO I WOULD SAY THE IDEAS WERE
13 WONDERFUL AND WELL RECEIVED.

14 IN ADDITION, WE SHARED A LOT OF EXCITING
15 UPDATES SINCE LAUNCHING OUR COMMUNICATIONS STRATEGY
16 IN DECEMBER. WE SHARED PROGRESS ON A LOT OF KEY
17 COMPONENTS OF OUR COMM STRATEGY WHICH I'M HAPPY TO
18 SHARE IN MORE DETAIL AT AN UPCOMING BOARD MEETING.

19 IN ADDITION, WE SHOWCASED AT LOT OF OUR
20 BRANDING UPDATES. SO WHAT YOU SEE HERE ON THIS
21 SLIDE, WE UPDATED A LOT OF OUR COLLATERAL AS WELL AS
22 DIFFERENT COLOR SCHEMES FROM OUR BRANDING
23 GUIDELINES. WE CREATED A NUMBER OF TEMPLATES FOR
24 BROCHURES, EMAIL SIGNATURES, LETTERHEAD, ET CETERA.
25 AND SO WE PREVIEWED THIS AT THE SUBCOMMITTEE

BETH C. DRAIN, CA CSR NO. 7152

1 MEETING, AND IT WAS WELL RECEIVED.

2 IN ADDITION, WE SPENT QUITE A BIT OF TIME
3 TALKING ABOUT OUR CIRM LOGO. SO IN DECEMBER THERE
4 WERE A LOT OF CALLS TO MAKE SURE THAT OUR CIRM LOGO
5 REFLECTED SORT OF A MODERN TOUCH. AND SO WE
6 RECEIVED A LOT OF VALUABLE FEEDBACK FROM THE
7 SUBCOMMITTEE. WE TALKED ABOUT INCORPORATING A
8 TAGLINE INTO SORT OF A MODERN VERSION OF THE CIRM
9 LOGO. AND SO WE HAVE CREATED A NUMBER OF POTENTIAL
10 OPTIONS THAT WE ARE CIRCULATING AND REVIEWING
11 INTERNALLY. AND I LOOK FORWARD TO SHARING THAT
12 RECOMMENDATION WITH YOU ALL.

13 OKAY. WE ALSO PRESENTED PROGRESS IN THE
14 DEVELOPMENT OF OUR NEW WEBSITE, AND THIS WAS REALLY,
15 REALLY WELL RECEIVED. I THINK WE RECEIVED SOME
16 HANDCLAPS VIRTUALLY ON THIS ONE. SO THE
17 SUBCOMMITTEE WAS VERY ENTHUSIASTIC TO HEAR UPDATES
18 ON THE UPDATE OF OUR CIRM WEBSITE.

19 THIS IS AN EXAMPLE OF A WIREFRAME THAT WAS
20 CREATED FOR OUR NEW WEBSITE. AND REALLY WE'VE BEEN
21 WORKING THROUGH THE WHOLE PROCESS THESE LAST COUPLE
22 OF MONTHS JUST MAKING SURE THAT WE ARE INCORPORATING
23 A LOT OF FEEDBACK INTO THE STRATEGY, DESIGN, AND
24 CONTENT OF OUR WEBSITE. AND THIS KIND OF GIVES YOU
25 JUST A HIGH LEVEL IDEA IN TERMS OF THE PROCESS THAT

BETH C. DRAIN, CA CSR NO. 7152

1 WE'VE GONE THROUGH.

2 STRATEGY, WE SPENT QUITE A BIT OF TIME
3 GOING THROUGH THE INFORMATION ARCHITECTURE, WHICH IS
4 BASICALLY A BLUEPRINT OF HOW OUR WEBSITE WILL BE
5 DESIGNED, THE DIFFERENT PAGES, THE DIFFERENT
6 NAVIGATION FEATURES, ET CETERA. AND, AGAIN, AS
7 MENTIONED, WE ARE GOING THROUGH THE PROCESS OF
8 LOOKING AT THE USER DESIGN AS WELL AS EXPERIENCE AND
9 WORKING THROUGH CONTENT. SO WE ARE MAKING QUITE A
10 BIT OF PROCESS, WHICH THE SUBCOMMITTEE WAS VERY
11 HAPPY TO HEAR ABOUT.

12 IN ADDITION, WE REPORTED ON OUR FIRST
13 OUTREACH CAMPAIGN SINCE LAUNCHING OUR COMMUNICATION
14 STRATEGY. THIS IS OUR SICKLE CELL DISEASE AWARENESS
15 CAMPAIGN. AND THERE'S A BUNCH OF MATERIALS BACK
16 THERE FOR YOU TO REVIEW. THE CAMPAIGN REALLY
17 FOCUSES ON RAISING AWARENESS AND UNDERSTANDING OF
18 SICKLE CELL DISEASE.

19 SO WE LAUNCHED THIS ON THE 25TH OF
20 FEBRUARY. AGAIN, JUST EMPHASIZES CIRM'S COMMITMENT
21 TO ADVANCING RESEARCH FOR SICKLE CELL DISEASE.
22 WE'VE HIGHLIGHTED PATIENT STORIES, IMPACT OF OUR
23 RESEARCH. WE WORKED WITH A NUMBER OF ORGANIZATIONS
24 TO PARTNER AND DEVELOP THIS CONTENT. SO NOT JUST IN
25 LAUNCHING, BUT ACTUALLY DEVELOPING THE COLLATERAL

BETH C. DRAIN, CA CSR NO. 7152

1 AND CREATIVE FOR THIS WHICH WE WERE VERY EXCITED
2 ABOUT. AND YOU CAN SEE THE ORGANIZATIONS THAT WE
3 WORKED WITH FROM UCSF TO GLOBAL GENES TO DEVELOP
4 THIS.

5 I JUST WANT YOU TO TAKE A MINUTE TO LOOK
6 AT THIS BEAUTIFUL SLIDE BECAUSE IT REALLY REPRESENTS
7 A LOT OF HARD WORK THAT WE PUT INTO THIS. IN
8 WORKING WITH OUR PARTNERS, WE DEVELOPED AND LAUNCHED
9 A LANDING PAGE WHICH FEATURES A NUMBER OF JUST
10 DIFFERENT FACTS ABOUT CIRM-FUNDED RESEARCH IN THIS
11 AREA, FEATURES OUR PARTNERSHIPS. WE HAVE COLLATERAL
12 EDUCATIONAL MATERIALS THAT WE DEVELOPED IN BOTH
13 ENGLISH AND IN SPANISH. THESE ARE SOCIAL MEDIA
14 ASSETS. WE HAVE POSTCARDS AND COLLATERAL PIECES TO
15 SHARE WITH THE COMMUNITY. AND SO WITHIN THREE
16 MONTHS, WE WERE ABLE TO DEVELOP THIS CAMPAIGN AND
17 IT'S STILL ONGOING.

18 AND WHAT'S REALLY EXCITING IS WE ACTUALLY
19 LAUNCHED AND KICKED OFF THE CAMPAIGN AT THE BLACK
20 JOY PARADE, WHICH WAS A HUGE COMMUNITY CELEBRATION
21 IN OAKLAND, CALIFORNIA. AND IT HAD ABOUT 20,000
22 PEOPLE THAT CAME TO THIS EVENT. IT WAS A VERY
23 JOYOUS AND VIBRANT OCCASION, BUT ALSO REALLY
24 REPRESENTS TREMENDOUS SUCCESS FOR OUR OUTREACH
25 EFFORTS.

BETH C. DRAIN, CA CSR NO. 7152

1 SO WE ACTUALLY HAD A PRETTY LARGE BOOTH
2 THAT WAS SITUATED ON SORT OF THE MAIN AREA OF THE
3 PARADE. AND WE HAD A LOT OF ENGAGEMENT. WE HAD
4 FOLKS STOPPING BY ASKING ABOUT WHO CIRM WAS, WHAT WE
5 DID, WHAT IS SICKLE CELL DISEASE. WE HAD PARTNERS
6 COME AND REALLY SPEAK TO THEIR MISSION. AND PEOPLE
7 GATHERED A LOT OF THE MATERIALS WE DEVELOPED. WE
8 HAD A LOT OF GREAT QUESTIONS. AND SO THERE WERE
9 HUNDREDS OF ATTENDEES. PEOPLE WERE REALLY ENGAGED
10 AND INTERESTED IN OUR WORK.

11 AND SO THIS WAS A SOCIAL MEDIA VIDEO THAT
12 WE ACTUALLY TOOK FROM THE EVENT. IDITI DESAI IS OUR
13 COMMUNITY OUTREACH MANAGER WHO IS FEATURED IN THE
14 VIDEO. SO I AM GOING TO SHARE THIS WITH YOU ALL.

15 (THE VIDEO WAS THEN PLAYED, NOT
16 HEREIN TRANSCRIBED.)

17 MS. TEMPLE-PERRY: SO, AGAIN, THAT WAS
18 JUST A SNAPSHOT OF THE DAY. IT WAS WONDERFUL. WE
19 WERE REALLY PROUD OF OURSELVES. WE WANT TO THANK A
20 LOT OF MEMBERS FROM THE CIRM TEAM THAT CAME OUT TO
21 REALLY SUPPORT US AT THIS EVENT. AND IT REALLY
22 REPRESENTS A LOT OF THE GREAT WORK THAT WE DO AND
23 REALLY CONNECTED US TO OUR MISSION.

24 SO THAT'S JUST A TEASER OF SOME OF THE
25 THINGS GOING ON IN THE LAST COUPLE OF MONTHS, AND

BETH C. DRAIN, CA CSR NO. 7152

1 I'M VERY EXCITED TO SHARE MORE SORT OF IN MORE
2 DETAIL THAN THIS QUICK UPDATE, BUT THANK YOU FOR
3 YOUR TIME.

4 CHAIRMAN IMBASCIANI: THANKS, KOREN. THAT
5 WAS GOOD.

6 (APPLAUSE.)

7 MR. JUELSGAARD: A QUICK QUESTION. SO
8 THERE ARE TWO APPROVED THERAPIES RIGHT NOW FOR
9 SICKLE CELL, ONE FROM VERTEX AND THE OTHER FROM
10 BLUEBIRD BIO. SO THERE'S ACTUALLY QUITE A BIT
11 THAT'S ALREADY EXISTING IN THAT AREA. SO DO YOU
12 TALK ABOUT THAT ALONG WITH THIS?

13 MS. TEMPLE-PERRY: WE DID. PART OF THE
14 REASON WHY WE WANTED TO SHOWCASE AND REALLY START TO
15 DEVELOP THIS CAMPAIGN IS BECAUSE THERE'S A LOT OF
16 TALK IN THE NEWS ABOUT THIS. THERE'S A LOT OF
17 ATTENTION BEING PAID TO THIS. AND REALLY FROM A
18 COMMUNICATIONS PERSPECTIVE, WE REALLY NEED TO KIND
19 OF JUMP ON AND REALLY UTILIZE A LOT OF THIS NEWS AS
20 SORT OF A VEHICLE TO EDUCATE COMMUNITIES TO CONNECT
21 IN WAYS THAT MATTER AND IN THE COMMUNITY. AND SO
22 THIS IS A GREAT WAY TO DO THIS.

23 DR. CHOU: FOLLOW-UP QUESTION WILL BE THEN
24 DO WE OFFER MEDIA OR BASE TO THE PATIENT OR EVEN THE
25 WIDER POPULATION, EVEN THE FAMILY, AWARE ABOUT

BETH C. DRAIN, CA CSR NO. 7152

1 CERTAIN ONGOING CLINICAL TRIAL WE ARE SPONSOR OR
2 SUPPORT? BECAUSE I FEEL THAT'S KIND OF LIKE THE
3 GAP. BEING A BIOTECH COMPANY, SOMETIME WE WANT LOOK
4 FOR PATIENTS AND PATIENT LOOKING FOR US. I FEEL
5 CIRM CAN PLAY A REALLY NICE ROLE IN BETWEEN TO OFFER
6 THOSE OTHER OPTIONS FOR THE PATIENT AND ALSO
7 PARTICULARLY FOR THE PATIENT.

8 MS. TEMPLE-PERRY: AND THAT WAS PART OF
9 THE DEVELOPING PARTNERSHIPS TO REALLY MAKING SURE
10 THAT WE COULD CONNECT PATIENTS TO CLINICAL TRIALS OR
11 RECEIVING INFORMATION ABOUT HOW TO PARTICIPATE IN A
12 CLINICAL TRIAL. SO REALLY THAT PARTNERSHIP IS KEY
13 TO CONNECTING PEOPLE WITH GREATER RESOURCES. AND SO
14 AT OUR BOOTH, WE HAD A NUMBER OF THAT SORT OF
15 INFORMATION THAT PEOPLE CAN UTILIZE, PEOPLE TO
16 CONNECT WITH SO THAT THEY CAN ANSWER A LOT OF
17 QUESTIONS YOU ASKED.

18 DR. CHOU: JUST TO BE CLEAR, IT'S NOT JUST
19 DISEASE AWARENESS.

20 MS. TEMPLE-PERRY: BOTH, YES.

21 DR. CHOU: THANK YOU.

22 VICE CHAIR BONNEVILLE: JUDY, THE
23 COMMUNITY CARE CENTERS OF EXCELLENCE ARE REALLY
24 GOING TO PLAY A HUGE PART IN ALSO DOING SOMETHING
25 THAT YOU'VE HIGHLIGHTED OF MAKING SURE WE CAN

BETH C. DRAIN, CA CSR NO. 7152

1 CONNECT THE PATIENTS WITH THE TRIALS THAT ARE
2 ONGOING OR THE THERAPIES THAT ARE THERE. SO THERE'S
3 A LOT OF EFFORT AROUND THAT. WE'VE ACKNOWLEDGED
4 IT'S REALLY IMPORTANT AND VERY NECESSARY.

5 DR. CHOU: THAT'S IMPORTANT.

6 CHAIRMAN IMBASCIANI: YES, MARVIN.

7 DR. SOUTHARD: SO I WAS WONDERING IF YOU
8 MIGHT INVESTIGATE THE OPPORTUNITY THAT IS POSED BY
9 THE PASSAGE OF PROP 1 AND THE CRISIS THAT THAT'S
10 GOING TO BE CREATING IN THE MENTAL HEALTH TREATMENT
11 COMMUNITY AND TO SEE IF THERE'S A WAY OF
12 HIGHLIGHTING CIRM'S COMMITMENT TO PROVIDING SERVICES
13 FOR PSYCHIATRIC DISORDERS AS OBVIOUSLY NOT ANY
14 SHORT-TERM, BUT AS A LONGER-TERM SOLUTION TO WHAT'S
15 GOING TO BE A HUGE CRISIS WITHIN OUR STATE.

16 MS. TEMPLE-PERRY: YEAH. IT'S SOMETHING
17 WE CAN DEFINITELY EXPLORE.

18 CHAIRMAN IMBASCIANI: OKAY. WELL, THANK
19 YOU. APPRECIATE THAT.

20 AND NOW THE LAST OF THE ITEMS LEFT OVER
21 FROM FEBRUARY IS A DISCUSSION OF MANAGEMENT'S
22 RESPONSE TO THE PERFORMANCE AUDIT. DISCUSSION LED
23 BY OUR CHIEF LEGAL COUNSEL, RAFAEL AGUIRRE-SACASA.

24 MR. AGUIRRE-SACASA: THANK YOU, VITO. AND
25 THANK YOU, BOARD. CAN YOU HEAR ME? BETH, YOU CAN

BETH C. DRAIN, CA CSR NO. 7152

1 HEAR ME OKAY? THANK YOU.

2 SO ON BEHALF OF THE LEADERSHIP TEAM AND
3 EVERYBODY, I'M PLEASSED TO REPORT OUT ON THE
4 MANAGEMENT'S RESPONSE TO THE 2023 PERFORMANCE AUDIT.
5 I'VE BEEN TOLD THAT, ALTHOUGH THE AGENDA HAS THIS
6 FOR 15 MINUTES, THAT I'VE BEEN ENCOURAGED TO CUT
7 THAT DOWN. SO IF I MOVE TOO FAST AND THERE'S A
8 PARTICULAR THAT YOU WOULD LIKE ME TO ELABORATE MORE
9 THAN I ALREADY DO, PLEASE LET ME KNOW. OKAY. THANK
10 YOU.

11 OUR MISSION STATEMENT. WE'VE SEEN THAT A
12 COUPLE TIMES TODAY, SO I'LL JUST MOVE ON.

13 TODAY'S AGENDA, WE'RE GOING TO GO OVER THE
14 22/23 PERFORMANCE AUDIT AND OUR RESPONSE. THAT'S
15 THE MOST RECENT PERFORMANCE AUDIT THAT WE JUST
16 UNDERTOOK AS WELL AS ADDRESSING SOME OPEN ITEMS FOR
17 THE 2019/2020 PERFORMANCE AUDIT AS WELL.

18 HIGHLIGHTS, NO COMPLIANCE FINDINGS IN THE
19 22/23 PERFORMANCE AUDIT. THE LAST ONE WE HAD THREE
20 COMPLIANCE FINDINGS. SO YAY US FOR DOING A LITTLE
21 BIT BETTER AND FOCUSING ON THAT.

22 MOVING ON IN, I'M GOING TO FOCUS ON THE
23 ACTIONS BY CIRM. I WILL SPEND SOME TIME, IF IT
24 MAKES SENSE, I'LL TALK ABOUT THE FINDINGS AND THE
25 RECOMMENDATIONS, BUT IN GENERAL I THINK YOU'RE MORE

BETH C. DRAIN, CA CSR NO. 7152

1 INTERESTED IN WHAT WE'RE DOING HERE.

2 FIRST FINDING, ESSENTIALLY 11 STAFF
3 MEMBERS REPORTED TO THE CEO. AND MOSS-ADAMS THOUGHT
4 THAT THAT WAS TOO MUCH OF A REPORTING STRUCTURE. SO
5 J.T. IS EVALUATING THE CURRENT REPORTING STRUCTURE
6 FOR THE LEADERSHIP TEAM AND CIRM AS A WHOLE. AND WE
7 WILL BE PRESENTING THAT, I'M SURE, AT SOME POINT TO
8 THE TEAM.

9 SECOND ONE, THIS WAS A COMMENT ON THE FACT
10 THAT WE HAVE A LARGE 35-MEMBER ICOC. THAT GIVES US
11 A LOT OF INPUT AND DIFFERENT OPINIONS, BUT THERE ARE
12 CONCERNS ABOUT MAKING SURE THAT THERE'S ENOUGH
13 INVOLVEMENT BY EVERYBODY. SO BOARD GOVERNANCE HAS
14 TAKEN THE EFFORT TO MAKE SURE THAT WE LEVERAGE OUR
15 SUBCOMMITTEES. WE'VE GONE AN EXTRA EFFORT IN THE
16 POST-COVID ENVIRONMENT TO ENCOURAGE IN-PERSON
17 ATTENDANCE TO BOARD MEETINGS. FIVE A YEAR ARE GOING
18 TO BE IN PERSON AS YOU CAN SEE HERE WHERE WE'RE
19 GOING TO BE EXPANDING OUR AREAS.

20 SO IN SEPTEMBER OUR MEETING WILL BE IN SAN
21 DIEGO SO THAT WE CAN HOPEFULLY MAKE THE COMMUTES A
22 LITTLE BIT EASIER FOR SOME OF THE BOARD MEMBERS
23 HERE. AND OBVIOUSLY WE, BOARD GOVERNANCE, AND THE
24 REST OF THE LT ARE TRYING TO DEVELOP SORT OF THESE
25 SMALL GROUP PRIMERS WHERE WE PRESENT TOPICS OF

BETH C. DRAIN, CA CSR NO. 7152

1 INTEREST TO THE BOARD MEMBERS. FOR EXAMPLE, I KNOW
2 THAT BEN HUANG PRESENTED TO THE IP AND INDUSTRY
3 SUBCOMMITTEE ON IP REGULATIONS. I KNOW BOARD
4 GOVERNANCE IS WORKING ON SOME OTHER PRESENTATIONS AS
5 WELL FOR THE BOARD. SO PLEASE BE ON THE LOOKOUT FOR
6 THOSE.

7 THIS ONE WAS A QUESTION ABOUT HOW WE
8 ADDRESS SOLE SOURCE CONTRACTS IN THE FI\$CAL SYSTEM.
9 THE RECOMMENDATION WAS THAT WE DEVELOP A PROCESS TO
10 ENSURE SOLE SOURCE CONTRACTS ARE CONSISTENTLY
11 RECORDED IN THE FI\$CAL PROCESS FOR REPORTING
12 PURPOSES. OUR FINANCE TEAM SPOKE WITH FI\$CAL, AND
13 THEY IDENTIFIED AND IMPLEMENTED A NEW PROCESS WHERE
14 SOLE SOURCE CONTRACTS ARE RECORDED CONSISTENTLY WITH
15 FI\$CAL.

16 WE AS A TEAM DISCLOSE CONTRACTS TO THE
17 BOARD ON A REGULAR BASIS. THIS INCLUDES OUR SOLE
18 SOURCE CONTRACTS. MOVING FORWARD, WE'RE GOING TO
19 IDENTIFY THOSE SOLE SOURCE CONTRACTS SPECIFICALLY IN
20 THAT REPORT SO THAT YOU CAN SEE WHICH ONES ARE SOLE
21 SOURCE AND WHICH ONES ARE PUT OUT FOR BID.

22 AND AS PART OF THAT, I AM WORKING WITH
23 FINANCE ON A NEW CONTRACTS POLICY WHICH WE WILL BE
24 PRESENTING HOPEFULLY IN THE NEXT GOVERNANCE
25 SUBCOMMITTEE, ICOC ROUNDS FOR REVIEW.

BETH C. DRAIN, CA CSR NO. 7152

1 THIS ONE, OUR CURRENT LOAN ELECTION
2 POLICY, WHICH IS WITHIN THE GRANTS ADMINISTRATION
3 POLICY, THE GAP, IT HAS A REFERENCE TO LIBOR WHICH
4 NO LONGER EXISTS. AND THE RECOMMENDATION WAS THAT
5 WE REPLACE IT WITH AN ALTERNATIVE BENCHMARK, SUCH AS
6 THE SECURED OVERNIGHT FINANCING RATE. CURRENTLY WE
7 HAVE DONE THAT. WE ARE GOING TO REVISE OUR CLIN
8 GAP. THAT'S AN EXTENDED PROCEDURE WHERE WE HAVE TO
9 GO THROUGH THE OFFICE OF ADMINISTRATIVE LAW. SO
10 WE'RE IN THE PROCESS OF LOOKING AT WHAT OTHER
11 CHANGES WE WANT TO MAKE WITH THE GAP. IN THE
12 MEANTIME WE ARE PERMITTED TO USE AN ALTERNATIVE
13 BENCHMARK SUCH AS THE SOFR, SECURED OVERNIGHT
14 FINANCING RATE. THAT'S WHAT WE'RE DOING IN OUR
15 NOTICE OF AWARDS PRESENTLY. SO WE'RE IN COMPLIANCE,
16 AND WE'RE JUST GOING TO MAKE SURE THAT WE CLEAN UP
17 THE GAP POLICY MOVING FORWARD.

18 THIS ONE, THIS IS A BIG ONE HERE. THE
19 FINDING WAS THAT OUR COMPLIANCE OF THE TECHNOLOGY
20 DISCLOSURE REQUIREMENTS FOR OUR GRANTEES IS AD HOC,
21 AND IT CAN CREATE A RISK OF NONCOMPLIANCE AND
22 NEGATIVELY IMPACT THE REVENUE SHARING, WHICH IS
23 OBVIOUSLY IMPORTANT.

24 SO WE WORKED WITH MOSS-ADAMS, AND I WANT
25 TO GIVE CREDIT TO MY COLLEAGUE BEN HUANG WHO DID

BETH C. DRAIN, CA CSR NO. 7152

1 THIS BEFORE I JOINED. HE CONDUCTED AN INITIAL
2 SURVEY OF ALL OF OUR CLIN LEVEL GRANTS TO IDENTIFY
3 ANY PROJECTS THAT HAVE BEEN LICENSED OR
4 COMMERCIALIZED. WE RECEIVED RESPONSES FROM OVER 60
5 PERCENT OF OUR GRANTEES. WE'RE GOING TO BE
6 FOLLOWING UP WITH OUR NONRESPONDERS, OF COURSE, TO
7 HOPEFULLY CLOSE THAT UP. AND WE ARE GOING TO
8 IMPLEMENT THIS SURVEY TRIENNIALLY AND ALSO TO EXPAND
9 IT TO OUR TRAN AWARDS AS WELL. WE ARE ALSO LOOKING
10 AT SOFTWARE SOLUTIONS WHEREBY WE CAN HELP TRACK AND
11 FOLLOW ANY SORT OF IP THAT IS LICENSED OR
12 COMMERCIALIZED BY OUR GRANTEES AS WELL. YES, SIR.

13 DR. LEVITT: CAN I INTERRUPT OR YOU WANT
14 TO WAIT?

15 MR. AGUIRRE-SACASA: PLEASE.

16 DR. LEVITT: SO FOR FEDERAL GRANTS, WHEN
17 YOU SUBMIT YOUR RPPR, YOUR PROGRESS REPORT, THERE'S
18 ACTUALLY A BOX THAT YOU HAVE TO FILL IN. AND SO
19 WHETHER IT'S QUARTERLY, AND THERE'S SOME
20 ORGANIZATIONS WITH QUARTERLY REPORTS, OR SEMIANNUAL
21 REPORTS WITHIN THE CONTEXT OF THE PROGRESS REPORT
22 ABOUT JUST THIS TOPIC. SO WOULD THAT -- IF IT'S
23 INCLUSIVE OF THAT AND THEY HAVE TO FILE THAT IN
24 ORDER TO CONTINUE TO SPEND THEIR DOLLARS, WHY NOT
25 INCLUDE IT IN THE PROGRESS REPORT THAT WOULD PROVIDE

BETH C. DRAIN, CA CSR NO. 7152

1 THAT INFORMATION. AND IF THEY SAY NO, THEY HAVE TO
2 ANSWER IT. THEY JUST CAN'T SAY N/A. THEY HAVE TO
3 SAY YES OR NO. AND IF IT'S NO, THEN YOU HAVE THE
4 DOCUMENTATION THAT THEY'RE MAYBE NOT BEING SO
5 FORTHCOMING. THAT'S JUST A SUGGESTION. INCORPORATE
6 IT IN THE PROGRESS REPORT.

7 MR. AGUIRRE-SACASA: THANK YOU VERY MUCH.
8 WE WILL. WE DO THAT IN OUR UTILIZATION REPORTS.
9 WE'VE JUST NOTICED THAT WE NEED TO TRUST AND VERIFY,
10 SO WE'RE CLOSING OUT THE LOOP HERE. I'M A MORE
11 TRUSTING PERSON THAN PAT, BUT THAT'S OKAY.

12 MOVING ON, WE HEARD ABOUT THE PATIENT
13 SUPPORT PROGRAM TODAY. THE FINDING WAS THAT IT HAS
14 SOME UNCERTAINTY RELATED TO FINANCIAL
15 SUSTAINABILITY. THE RECOMMENDATION WAS THAT, AS WE
16 IMPLEMENT THE PSP, WE SHOULD CONDUCT REGULAR
17 REPORTING TO THE ICOC ON THE NUMBER OF PATIENTS
18 SERVED AND AVERAGE COST PER PATIENT AS WELL AS
19 DEVELOP DATA-INFORMED EVALUATION OF THE POTENTIAL
20 REACH AND DURATION OF THE PSP.

21 THESE REPORTING METRICS ARE ALREADY A
22 REQUIREMENT IN THE PSP APPLICATION. SPECIFIC
23 OPERATIONAL DETAILS WILL BE PART OF THE BUSINESS
24 RULES FOR THE REPORTING PROCESS TO BE AGREED ON.
25 AND THIS WILL BE PROVIDED TO THE AAWG SO THEY CAN

BETH C. DRAIN, CA CSR NO. 7152

1 PROVIDE RECOMMENDATIONS FOR EACH ON DURATION.

2 THIS FINDING DEALT WITH TRYING TO
3 ESTABLISH A DATA GOVERNANCE STRUCTURE BECAUSE,
4 OBVIOUSLY, THERE'S A LOT OF DATA THAT WE COLLECT
5 THAT'S VALUABLE TO STEM CELL AND REGENERATIVE
6 MEDICINE RESEARCHERS. WE HAVE AGREED TO DEVELOP A
7 DATA INFRASTRUCTURE FRAMEWORK FOR ALL OF OUR DATA,
8 AND THAT'S GOING TO INCLUDE IMPLEMENTATION OF A DATA
9 SHARING AND MANAGEMENT PLAN THAT WILL APPLY TO ALL
10 OF OUR RESEARCH AWARDS. AND IT'S ALSO GOING TO --
11 WE'RE ALSO GOING TO DEVELOP AND DEPLOY A METADATA
12 DASHBOARD. AND DR. ROSA, I BELIEVE, IS LEADING THAT
13 EFFORT IF I'M NOT MISTAKEN. SO BE LOOKING FORWARD
14 TO THAT.

15 SO THIS DEALS WITH, AGAIN, THE FACT THAT
16 WE HAVE A LOT OF WORKLOAD. I THINK THE BOARD IS
17 AWARE OF HOW MANY PROJECTS AND HOW MUCH TIME THE
18 TEAM WORKS ON THIS. THE RECOMMENDATION WAS THAT WE
19 INCORPORATE DATA-DRIVEN WORKLOAD ANALYSIS TO COME UP
20 WITH REALISTIC TIMELINES AND STAFFING AIDS. THE HR
21 TEAM IS WORKING WITH J.T. AND THE LEADERSHIP TEAM TO
22 MAKE SURE THAT WE HAVE PROPER STAFFING LEVELS TO
23 MEET OUR OPERATIONAL GOALS AND REQUIREMENTS AND ALSO
24 TRYING TO MAKE SURE THAT WE SET EXPECTATIONS SO THAT
25 PEOPLE AREN'T OVERLOADED AND BURNED OUT, TO BE

1 HONEST.

2 SORT OF ALONG WITH THAT SAME PROCESS, WE
3 HAVE THE PROGRAMMATIC AND OPERATIONAL CHANGES AT
4 CIRM THAT HAVE LED TO CHALLENGES IN MAINTAINING
5 PRIORITIES, WORKSTREAMS, ET CETERA. THE
6 RECOMMENDATION IS TO ADOPT A STANDARDIZED CHANGE
7 MANAGEMENT TEMPLATE AND PROMOTE COMMUNICATION AND
8 ACCOUNTABILITY THROUGHOUT ALL CHANGE PROCESSES. WE,
9 AS THE LEADERSHIP TEAM, ARE REVIEWING THESE CHANGE
10 MANAGEMENT CONSULTING OPTIONS, AND WE'RE GOING TO
11 IDENTIFY ORGANIZATIONAL GAPS TO IMPLEMENT BEST
12 PRACTICES AND TRAINING FOR THE STAFF.

13 OBVIOUSLY, THIS IS CONSISTENT WITH
14 EVERYTHING THAT WE'VE BEEN TALKING ABOUT TODAY. SO
15 MOVING FORWARD, NOW WE'RE GETTING INTO AN AREA
16 THAT'S OBVIOUSLY VERY IMPORTANT. IT'S THE HUMAN
17 RESOURCES DEPARTMENT. AND THE FINDING WAS THAT
18 HISTORICALLY CIRM HAS RELIED ON MANUAL AND
19 UNDOCUMENTED HR PROCESSES WITH MINIMAL EMPLOYEE
20 SELF-SERVICE OPTIONS. THE HR TEAM HAS TAKEN THIS TO
21 HEART, AND WE'RE UPDATING ALL OF OUR OUT-OF-DATE
22 POLICIES AND PROCEDURES AS WELL AS DRAFTING NEW ONES
23 THAT ADDRESS ANY GAPS THAT MIGHT BE EXISTING.

24 MY APOLOGIES. I WAS HOPING TO HAVE THE
25 COMPENSATION POLICY READY FOR THIS ROUND OF

BETH C. DRAIN, CA CSR NO. 7152

1 APPROVALS, BUT WE NEEDED TO DO A LITTLE BIT MORE
2 WORK. SO YOU WILL BE SEEING THAT IN THE NEXT ROUND
3 OF GOVERNANCE SUBCOMMITTEE AS WELL AS THE ICOC.

4 WE'VE ALSO TAKEN SEVERAL STEPS TO MAKE
5 MORE SELF-SERVICE OPTIONS FOR OUR EMPLOYEES. WE'VE
6 ADOPTED A BAMBOO HR SOFTWARE THAT HELPS TRACK
7 EMPLOYEE TIME OFF, VACATIONS, GOALS, ETC. WE'RE
8 ALSO IMPLEMENTING AN ELECTRONIC TIMESHEET PROCESS
9 WHICH MAKES IT A LITTLE BIT EASIER. BEFORE IT WAS
10 ALL MANUAL. SO WE'RE TRYING TO GET UP INTO THE
11 MODERN WORLD HERE, AT LEAST THE 20TH CENTURY IF NOT
12 THE 21ST CENTURY IN HR.

13 SORT OF SIMILAR COMMENT HERE. WE HAVE
14 LIMITED HR POLICY DOCUMENTATION AND SIGNIFICANT HIRE
15 NEEDS FOLLOWING PROP 14. AND THAT RESULTED IN
16 DELAYED HIRING AND INCONSISTENT NEW EMPLOYEE
17 ONBOARDING AND TRAINING. SINCE THEN WE ARE
18 ADDRESSING THIS VERY SPECIFICALLY. WE THINK THAT
19 ONBOARDING IS OBVIOUSLY THE FIRST TIME AN
20 EMPLOYEE -- WELL, THE FIRST TIME AN EMPLOYEE GETS TO
21 MEET -- GETS THE FULL BREADTH OF CIRM. AND SO WE
22 WANT TO MAKE SURE THAT THAT IS A CLEAN AND
23 CONSISTENT AND, FRANKLY, HELPFUL PROCESS.

24 AND SO WE NOW HAVE TWO FULL-TIME
25 EMPLOYEES, ONE RA. THAT INCLUDES A NEW DIRECTOR OF

BETH C. DRAIN, CA CSR NO. 7152

1 HR WHO IS HELPING ME REVAMP THE ENTIRE -- FRANKLY,
2 DO AN AUDIT OF THE WHOLE HR DEPARTMENT AND SEE WHERE
3 WE NEED TO ADDRESS ALL OF THESE CONCERNS THAT WERE
4 RAISED BY MOSS-ADAMS.

5 ONE OF THE THINGS THAT WE'RE PROUD OF IS
6 THAT WE HAVE REDUCED THE HIRING TIME FROM FOUR TO
7 SIX MONTHS TO ABOUT TWO MONTHS. THAT'S SOMETHING
8 THAT WE'RE PROUD OF BECAUSE, AGAIN, WE THINK THAT
9 THAT'S IMPORTANT TO BRING IN TOP TALENT TO THE TEAM.
10 AND BECAUSE WE'RE ALSO STRESSED OUT, NOT STRESSED
11 OUT, BUT BECAUSE THE WORKLOAD IS VERY STRETCHED
12 THIN, WE WANT TO MAKE SURE THAT WE GET PEOPLE IN
13 SOONER RATHER THAN LATER TO GIVE SUPPORT TO OUR TEAM
14 PLAYERS HERE.

15 THE FINDING WAS THAT DUE TO HISTORICAL
16 COMPENSATION PRACTICES, PAY INEQUITIES MAY HAVE
17 DEVELOPED BETWEEN TENURED AND NEW EMPLOYEES.
18 RECOMMENDATION IS COMPLETE A REVISION OF THE
19 COMPENSATION POLICY TO PREVENT INSTANCES OF PAY
20 INEQUITY. WE'VE REVIEWED OUR COMP PLAN. AS I SAID,
21 WE ARE REVISING THAT AS WELL AS LOOKING AT OUR
22 POSITIONAL SALARIES TO MAKE SURE THAT WE DON'T HAVE
23 ANY ISSUES OF COMPACTION OR THERE'S NO INEQUITY
24 AMONG THE DIFFERENT GROUPS AND THINGS LIKE THAT.
25 SO, AGAIN, WE WILL BE PRESENTING A NEW COMP POLICY

BETH C. DRAIN, CA CSR NO. 7152

1 TO THE BOARD SHORTLY.

2 SO ON THIS ONE -- THIS ONE, I THINK, THIS
3 COMMENT AROSE, I THINK, MOSTLY DURING THE COVID TIME
4 PERIOD. REMEMBER THIS IS A THREE-YEAR LOOK BACK ON
5 THE PERFORMANCE AUDIT. SO A LOT OF EMPLOYEES WERE
6 QUESTIONING THE CONSISTENT APPLICATION OF OUR HYBRID
7 TELEWORK POLICY. AND SO THE RECOMMENDATION WAS TO
8 EVALUATE IT AND SEE HOW WE COULD IMPROVE IT.

9 WITH J.T'S. LEADERSHIP AS WELL AS THE LT,
10 WE HAVE DECIDED TO GO TO TWO ANCHOR DAYS IN THE
11 OFFICE, TUESDAYS AND WEDNESDAYS FOR MOST PEOPLE.
12 THAT WAY WE CAN BREAK DOWN SILOS, IMPROVE
13 CAMARADERIE, AND COLLABORATION. AND SO WE THINK
14 THAT THAT -- WE HAVE HAD ANECDOTAL FEEDBACK THAT
15 THAT IS ACTUALLY IMPROVING THE MORALE IN THE
16 ORGANIZATION. AND SO WE THINK THAT THAT'S HEADING
17 IN THE RIGHT DIRECTION THERE AS WELL.

18 OKAY. SO THAT'S IT FOR THE 22/23
19 PERFORMANCE AUDIT. HERE WE'RE GOING TO GO BACK TO
20 SOME OF THE OPEN ITEMS THAT WERE LEFT FROM THE
21 PREVIOUS AUDIT. MY COMMITMENT TO THE ICOC IS TO
22 COME BACK EVERY SIX MONTHS OR SO AND GIVE YOU
23 CONSTANT UPDATES UNTIL WE CLOSE OUT ALL OF OUR
24 PERFORMANCE AUDIT FINDINGS. SO HOPEFULLY YOU WON'T
25 GET TOO BORED FROM ME.

BETH C. DRAIN, CA CSR NO. 7152

1 SOME OF THESE ARE IN THE PAST. SO I'LL
2 TRY AND GET THEM REAL QUICKLY. WHEN THEY TESTED THE
3 GRANTS MANAGEMENT PROCESS BACK IN THE DAY,
4 MOSS-ADAMS IDENTIFIED THREE EXCEPTIONS TO THE GAP
5 STANDARD OPERATING PROCEDURES. SPECIFICALLY THE
6 THREE EXCEPTIONS WERE RELATED TO TWO GRANTS UNDER
7 THE EDUC1 CONFERENCE GRANT PROGRAM. ALL OF THESE --
8 ALL THREE EXCEPTIONS HAVE BEEN ADDRESSED BY CREATING
9 A CONFERENCE GRANT PROGRESS REPORT IN THE GRANTS
10 DATABASE APPROVED BY BOTH THE GRANTS MANAGER AND
11 GRANTS MANAGEMENT OFFICER AND THE SCIENCE OFFICER.

12 THE GRANTS MANAGEMENT TEAM ALSO AUTOMATED
13 THE CONTRACT AMENDMENT TEMPLATE TO INCLUDE
14 PREPOPULATED DATA FROM GMS, AND THEN THEY UPDATED
15 THE GRANTS MANAGEMENT SOP WITH A COMPLIANCE CHECK
16 EVALUATION BY THE DIRECTOR OF GM ON ALL AMENDMENTS
17 AND NOTICE OF AWARDS. SO THOSE ARE THREE SPECIFIC
18 RESPONSES TO THE EXCEPTIONS.

19 I'M SORRY. THIS IS -- I SPOKE ABOUT THE
20 IP SURVEY. THIS IS A REMNANT OF THAT. SO, AGAIN,
21 IN 2018 MOSS-ADAMS FOUND THAT OR RECOMMENDED THAT WE
22 HAVE AN I.T. AND CONTROL FOR FLAGGING MISSING
23 DOCUMENTATION AND REPORTS. MOST IMPORTANT FOR US
24 WERE THE UTILIZATION REPORTS, ET CETERA, THAT
25 INCLUDE ALL THE INFORMATION. WE'RE NOW ADDRESSING

BETH C. DRAIN, CA CSR NO. 7152

1 THAT WITH OUR SURVEYS, ET CETERA. SO I'M JUST GOING
2 TO MOVE ON TO THIS ONE.

3 THIS ONE, THE FINDING WAS THAT WE DID NOT
4 HAVE AN EFFECTIVE POLICY OR PROACTIVE PROCESS FOR
5 MONITORING AND ENFORCING AWARDEE PUBLICATION
6 DISCLOSURES. THINK OF CITATIONS FOR CIRM, ET
7 CETERA. THESE ARE A REQUIREMENT OF OUR AWARDEE
8 REPORTING REQUIREMENTS. AND SO WE ARE LOOKING AT
9 THIRD-PARTY SOLUTIONS TO TRACK PUBLICATIONS. AND WE
10 HAVEN'T FOUND ONE YET, BUT WE ARE CONTINUING THIS
11 WORK TO MAKE SURE THAT, AGAIN, CIRM GETS ALL THE
12 CREDIT THAT IT SHOULD.

13 THIS ONE, WE'VE RELIED HISTORICALLY ON
14 SCIENTIFIC EXPERTS FOR OUR GRANT REVIEW. AS A
15 PUBLIC AGENCY, IT'S IMPORTANT TO CIRM TO DILIGENTLY
16 SEEK DIVERSE PERSPECTIVES AND EXPERTISE TO ENSURE
17 THE PERCEPTION OF INDEPENDENCE IN APPLICATION
18 REVIEW.

19 THE RECOMMENDATION WAS TO CONTINUE TO
20 IMPLEMENT RECENTLY ADOPTED PRACTICES, TO SEEK MORE
21 DIVERSE MEMBERS. WHAT WE ARE DOING IS YOU HAD A
22 PRESENTATION, I THINK IT WAS, IN DECEMBER FROM
23 DIVERSITY NORTH ON THE DEI RUBRIC AS PART OF THE
24 GWG. WITH J.T'S LEADERSHIP, WE HAVE NOW TAKEN A
25 STEP BACK AND WE'RE NOW LOOKING AT THE WHOLE DEI

BETH C. DRAIN, CA CSR NO. 7152

1 STRATEGY OVERALL FOR CIRM. WE'RE WORKING WITH
2 DIVERSITY NORTH AT THIS POINT TO TRY AND DEVELOP A
3 STRATEGY. AND AS THAT STRATEGY CRYSTALLIZES, WE
4 WILL BE GIVING YOU UPDATES ON THAT.

5 OUR RECORD RETENTION SCHEDULE EXPIRED IN
6 2018. THERE WAS SOME CONFUSION AS TO WHAT THE
7 RECORD RETENTION REQUIREMENTS WERE BACK THEN. SINCE
8 THEN THE FINANCE TEAM HAS WORKED WITH SECRETARY OF
9 STATE'S RECORDS DIVISION. AND THEY HAVE PROVIDED
10 TRAINING TO ALL CIRM STAFF ON MARCH '23 AND '22.
11 SELECT CIRM STAFF COMPLETED ADDITIONAL RECORDS
12 MANAGEMENT TRAINING AND CERTIFICATION. SINCE THEN
13 WE'VE UPDATED OUR RECORDS RETENTION SCHEDULE WITH
14 THE SECRETARY OF STATE IN SEPTEMBER OF '22. THE
15 SECRETARY OF STATE RESPONDED BACK, AND WE HAVE
16 RESPONDED TO THAT RESPONSE WITH OUR REVISED
17 INFORMATION, AND WE ARE WAITING TO HEAR BACK ON THAT
18 FROM THE SECRETARY OF STATE. BUT WE EXPECT TO
19 HOPEFULLY CLOSE THAT OUT SOONER RATHER THAN LATER.

20 THIS FINDING WAS THAT WE USED THREE
21 DOCUMENT MANAGEMENT SYSTEMS, AND THIS MAY PRESENT
22 CONFUSION TO CIRM EMPLOYEES AND MAYBE THE BOARD IN
23 SOME CASES. THE RECOMMENDATION WAS TO, WHENEVER WE
24 IMPLEMENT A NEW DOCUMENT MANAGEMENT SYSTEM, TO
25 DEVELOP AN ADOPTION STRATEGY. RIGHT NOW THE I.T.

BETH C. DRAIN, CA CSR NO. 7152

1 DEPARTMENT HAS THREE FULL-TIME PEOPLE. WE HAD A
2 DEPARTURE OF THE DIRECTOR OF I.T. IN 22/23, AND SO
3 WE DELAYED THE IMPLEMENTATION OF A NEW DOCUMENT
4 MANAGEMENT SYSTEM TO KEEP OTHER CRITICAL PROJECTS ON
5 TRACK. WE NOW HAVE A NEW ASSOCIATE DIRECTOR OF I.T.
6 SINCE NOVEMBER OF '22, AND WE'VE ALREADY
7 PERFORMED -- NOT WE, BUT THE I.T. TEAM HAS PERFORMED
8 A NEEDS ASSESSMENT. THEY PILOTED SOME SOLUTIONS AND
9 HAVE SELECTED MICROSOFT OFFICE 365 AS OUR DOCUMENT
10 MANAGEMENT PLATFORM FOR CIRM.

11 THE ASSOCIATE DIRECTOR HAS ALSO BUILT AN
12 ADOPTION STRATEGY WHICH WILL BE IMPLEMENTED BY THE
13 END OF CALENDAR YEAR 2024.

14 FINDING IS WE MADE SOME SIGNIFICANT
15 IMPROVEMENT IN THE GRANTS MANAGEMENT SYSTEM;
16 HOWEVER, ADDITIONAL OPPORTUNITIES JUST TO LEVERAGE
17 THE GMS TO IMPROVE OPERATIONAL EFFICIENCY AND
18 EFFECTIVENESS.

19 AGAIN, WE TALKED ABOUT THE DEPARTURE OF
20 I.T. AT THE TIME CIRM ENGAGED A CONSULTANT TO
21 EVALUATE THE FUTURE OF OUR GRANTS DATABASE AND
22 PERFORM A NEEDS ASSESSMENT. THE CONSULTANT
23 RECOMMENDED THAT WE CONTINUE WITH THE IN-HOUSE
24 GRANTS MANAGEMENT SYSTEM AS IT WAS TECHNOLOGICALLY
25 STABLE AND WELL INTEGRATED. THE CIRM SOFTWARE

BETH C. DRAIN, CA CSR NO. 7152

1 DEVELOPMENT TEAM HAS BEGUN IMPLEMENTING A ROADMAP
2 FOR EVOLVING AND DEVELOPING THE SYSTEM TO MOVE
3 FORWARD.

4 THIS KIND OF TALKS TO THE DATA MANAGEMENT
5 FINDING THAT WE HAD IN 22/23. THE RECOMMENDATION
6 WAS TO CONSIDER IMPLEMENTING A CUSTOMER RELATIONSHIP
7 MANAGEMENT SYSTEM. WE ARE LOOKING AT THAT. THE NEW
8 ASSOCIATE DIRECTOR OF I.T., BEN CHOU, IS EVALUATING
9 SOLUTIONS. AND WE HOPE TO SELECT ONE BY THE END OF
10 FY 23/24, WHICH WOULD BE JUNE, AND TO INCORPORATE
11 AND IMPLEMENT IT BY THE END OF FY 24/25.

12 AND THAT'S IT.

13 CHAIRMAN IMBASCIANI: THERE WAS A
14 QUESTION. IF ANYONE HAS ANY COMMENTS OR QUESTIONS
15 TO RAFAEL, THIS IS THE TIME. MARV.

16 DR. SOUTHARD: I WAS JUST WONDERING IF YOU
17 COULD SPEAK ANY MORE ABOUT THE DEFICIENCIES THAT
18 THEY SAW IN THE DEI STRATEGY.

19 MR. AGUIRRE-SACASA: HONESTLY IT WAS
20 BEFORE MY TIME. GIL, DO YOU HAVE ANY COMMENTS ON
21 THAT BECAUSE IT WAS RELATED TO THE GWG?

22 DR. SAMBRANO: NOT REALLY, NO.

23 MR. AGUIRRE-SACASA: MARV, LET ME LOOK
24 INTO THAT AND I'LL GET BACK TO YOU.

25 VICE CHAIR BONNEVILLE: DO YOU WANT ME TO

BETH C. DRAIN, CA CSR NO. 7152

1 FILL IN?

2 MR. AGUIRRE-SACASA: YEAH. PLEASE GO
3 AHEAD.

4 VICE CHAIR BONNEVILLE: SO ORIGINALLY WE
5 BROUGHT ON CONSULTANTS TO ADVISE US AROUND THE DEI,
6 THAT WE DO THE WORK AT THE GRANTS WORKING GROUP.
7 AND WE ALSO HAD ASKED THAT PERHAPS THEY TAKE A LOOK
8 AT THINGS FOR INTERNAL -- A MODULE FOR US INTERNALLY
9 ABOUT HOW WE TALK ABOUT THINGS, A LEXICON THAT WE
10 MIGHT USE, AND JUST TO BRING THE TEAM UP TO DATE ON
11 HOW DEI IS BEING IMPLEMENTED ACROSS THE COUNTRY,
12 ALTHOUGH IT'S BEING DISMANTLED IN A LOT OF PARTS OF
13 THE COUNTRY, BUT NOT HERE, THANK GOODNESS.

14 DR. SOUTHARD: I SEEM TO RECALL THAT THE
15 DISCUSSION WAS MORE INTERNAL TO THE TEAM THAN
16 EXTERNAL TO THE REVIEW PROCESS.

17 VICE CHAIR BONNEVILLE: YES. IT'S BOTH.

18 MR. AGUIRRE-SACASA: YES, THAT'S CORRECT,
19 MARV.

20 CHAIRMAN IMBASCIANI: JUDY.

21 DR. CHOU: SO MY COMMENT, WHICH MAY BE A
22 BIG PROJECT, I'M NOT QUITE SURE ALL THE BOARD MEMBER
23 WILL SUPPORT, BUT I DO THINK FROM THE FINDING NO. 7
24 OF THIS YEAR AND ALSO FINDING NO. 11 LAST YEAR, IT
25 CONSISTENTLY POINT OUT WE ARE SITTING ON VERY

BETH C. DRAIN, CA CSR NO. 7152

1 POWERFUL, A LOT OF GREAT INFORMATION NO MATTER IS IT
2 CLINICALLY OR SCIENTIFICALLY. AND GIVEN OUR MISSION
3 IS TO PROGRESS THIS URGENT THERAPY, I DON'T THINK WE
4 CAN JUST SIT AROUND TO SAY WE ARE COLLECTING THOSE
5 INFORMATION. COLLECTING INFORMATION IS ONE THING.
6 MAKING IT USEFUL IS TOTALLY THE OTHER. SO IT TAKES
7 SOME INVESTMENT FROM US TO SEE WHAT ARE WE GOING TO
8 IMPLEMENT IN THOSE TOOLS.

9 PARTICULARLY I CANNOT HELP TO MENTION
10 ABOUT AI TOOLS, AND WE HAVE NEVER DISCUSSED ABOUT
11 IT. I KNOW IN THE INTEREST OF TIME, WE PROBABLY
12 CANNOT DISCUSS TODAY, BUT I WOULD PROPOSE WE THINK
13 ABOUT WHAT WE AS ORGANIZATION CAN DO TO IMPLEMENTING
14 CERTAIN TOOLS TO HELP MAKING THOSE INFORMATION
15 REALLY BECOME KNOWLEDGE INSTEAD OF JUST INFORMATION.

16 DR. THOMAS: IF I MIGHT SPEAK TO THAT. SO
17 THAT'S A GREAT POINT. AND WE SPENT A LOT OF TIME
18 TALKING ABOUT DATA SHARING, AND IT'S A MAJOR TOPIC.
19 AND I WOULD SUGGEST IT WOULD BE ONE THAT WOULD BE
20 GOOD TO DO A PRESENTATION ON TO THE BOARD IN A
21 FUTURE MEETING TO SOLICIT COMMENTARY AND IDEAS. BUT
22 WE'RE VERY ATTUNE TO THAT ISSUE, AND WE WILL BE BACK
23 TO YOU MORE ON THAT.

24 DR. CHOU: THANK YOU.

25 CHAIRMAN IMBASCIANI: THANK YOU. AND

BETH C. DRAIN, CA CSR NO. 7152

1 THANK YOU, RAFAEL.

2 MR. AGUIRRE-SACASA: THANK YOU, EVERYBODY.

3 CHAIRMAN IMBASCIANI: WE'VE REACHED THE
4 POINT IN THE MEETING WHERE I WOULD LIKE TO ASK ANY
5 MEMBER OF THE PUBLIC IF THEY HAVE ANY COMMENT,
6 INCLUDING ON ITEMS THAT ARE NOT ON TODAY'S AGENDA.
7 YES, MR. PRESIDENT.

8 DR. THOMAS: ONE LAST POINT ON THE
9 PERFORMANCE AUDIT. RAFAEL SORT OF PASSED IT OVER
10 WITH NOT MUCH FANFARE, BUT THE FACT THAT WE HAD NOT
11 A SINGLE COMPLIANCE FINDING WITH ALL THE AMOUNT OF
12 GRANTS THAT WE'RE DEALING WITH AND THE MASSIVE
13 CHALLENGES OF GRANTS MANAGEMENT, ET CETERA, THAT'S A
14 HUGE DEAL. SO I WANT TO MAKE SURE THE BOARD HEARD
15 THAT AND IS VERY APPRECIATIVE THAT OUR CRACKERJACK
16 GMS TEAM IS DOING A WONDERFUL JOB.

17 (APPLAUSE.)

18 CHAIRMAN IMBASCIANI: WELL, WITH THAT, I
19 WANT TO THANK THE BOARD MEMBERS WHO TRAVELED HERE
20 FROM NEAR AND FAR FOR ATTENDING TODAY'S MEETING AND
21 GIVING YOUR ATTENTION. THE NEXT MEETING OF THIS
22 BOARD WILL BE AT 9 O'CLOCK IN THE MORNING ON
23 THURSDAY, JUNE 27TH IN THIS VERY HOTEL IN THIS VERY
24 ROOM. THE MEETING IS ADJOURNED.

25 (THE MEETING WAS THEN CONCLUDED AT 3:12 P.M.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON MARCH 28, 2024, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152
133 HENNA COURT
SANDPOINT, IDAHO
(208) 920-3543